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Abstract
Systemic Sclerosis (SSc) is a connective tissue disease characterised by
inflammation and autoimmunity, vasculopathy, and interstitial remodelling
and fibrosis. This thesis focuses on CTGF (CCN2), a member of the CCN
family of matricellular proteins, as elevated CTGF expression is a hallmark of
chronic fibrotic diseases such as SSc. In addition to the association of CTGF
expression and fibrosis in human disease, experimentally, fibroblast-specific
overexpression of CTGF has been shown to induce a fibrotic phenotype, as
demonstrated in the Col1a2-CTGF transgenic mice. Prominent features of
fibrosis included a thickened dermis, as well as excess collagen deposition in
the skin and lung.
This CTGF overexpression also provoked changes in the alveolar epithelium.
In the lung of Col1a2-CTGF mice, immunostaining revealed a marked
increase in the number of cells co-expressing the epithelial marker, TTF-1
and mesenchymal cell markers α-SMA and Snai1, indicative of epithelial-to-
mesenchymal transition (EMT)-like changes. This suggested a role for the
paracrine effects of CTGF in promoting the phenotypic switching of alveolar
epithelial cells. EMT is likely to contribute, at least in part, to the
accumulation of interstitial fibroblasts during fibrosis.
Complementary in vitro studies in alveolar epithelial cells (AECs) showed that
CTGF knockdown using siRNA suppressed TGF-β-induced mesenchymal 
cell proteins while inducing redistribution of the epithelial cell marker E-
cadherin. Immunostaining and Western blotting showed that recombinant
CTGF induced EMT-like morphological changes and expression of α-SMA in
AECs.
Finally, we were interested in whether the reduction or absence of CTGF
could abrogate fibrosis. Knockdown of CTGF suppressed the induction of
fibrotic proteins in TGF-β-treated control fibroblasts and SSc lung fibroblasts.  
Deletion of the CTGF gene showed reduced bleomycin-induced pulmonary
fibrosis in mice. Overall, these results support that CTGF plays a pivotal role
in fibrosis and blocking CTGF activity may be useful as a specific target of
attenuating fibrosis in SSc.
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Chapter 1. Introduction
1.1 Overview
A pathogenic hallmark of systemic sclerosis (SSc) is tissue fibrosis, a
process also referred to as “dysregulated wound healing” to reflect the
excessive and persistent deposition of extracellular matrix (ECM). In SSc as
well as other fibrotic disorders, treatments to control or prevent fibrosis
represent an unmet medical need. Understanding the underlying cellular
basis and molecular mechanisms of initiation and propagation of fibrosis is
crucial in the search for candidate anti-fibrotic therapies. This project focuses
on the role of connective tissue growth factor (CTGF, CCN2) a protein which
is overexpressed in SSc fibroblasts, notably in skin and lung tissue. Before
investigating the function and role of CTGF, the current understanding of
CTGF regulation and function under physiological conditions is reviewed, as
well as its significance in the process of fibrosis.
Chapter 1 provides the background to SSc, introducing its pathological
features, including vasculopathy, immune activation and inflammation, and
fibrosis, one of the disease’s most distinctive characteristics, which forms the
basis of the next section. This leads on to an overview of growth factors and
cytokines involved in mediating fibrotic responses, including a major regulator
of fibrosis, transforming growth factor- β (TGF-β), which is an inducer of 
CTGF expression. Chapter 2 describes the methods and materials used in
this project. Chapter 3 investigates an animal model of SSc involving the
overexpression of CTGF in mice, in particular looking at lung fibrosis.
Chapter 4 examines the role of CTGF in epithelial-to-mesenchymal transition
in rat lung epithelial cells to confirm and as a continuation to findings in the
animal model described in chapter 3. Some of the signalling pathways that
mediate CTGF function are explored. Chapter 5 investigates the role of
CTGF signalling in human lung tissue and fibroblasts from SSc patients.
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As each chapter deals with a particular aspect of CTGF’s role in fibrosis, a
review of the literature relevant to that chapter is provided at the beginning of
each chapter. Specific methods used to obtain the results of each chapter
are described within. The findings are discussed within the context of
published literature in chapter 6, followed by future research directions
arising from these studies in chapter 7.
1.2 Systemic sclerosis
1.2.1 What is Systemic sclerosis (scleroderma, SSc)?
Systemic sclerosis (SSc), also referred to as scleroderma, is a multi-system,
connective tissue disease with a heterogeneous spectrum of clinical
manifestations (Leroy et al., 1988). Although the exact cause of the disease
remains elusive, the pathological hallmarks of this connective tissue disease
are well known: inflammation and autoimmunity, which includes characteristic
autoantibodies (antibodies against nuclear antigens (ANA)) against various
cellular antigens; vasculopathy affecting multiple vascular beds; and
progressive interstitial and perivascular remodelling, which results in
connective tissue scarring and fibrosis (Varga and Abraham, 2007). Despite
improvements in clinical outcomes, most likely as a result of better
management of complications (such as the use of angiotensin-converting–
enzyme (ACE) inhibitors to control hypertension associated with SSc renal
crisis) (Steen and Medsger, 2007), there is currently no effective treatment
for this potentially fatal disease.
1.2.2 Disease aetiology
It is generally accepted that SSc is triggered in genetically susceptible
individuals by an environmental cue (Varga and Abraham, 2007).
Environmental causes that have been documented include exposure to a
drug, toxin, solvents, vinyl chloride, silica, and infection (Englert et al., 1999;
Reveille, 2003). Viruses such as human cytomegalovirus (CMV) have been
implicated as a potential causative agent as antibodies against human CMV
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are often detected in SSc patients (Moroncini et al., 2013). The suggestion
of a link between CMV and SSc is supported by in vivo experiments involving
CMV infection in rats, which induced expression of profibrotic factors
including transforming growth factor-β (TGF-β), platelet-derived growth factor 
(PDGF)-AA and connective tissue growth factor (CTGF, CCN2) (Jimenez
and Derk, 2004), reminiscent of the cytokine profile observed in SSc.
1.2.3 Disease subtypes
The current classification of disease subtype is based on the system reported
by Leroy et al. (Leroy et al., 1988). SSc is most commonly divided into two
major subtypes (Table 1.1) based on the degree of skin involvement: limited
cutaneous SSc (lcSSc, limited systemic sclerosis) and diffuse cutaneous SSc
(dcSSc, diffuse systemic sclerosis) (van den Hoogen et al., 2013). The
severity of skin thickening is usually defined by the modified Rodnan skin
score (Medsger, Jr., 2003). LcSSc involves skin fibrosis that is mainly
confined to the face, hands and arms. On the other hand, dcSSc is a rapidly
progressing disease where fibrosis occurs over a large area of the skin as
well as in internal organs such as the lungs, heart, kidneys, oesophagus,
gastrointestinal tract and endocrine glands, and in tendons and ligaments.
Each of these subsets are often further classified into early and late diseases.
Characteristics of inflammation have been well documented in early disease
while incidence of vascular and other organ changes have been reported
principally in late disease (Leask and Abraham, 2006; Leroy et al., 1988;
Medsger, Jr., 2003).
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Subset Clinical features
Autoimmunity and
inflammation
Vasculopathy Tissue remodelling /
fibrosis
Pre-
scleroderma
Anti-topoisomerase-1
(Scl-70), anti-
centromere (ACA),
anti-RNA polymerase-
I, II, or III
autoantibodies
Raynaud’s
phenomenon,
nailfold capillary
changes, digital
ischemia
-
Limited
cutaneous
scleroderma
ACA in 70-80% of
cases
Raynaud’s
phenomenon
(several years),
late and
significant
incidence of
pulmonary
hypertension
Skin sclerosis limited
to hands, face, feet
and forearms, skin
calcification,
gastrointestinal
disease,
telangiectasias,
interstitial lung
fibrosis
Diffuse
cutaneous
scleroderma
Anti-Scl-70 in 30% of
cases and anti-RNA
polymerase-I, II or II in
12-15% of cases;
presence of tendon
friction ribs
Skin changes
within 1 year of
Raynaud’s
phenomenon;
nailfold capillary
dilation and
capillary drop-out
Sclerosis in truncal
and peripheral skin;
early and significant
lung, myocardial,
gastrointestinal and
renal disease
Scleroderma
sine
scleroderma
Anti-Scl-70, ACA or
anti-RNA polymerase-
I, II or II may be
present
Raynaud’s
phenomenon may
be present
Lung fibrosis,
gastrointestinal
disease, or renal
crisis; no skin fibrosis
Overlap
syndromes
Features from at least two connective tissue / autoimmune
diseases e.g. systemic sclerosis, Sjögren’s syndrome, systemic
lupus erthematosis, rheumatoid arthritis, dermatomyositis,
vasculitis.
Table 1.1 Clinical subsets of SSc
The table shows major clinical subsets of SSc and the clinical features
typically observed in each subset of patients. Adapted from Medsger et al.
2003 and Black et al. 2013.
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1.2.4 Epidemiology
Results of epidemiological studies have been inconsistent, most likely due to
differences in methodology of case determination and geographic variations.
SSc is more common in women than men, although the ratio of affected
females to males varies immensely from 4:1 to 14:1 (Kahaleh et al., 1979).
Various hypotheses have been presented for the higher incidence of disease
in women. For example, the peak in disease incidence in the years following
pregnancy has led to the suggestion that SSc in women may be caused by
an anti-maternal graft-versus-host response triggered by the
immunocompetent foetus (Scaletti et al., 2002), although validation of this
proposition is required in further studies with a larger sample size. In 2006 it
was reported that 1 in 8000 of the UK population have SSc (Abraham and
Varga, 2005). The disease is potentially fatal with only 55% of dcSSc patients
surviving for 10 years after diagnosis (Mayes, 2003). Shand et al. reported
that one in three dcSSc patients will die or develop major lung, heart, or
kidney complications within 3 years (Shand et al., 2007).
Phenotypic variations observed with different races and ethnicities (Abraham
et al., 2007), suggest that genetics may contribute to the susceptibility of an
individual to SSc (Kurita et al., 2012). Increased prevalence among African-
Americans and Native Americans of the Choctaw tribe has been reported
(Harris and Rosen, 2003). A recent study suggested that increased
susceptibility and severity of SSc in African-Americans may result in part
from an imbalance of profibrotic and anti-fibrotic factors, for example, due to
differences in expression of TGF-β1 and caveolin-1, hepatocyte growth factor 
(HGF) and peroxisome proliferator-activated receptor gamma (PPAR-γ), in 
this ethnic group. Individuals with a family history of SSc and/or other
immune disorders are at higher risk of SSc than the general population
(Desmouliere et al., 2005).
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1.2.5 The genetic basis of SSc
The higher ratio of affected women compared to men, and familial clustering
of SSc (Arnett et al., 2001; Englert et al., 1999) suggests an association of
genetics with SSc. Genetic susceptibility to SSc is complex and is likely to
involve multiple genes or chromosomal loci, which have limited but additive
effects individually. Two main approaches exist to study genes associated
with disease: candidate gene studies and genome-wide association studies
(Mayes, 2012). Although genetic polymorphisms have been reported in SSc,
they seem to apply only within particular cohorts of patients and have
generally not been verified independently. Recent studies reveal that the
most compelling gene associations linked to SSc relate to genes involved in
innate and adaptive immunity (Dieudé et al., 2011) and hence are shared
with gene associations of other autoimmune diseases. Notably, the single
nucleotide polymorphisms (SNPs) conferring susceptibility to SSc are
different from those associated with systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA) (Mayes, 2012).
1.2.5.1 Candidate genes
A number of candidate gene studies have elucidated genetic factors that
increase SSc susceptibility in individuals. Candidate genes have been
selected based upon biological or experimental reasons, or their association
with other autoimmune diseases (Mayes, 2012). These include genes
involved in immune regulation and the clotting cascade such as TGF-β, 
CTGF, TNF-α, inteferon-γ (IFN-γ), angiotensin, and cytokine and chemokines 
related genes such as CCR5 (Mayes, 2012). Association of the CTGF-945
promoter polymorphism with SSc was first demonstrated in a UK cohort
(Fonseca et al., 2007) and then confirmed in a Japanese cohort (Kawaguchi
et al., 2009), which identified association of the SNP mainly with the dcSSc,
interstitial lung disease and topoisomerase I-positive subsets of patients.
Although a later North American cohort (with a lower proportion of dcSSc and
topo-positive patients), a European cohort and a Thai cohort were unable to
replicate the -945 SNP with SSc, the significance of CTGF in SSc and
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associations with particular subsets of SSc warrants further studies to resolve
these contradictory results (Dendooven et al., 2011b; Louthrenoo et al., 2011;
Rueda et al., 2009). Major drawbacks of these studies have been the
involvement of small cohorts, lack of replication and heterogeneity of SSc
(Agarwal and Reveille, 2010). The relatively modest risk posed by individual
SSc-susceptibility genes provides support that SSc is a polygenic disease
and has shifted the focus of emerging studies to gene-gene interactions and
epigenetic regulation, which are likely to pose greater risk to the development
of SSc (Agarwal and Reveille, 2010).
1.2.5.2 GWAS
Genome-wide association studies (GWAS) scan the genome for genetic
variations, or SNPs which occur more frequently in individuals with a
particular disease than in those without (Mayes, 2012). Their advantage over
candidate gene studies is that they can be used to generate novel genes and
pathways associated with a disease. As with the candidate gene approach,
a discovery cohort is used and findings are subsequently validated in a
confirmatory cohort. Studies have identified a number of loci involved in
eliciting adaptive (T cell and B cell) autoimmune responses, T-cell regulation,
and cytokine production, as SSc susceptibility genes such as PTPN22, IRF5,
STAT4, C8orf13-BLK, BANK1 and TNFSF4; many of which have also been
associated with other autoimmune fibrotic disorders including SLE and type I
diabetes (Dieudé et al., 2011).
1.2.5.3 Human leukocyte antigen
Since there is a strong association of the major histocompatibilty complex
(MHC, human leukocyte antigen, HLA) with autoimmune or inflammatory
disorders such as multiple sclerosis, type 1 diabetes, SLE, ulcerative colitis,
Crohn's disease, and RA (Fernando et al., 2008; Rioux et al., 2009), the
association of MHC alleles with SSc has been of great interest. Various
HLA haplotypes are associated with SSc overall and exclusive associations
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exist for each SSc-specific autoantibody subset (Agarwal and Reveille,
2010), such as NOTCH4 in the HLA class III (Mayes, 2012).
1.2.5.4 Epigenetics
Studying concordance in twins is a useful tool for weighing up the relative
contribution of genetic and environmental impact on disease. High
concordance rates among monozygotic twins suggest genetic factors being
major contributors while low rates are indicative of environmental factors. In
SSc, there is no significant difference in concordance rate for the disease
among identical nor non-identical twins, which had suggested a limited role of
genetics in SSc (Leroy et al., 1988). However, evidence for a genetic
predisposition for SSc is provided by a microarray study of twins which
showed that SSc patients and their monozygotic twins shared gene profiles
which were not significantly different from each other (Zhou et al., 2005).
Furthermore, twins discordant for SSc simultaneously show higher
concordance for SSc-associated autoantibodies (also higher in monozygotic
than dizygotic twins) (Leroy et al., 1988) as well as fibroblast gene
expression profiles, which suggests that environmental factors play a role,
and that these act through epigenetic regulation, such as DNA methylation,
histone acetylation and microRNA (miRNA) regulation.
Emerging links have been reported between dysregulated miRNA expression
and autoimmune diseases, including SSc (Dai and Ahmed, 2011). Recent
studies have implicated miR-29 (Maurer et al., 2010; Peng et al., 2012), miR-
7 (Etoh et al., 2013) and miR-196a (Honda et al., 2012) as important
regulators of collagen expression, which are downregulated in SSc and
bleomycin-induced mouse dermal fibroblasts by factors such as TGF-β, 
PDGF and IL-4. MiR-29 is associated with cardiac, lung and liver fibrosis,
and is also downregulated in SSc skin sections and serum (Peng et al.,
2012). A recent study by Selmi et al. suggested that susceptibility to SSc
may be attributed to differential methylation patterns on certain X
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chromosome genes, as found in peripheral blood monocytes, which may
account for the predominance of SSc in females and the low concordance in
the disease between twins (Selmi et al., 2012).
1.2.5.5 Gene expression profiling in SSc
Gene profiling has revealed distinct expression profiles in SSc (Table 1.2). In
contrast to gene expression profiling of explanted fibroblasts in culture, direct
profiling of SSc patient tissue samples, which contains a variety of cell types,
identified a larger set of gene changes compared to normal tissue, and with
less variability between samples (Gardner et al., 2006). This suggests that
full expression of the SSc phenotype is likely to be dependent on other cell
types in addition to fibroblasts, or other properties of the tissue.
The presence of a heterogeneous population of fibroblasts in SSc may
explain the distinct gene expression patterns observed between control
fibroblasts and SSc fibroblasts from anatomically-matched sites, including the
skin (Bhattacharyya et al., 2011; Chen et al., 2005; Gardner et al., 2006;
Leask et al., 2002; Shi-Wen et al., 2000; Whitfield et al., 2003), and lung (Hsu
et al., 2011; Renzoni et al., 2004), and also in peripheral blood cells (Tan et
al., 2006). Perhaps predictably for such a heterogeneous disease, there
appears to be considerable variation in the expression profiles of individual
genes. However, these variations can usually be grouped into genes that are
implicated in proliferation, inflammation or fibrosis (Sargent et al., 2008).
Gene changes could be grouped based on these SSc phenotypes,
independent of the anatomical site of origin of the skin (Gardner et al., 2006).
Genes which are dysregulated in SSc patients include TGF-β, ECM proteins, 
Wnt signalling proteins and CCN proteins such as CTGF.  A TGF-β-
responsive gene signature, which correlates with disease severity has been
documented in a subset of dcSSc patients (Sargent et al., 2010).
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Functional cohorts Genes differentially expressed in SSc
ECM modulators EGR-1, TIMP-1 and 3; collagen I, IV, V, VI, VII, VIII, X,
and XV; syndecan 2, 3, and 4; lumican;
thrombospondin; lysyl oxidase; COMP; PAI-1 and 2;
gamma-sarcoglycan;  ﬁbronectin; osteonectin; HSP47; 
ADAM 19; nidogen;  LTBP-1 and 2; PLOD-2; ﬁbrillin; 
decorin; ﬁbulin; biglycan; versican.  
Pro-contractile factors Integrin α7, β3, αV, α5, actin α2, α-cardiac actinin- α1. 
Cytoskeletal molecules Paxillin, vinculin, smoothelin, tenascin, tropomyosin,
OB-cadherin.
Cell surface receptors Endoglin, ICAM-1.
Cytokines, growth
factors and receptors
CTGF, Cyr-61, IGF-1, IGFBP 3 and 6, BMP-1, activin-
A receptor, BMP-10, PPAR-γ, TGF-β2, FGF-7, SDF-1.
Table 1.2 Differentially expressed genes in SSc.
Genes which are differentially expressed in SSc are grouped into various
functional cohorts. Table modified from Abraham et al. (Abraham et al., 2007)
with data adapted from Renzoni et al. (Renzoni et al., 2004), Shi-wen et al.
(Shi-Wen et al., 2000), Leask et al. (Leask et al., 2002), Whitﬁeld et al.
(Whitfield et al., 2003), Chen et al. (Chen et al., 2005), Gardner et al. (Gardner
et al., 2006), and Bhattacharyya et al. (Bhattacharyya et al., 2011). EGR-1,
epidermal growth factor; TIMP-1, tissue inhibitor of metalloproteinase; COMP,
cartilage oligomeric matrix protein; PAI, plasminogen activator inhibitor; ADAM,
a disintegrin and metalloproteinase; LTBP, latent TGF-β-binding protein; 
PLOD, procollagen-lysine, 2-oxoglutarate 5-dioxygenase; ICAM, intracellular
adhesion molecule; Cyr61, cysteine-rich protein 61, CCN1; IGF, insulin growth
factor; IGFBP, IGF-binding protein; BMP, bone morphogenetic protein; PPAR,
peroxisome proliferator activated receptor; FGF, fibroblast growth factor; SDF,
stromal cell-derived factor.
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Controversially, a recent study by Pendergrass et al. suggested that the gene
expression profiles of patients are fixed over time, rather than changing from
an inflammatory profile to a fibroproliferative one later (Pendergrass et al.,
2012). The authors reported that the morphea, lcSSc and a small proportion
of the dcSSc patients express an inflammatory profile while most of the
dcSSc patients express a fibrotic profile, and that these patients remain with
these profiles (Pendergrass et al., 2012). In any case, being able to
distinguish between patient subsets based on unique gene expression
signatures may be useful clinically, for example in determining the
fibroproliferative subset to be treated with anti-fibrotic agents.
1.2.6 Pathological features of SSc
In the sequence of events in SSc pathogenesis, damage to the vasculature
precedes fibrosis. In almost all organs, large gaps appear between the
endothelial cells and integrity of the endothelial lining is lost. Immune cells
infiltrate the tissue, causing inflammation. This vascular inflammatory stage
is progressively replaced by fibrosis (Pannu and Trojanowska, 2004).
Excessive scarring leading to fibrosis is considered the most distinctive
pathological feature of SSc and is particularly prominent in dcSSc (Pannu
and Trojanowska, 2004). Indeed, organ damage due to fibrosis contributes
to much of the morbidity and mortality related to SSc (Varga and Abraham,
2007).
Microvascular injury and damage lead to vascular remodelling. Integrity of
the endothelial cell layer becomes compromised along with increased
capillary permeability, elevated expression of vascular cell adhesion protein-1
(VCAM-1) and endothelial leukocyte adhesion molecule 1, secretion of
vasoactive mediators such as the vasoconstrictor endothelin-1 (ET-1), and
activation of platelets and fibrinolytic pathways. ET-1, which is increased in
the blood and in bronchoalveolar lavage fluids of SSc patients, also promotes
leukocyte adhesion to the endothelium, vascular smooth muscle cell (vSMC)
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proliferation and fibroblast activation (Bhattacharyya et al., 2012; Lakota et al.,
2012; Wei et al., 2012). These changes facilitate infiltration of immune cells
from the blood into the sites of injury.
1.2.6.1 Immune activation and inflammation
The innate and the adaptive immune systems both play a part in the
pathogenesis of SSc (Abraham and Varga, 2005). In early stage SSc lesions
and peripheral blood, leukocytes are activated, and there is perivascular
infiltration, mainly of activated mononuclear cells (expressing CD45, HLA-DR,
and the interleukin (IL)-2 receptor), which secrete fibrogenic cytokines and
chemokines. T-cells infiltrating into SSc skin lesions have limited receptor
specificities indicative of oligoclonal expansion of T cells and antigen-driven
T-cell proliferation (O'Reilly et al., 2012; Sakkas et al., 2002). Peripheral
blood leukocytes from SSc patients show increased expression of the
transcription factor GATA3, which drives differentiation of T helper (Th) cells
towards the Th2 subtype (Tan et al., 2006). Mature (CD4+) Th cells isolated
from SSc skin express a Th2 cytokine profile, releasing IL-4, IL-5, and IL-13
but not the prototypical Th1 cytokine, IFN-γ (Mavalia et al., 1997; Wynn,
2004). Furthermore, alveolar CD8+ cells express higher levels of Th2
cytokines, and Th2 predominance correlates with decline in lung function.
SSc bronchoalveolar lavage fluids also show a primarily Th2 cytokine profile
(Rottoli et al., 2005). The predominance of a Th2 profile is perhaps not
surprising as Th2 cells have been shown to induce fibrosis when passively
transferred in mice (Wangoo et al., 2001), and deletion of the T-bet gene, a
Th1-specific transcription factor, increased sensitivity to bleomycin-induced
skin fibrosis in mice (Lakos et al., 2006).
Specific autoantibodies are present in the serum of most SSc patients, and
are associated with individual disease phenotypes (Nihtyanova and Denton,
2010), and levels correlate with disease activity (Hu et al., 2003). There are
three main classes of autoantibodies associated with SSc, anti-
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topoisomerase I (anti-Scl-70), anti-centromere (ACA), and anti-RNA
polymerase antibodies (Bunn et al., 1998; Falkner et al., 1998; Kuwana et al.,
1994) (Table 1.3). Molecular mimicry, chronic B-cell hyperactivity, and
elevated expression or altered subcellular localisation of autoantigens
contribute to autoantibody production (Harris and Rosen, 2003). As well as
being markers of disease, these autoantibodies may also have pathogenic
roles in SSc, as antibodies specifically against fibroblasts, endothelial cells,
and PDGF receptors may directly activate these cell types to express
adhesion molecules or collagen, leading to tissue damage (Baroni et al.,
2006; Carvalho et al., 1996; Henault et al., 2006).
B lymphocytes in SSc skin (Whitfield et al., 2003) and blood (Sato et al.,
2004) show increased expression of activation genes, such as CD95 and
CD19, although fewer B-cells are present overall in the blood. Altered B-cell
function in SSc might account not only for autoantibody production but also
for fibrosis, since activated B-cells secrete IL-6, which directly stimulates
fibroblasts (Hasegawa et al., 2006). Patients with SSc also have elevated
levels of B-cell–activating factor (BAFF) in the serum and in lesional skin, and
BAFF receptor in B-cells (Matsushita et al., 2006).
1.2.6.2 Tissue remodelling, scarring and fibrosis
As SSc progresses, vasculopathy, immune activation and inflammation
develops into fibrosis and tissue remodelling. While skin fibrosis is the most
prominent feature of SSc, fibrosis also occurs in other organs including the
lungs, kidney and gastrointestinal tract. The fibrosis aspect of SSc, including
a distinctive fibroblast phenotype associated with SSc, and profibrotic factors
are discussed in section 1.3.
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Type of autoantibody Association with clinical phenotype
Anti-centromere
(ACA)
LcSSc; PAH without pulmonary fibrosis; gastrointestinal
involvement; primary bilary cirrhosis
Anti-topoisomerase-1
(ATA)
DcSSc; pulmonary fibrosis; severe digital vasculopathy
Anti-RNA polymerase
III (ARA)
DcSSc; renal crisis
Anti-fibrillarin (AFA) /
U3RNP
DcSSc; severe disease; PAH; muscle involvement
(myositis)
Anti-PM-Scl Myositis
Anti-Th/To LcSSc with respiratory involvement
Anti-U1-RNP Renal crisis, PAH
Table 1.3 Autoantibodies in SSc
Specific autoantibodies are associated with the various subtypes,
pathological features and genetic polymorphisms in SSc. Anti-U3RNP, anti-
U3 ribonucleoprotein; anti-PM-Scl, anti-polymyositis-scleroderma; anti-Th/To,
anti-Th (RNase for mitochondrial RNA processing (MRP) or 7-2 RNA)
ribonucleoprotein / anti-To (RNase P or 8-2 RNA) ribonucleoprotein. Table
modified from review by Nihtyanova and Denton 2010.
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1.2.7 Current and emerging treatments for SSc
A universal disease-modifying drug is currently unavailable for SSc and only
a handful of therapies offer modest improvements (Kowal-Bielecka et al.,
2013). Due to the clinical heterogeneity of SSc, an organ-targeted approach
is used; treatment is administered based on the specific organ involvement
present, as recommended by the European League Against Rheumatism
(EULAR) (Kowal-Bielecka et al., 2009). Current treatments mainly fall into
one of the following categories: immunomodulatory therapies such as
cyclophosphamide; agents promoting vascular repair such as endothelin
receptor antagonists, phosphodiesterase-5 inhibitors and prostacyclin
analogues, and tyrosine kinase inhibitors such as imatinib mesylate (Ong and
Denton, 2010).
There is a risk that broad-range immunosuppressors, which have been
effective in treating other autoimmune diseases, remove the anti-fibrotic
properties of the immune system, which can intensify fibrosis (Leask, 2012a).
For example, although tumour necrosis factor-α (TNF-α) and prostacyclins 
are essential for the inflammatory stages immediately before the
development of fibrosis in SSc (McCann et al., 2011; Oga et al., 2009;
Oikonomou et al., 2006; Ortiz et al., 1999; Sudo et al., 2005), and for
bleomycin-induced fibrosis, they can also be anti-fibrotic agents in the
context of later stages of fibrosis, acting as repressors of collagen and CTGF
expression (Abraham et al., 2000; Stratton and Shiwen, 2010). Furthermore,
synthetic prostacyclins have been shown to attenuate the SSc vascular
phenotype in in vivo and in vitro studies (Dackor et al., 2011; Stratton and
Shiwen, 2010; Walker et al., 2012; Zhu et al., 2010). These observations
suggest that TNF-α antagonists may be more effective restricted to patients 
in the inflammatory stage, and blocking against the inflammatory response
should be specific to avoid unwanted side effects. The association of patient
subsets to particular classes of autoantibodies (Nihtyanova and Denton,
2010) and other biomarkers (Moinzadeh et al., 2012) may also be valuable
for the customised therapy approach. Therapies already approved for clinical
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use against rheumatic or other diseases with related clinical features are of
interest for treating SSc.
Emerging treatments also include stem cell transplantation as an alternative
method to traditional immunosuppression, as well as the use of biological
therapies such as TNF-inhibitors such as infliximab, B cell-targeting agents
such as anti-CD20 antibody, rituximab, and therapies targeting TG-β 
signalling (Kowal-Bielecka et al., 2013). Surgery such as lung transplantation
for patients with end-stage pulmonary fibrosis, and cell-based therapies are
also available but not routinely performed, perhaps due to the absence of any
randomised controlled trials on this treatment (Ong and Denton, 2010). The
shortage of donors for transplantation means this is unlikely to become a
major therapeutic option. In terms of cell-based therapy, stem cell and
alveolar type II cell transplantation is possible as mesenchymal stem cells
can enhance lung repair while the patient’s own alveolar cells would avoid
host-graft rejection.
While there is a consensus in the use of an angiotensin-converting enzyme
inhibitor (ACEi) as first line treatment for SSc-renal crisis, second and third
line treatments for complications of SSc used by health professionals are
more varied, especially when there is a lack of clinical trial evidence for those
treatments (Walker and Pope, 2012). Clinical data is available for a number
of anti-fibrotic therapies in SSc (Table 1.4), and preclinical studies have been
conducted on other putative candidate therapeutic compounds such as
inhibitors against IL-4, IL-13, IL-33 and canonical Wnt signalling (Beyer et al.,
2012). Clinical trials have implicated tyrosine kinase molecules as potential
therapeutic targets, particularly in the fibrotic stage of disease.
Cyclophosphamide is routinely used to delay the progression of lung fibrosis
in the early inflammatory stage and severe skin disease in SSc patients
although the efficacy of this cytotoxic drug remains controversial (Hoyles et
al., 2006; Kowal-Bielecka et al., 2005; Tashkin et al., 2007).
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1.2.8 Animal models of SSc
A variety of animal models have been developed to date for the experimental
study of SSc, which may be categorised into spontaneous models, induced
models, and genetically modified models (Artlett, 2010; Beyer et al., 2010;
Derrett-Smith et al., 2009; Varga and Abraham, 2007). Each model is able to
recapitulate various components of the disease but none replicate all of its
features (Table 1.5). The models are therefore useful for studying specific
features such as autoimmunity, inflammation, vasculopathy, or fibrosis.
1.2.8.1 Naturally occurring models
Two naturally occurring models of SSc exist. Homozygous tight skin
(Tsk1/Tsk1) mice are embryonic lethal while the heterozygous (Tsk1/+) mice
are characterized by diffuse thickening and tight skin tethered to the
subcutaneous layer but do not show dermal thickening characteristic of SSc
skin, nor pulmonary fibrosis and vasculopathy (Baxter et al., 2005). The
Tsk1 genotype involves a mutation in fibrillin-1, a gene which regulates TGF-
β bioavailability, implicating that the Tsk1 mouse phenotype can be attributed
to dysregulated and enhanced TGF-β activation and profibrotic signalling 
(Kielty et al., 1998).
The UCD-200/206 chicken model can be considered a model which most
closely resembles the condition in human SSc based on the range of disease
features which are present, including the altered ratio of TGF-β1 (profibrotic) 
and TGF-β2 and -3 (anti-fibrotic) isoforms.  However, mammalian animal 
models may be more relevant (Sgonc and Wick, 2008).
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Drugs and compounds Mechanism of action and other comments
Targeting inflammatory signalling pathways
Rituximab B-cell depletion; used to successfully treat patients
non-responsive to cyclophosphamide and
prednisolone
Mycophenolate mofetil Inhibits inosine monophosphate dehydrogenase in
purine (adenosine and guanine nucleotides)
synthesis, leading to inhibition of lymphocyte
proliferation and antibody production cytostatic effects
on T and B-cells; well tolerated in patients
Imatinib, dasatinib,
nilotinib
Tyrosine kinase inhibitors; well tolerated in patients
Methylprednisolone Used in combination with cyclophosphamide
Cyclophosphamide Most common in treating SSc-ILD; recommended by
EULAR and EUSTAR
Tocilizumab Blocks IL-6 receptor
Targeting profibrotic factors
CAT-192 Antibodies neutralising TGF-β1 
Thiazolidinediones Agonists of PPAR-γ 
Terguride Blocks 5-HT2b
Targeting epigenetic regulators
Trichostatin A, selective
HDAC inhibitors
Inhibits histone deactylase
5-Aza-2-deoxycytidine Inhibits DNA methyltransferase
Targeting morphogenic pathways
Smo antagonists Inhibits Hedgehog signalling
γ-secretase inhibitors Inhibits Notch signalling
Table 1.4 Drug treatments for SSc
Drug treatments currently in use or being tested in experimental, pre-clinical
or clinical trials, and the mechanism of action of these agents. ILD, interstitial
lung disease; EULAR, European League Against Rheumatism; EUSTAR,
EULAR scleroderma trials and research. Adapted from (Beyer et al., 2012).
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1.2.8.2 Induced models
Bleomycin, an antibiotic used in cancer treatment, can be used to induce skin
or pulmonary fibrosis by injection subcutaneously or into the lung,
respectively, presenting a very similar series of changes observed in SSc
(Nakao et al., 1999; Yamamoto et al., 1999). These include accumulation of
early mononuclear cells, induction of TGF-β expression, chemokine 
expression as well as fibrosis with increase in α-SMA–expressing 
myofibroblasts (Ferreira et al., 2006; Lakos et al., 2004; Takagawa et al.,
2003). Transplantation of MHC-mismatched bone marrow (BM) or spleen
cells into sublethally irradiated recipient mice provides another induced
model of SSc presenting a phenotype similar to chronic graft-versus-host
disease including skin and lung fibrosis, and autoimmunity (Ruzek et al.,
2004).
1.2.8.3 Genetically modified models
The growing number of genetically modified models highlights transgenic
models as powerful tools in SSc research (Del and Matucci-Cerinic, 2014;
Derrett-Smith et al., 2009).   Postnatal deletion of genes such as TGF-β and 
CTGF can be lethal, and hence the use of heterozygotes or development of
inducible transgenic models have been useful for studying alterations of gene
expression in adult animals, which may provide more accurate
representations of human SSc. Transgenic and knockout animals designed
with conditional or cell-specific regulation can be used alone or in
combination with experimental injury, to study the contribution of individual
factors in disease pathogenesis. Transgenic models developed include mice
deficient in the relaxin (Samuel et al., 2005), caveolin (Razani et al., 2001),
Thy-1 (Hagood et al., 2005), or Friend leukemia integration-1 (Fli-1) (Kubo et
al., 2003) genes, and transgenic mice expressing a mutant TGF-β receptor 
type II (TGFBRII) in fibroblasts (Derrett-Smith et al., 2010), which present
various fibrotic or vascular components of SSc or show greater sensitivity to
bleomycin-induced fibrosis. Fli-1 is downregulated in SSc and is associated
with elevated CTGF and decreased MMP1, which may be a result of TGF-β-
Introduction | 36
induced acetylation and degradation of Fli1 (Smith and Chan, 2010). A
transgenic model over-expressing CTGF specifically in fibroblasts
recapitulates the fibrotic features of SSc including fibrosis in the skin, lung
and kidney (Sonnylal et al., 2010).
1.3 Fibrosis – “dysregulated wound healing”
1.3.1 Wound healing
Wound healing consists of an intricate program of repair following tissue
injury, and has been most studied in the context of the skin (Singer and Clark,
1999). The wound healing responses in the skin are representative of those
that occur in other organs, and involve a number of overlapping stages, from
inflammation to development of granulation tissue and re-epithelialisation,
followed by matrix formation and remodelling (Stuart et al., 2006).
Several cell types, including fibroblasts, keratinocytes, endothelial cells,
macrophages and platelets, cooperate to orchestrate the wound healing
response (Gailit and Clark, 1994). Wound healing is tightly regulated by a
network of growth factors and cytokines, which are essential for achieving the
desired end-point of wound closure (Figure 1.1). A dysregulated, persistent
wound healing response is often considered to lead to the initiation of fibrosis.
Upon injury to the skin, the epidermal barrier is compromised, inducing
keratinocytes to release the pro-inflammatory cytokine IL-1. IL-1 provides the
initial signal to adjacent cells of the epidermal barrier damage, and attracts
neutrophils to the site of injury. Haemostasis is initiated as components of
the blood infiltrate the wound site and the clotting cascade is activated,
providing a matrix (including fibrin, fibronectin, vitronectin and
thrombospondin) for the entry of inflammatory cells as well as a barrier to the
external environment (Singer and Clark, 1999). Platelets de-granulate and
secrete growth factors such as epidermal growth factor (EGF), PDGF, TGF-β,  
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Disease /
Model
Pathological features CTGF Notes & References
Autoimmunity Inflammation Vasculopathy Fibrosis
Human SSc + + + + ↑ Fibrosis can be widespread in skin, 
lung, kidney and heart (Leroy et al.,
1988)
Naturally occurring
Tsk1/+ + - - + ↑ Skin thickening (Baxter et al., 2005)
Tsk2 + + - + ? (Christner et al., 1995)
UCD-200/206 + + + + ? Non-mammalian (chicken) model;
hereditary systemic scleroderma-like
CTD; severe lymphocytic infiltration;
excessive collagen deposition in skin
and internal organs (Sgonc et al., 1995)
Experimental injury
Bleomycin - + - + ↑ Subcutaneous injection of bleomycin 
induces fibrosis in skin, lungs, and
kidneys (Yamamoto et al., 1999)
GVHD I - + + + ? Presence of cutaneous immune cells;
collagen type I and TGF-β expression 
(Jaffee BD and Claman, 1983)
GVHD II + + + + ? (Ruzek et al., 2004)
Genetically modified
TβRII∆k-fib, 
DNR
- + + + ↑ Kinase-deficient TβRII gene in 
fibroblasts; fibrosis in skin and lungs;
vasculopathy in lungs, large elastic
arteries (Denton et al., 2003)
TBRICA Cre-
ER
- + + + ? Conditional fibroblast-specific expression
of TGFBRI postnatally; fibrosis in the
skin, small vessels, abnormal lung and
renal smooth muscle and endothelial
cells (Sonnylal et al., 2007)
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TβRII-null-fib ↓ ↓ Conditional fibroblast-specific deletion of 
TβRII, neonatal lethal; normal wound 
healing disrupted, failure of
myofibroblast differentiation
(Denton et al., 2009; Hoyles et al., 2011)
Col1A2-
CTGF
- - + + ↑ Skin, lung and kidney fibrosis (Sonnylal et
al., 2010)
Gsk3b-CKO - - - + ? Gsk3b-conditional-KO mice; accelerated
wound closure, fibrogenesis; elevated
collagen, α-SMA, and ET-1; decreased 
cell apoptosis; increased myofibroblast
formation during wound healing (Kapoor
et al., 2008)
Cav1-null - - + + ? Increased TGF-β signalling, lung fibrosis
(Razani et al., 2001)
Fra-2 - + + + ? Fibrosis and inflammation in lung,
vasculopathy in lung and skin (Eferl et al.,
2008; Maurer et al., 2009)
Relaxin-null - - - + ? Skin, lung, kidney, heart fibrosis (Samuel et
al., 2005)
Thy-1-null + - - + (Hagood et al., 2005)
Fli-1-null - - - (+)* ? Collagen increased due to lack of collagen
expression repressor, Fli-1; *enhanced
fibrosis in Fli-1-null bleomycin vs
WT+bleomycin (Kubo et al., 2003)
Table 1.5 Animal models of SSc
Examples of naturally occurring, induced and genetically modified mouse models and the pathological features of SSc in
humans that each model recapitulates. The “CTGF” column indicates tissue expression of CTGF in the animals: increased
(↑) or decreased (↓) compared to wildtype, or unknown (?).  + denotes a feature of SSc that has been identified in the 
model. CTD, connective tissue disease.
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and VEGF which attract neutrophils (Hantash et al., 2008; Kubota et al., 2004;
Liu et al., 2003; Singer and Clark, 1999).
TGF-β stimulates differentiation of macrophages, which help to mediate the 
inflammatory response and tissue debridement. Macrophages initiate the
formation of granulation tissue and release pro-inflmammatory cytokines (IL-
1 and Il-6), and growth factors (FGF, EGF, TGF-β, PDGF). VEGF and FGF 
stimulate endothelial cell proliferation and angiogenesis, which allows for the
subsequent ECM synthesis, deposition and organisation (Singer and Clark,
1999).  FGF, TGF-β and PDGF facilitate fibroblasts, and other cell types 
such as fibrocytes and pericytes, to migrate into the site of injury while TGF-β 
and PDGF also induce differentiation of these cells into myofibroblasts, which
align along the boundaries of the ECM via adhesion to the collagen and
fibronectin-filled matrix to form a contractile force, promoting wound closure
(Abe et al., 2001; Hantash et al., 2008; Singer and Clark, 1999).
Re-epithelialisation occurs within hours of injury with the release of EGF,
FGF and TGF-β promoting epithelial cell migration and proliferation.  This 
involves firstly, disruption of the cell-cell and cell-substratum contacts, and
secondly, polarisation and migration of keratinocytes over the interim ECM.
Thirdly, on complete wound closure (epithelialisation), keratinocytes stratify
and differentiate to restore the barrier. Matrix turnover is mediated by the
balance of proteolytic enzymes, matrix metalloproteinases (MMPs), and
endogenous repressors of MMP activity, tissue inhibitors of
metalloproteinases (TIMPs) (Brew et al., 2000; Visse and Nagase, 2003).
Removal of granulation tissue and re-vascularisation is necessary for matrix
formation. Collagen and elastin fibres replace the granulation tissue, and the
matrix is filled with proteoglycans and glycoproteins. Tissue remodelling is
mediated by TGF-β-induced collagen synthesis and the degradation of old 
collagen by PDGF-BB-induced interstitial collagenase (Tan et al., 1995).
Endothelial cells and myofibroblasts undergo apoptosis, finally resulting in
formation of acellular, collagen-rich scar tissue (Clark, 1988), which is notably
Figure 1.1 Phases of acute wound healing.
The stages of normal wound healing
inflammation, matrix deposition and matrix remodelling returns to baseline
levels of response as the wound resolves.
over time. The processes of
Adapted from Enoch et al. 2006.Introduction | 40
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weaker than the original un-injured skin (Martin, 1997). In contrast to this
process in postnatal skin, embryonic wound healing, and repair conducted by
gingival fibroblasts in the oral mucosa, result in resolution of wounds without
scars (Martin, 1997; Schor et al., 1996).
1.3.2 The extracellular matrix (ECM) and fibrosis
The ECM is a meshwork of proteins and sugars, which surrounds cells in
solid tissues (Cox and Erler, 2011). ECM components can be divided into two
classes: fibre-forming and non-fibre-forming (interfibrillar) (Järveläinen et al.,
2009). The four major fibre forming proteins in the ECM are collagens,
fibrillins, fibronectins, and elastin. Mostly proteoglycans and other
glycoproteins such as laminin and entactin, constitute the interfibrillar
components. These macromolecules are mainly synthesized and secreted
by cells residing within the ECM, namely fibroblasts (Varga and Abraham,
2007). As well as providing structural support for the cells it surrounds, the
ECM also acts as a reservoir for growth factors such as TGF-β and 
matricellular proteins – a group of proteins which mediate cell-matrix
interactions or cell functions rather than providing a structural function - such
as secreted protein acidic and rich in cysteine (SPARC), thrombospondin-1
and -2, osteopontin, and cartilage oligomeric matrix protein (COMP), and
CTGF (CCN2) (Bornstein and Sage, 2002; Kyriakides and Bornstein, 2003;
Varga and Abraham, 2007). The balance of growth factors and cytokines, as
well as cell-cell and cell-ECM contact inhibition, and hypoxia means ECM
gene expression is normally tightly regulated (Distler et al., 2007; Ramirez et
al., 2006).
New ECM may be deposited during wound healing, when fibroblasts migrate
into the wound to initiate the proliferative phase. The newly synthesised
matrix is cross-linked and organized during the final remodelling phase. In
contrast to this efficient and tightly regulated repair process, fibrosis is
characterised by excessive deposition of abnormal, collagen-rich ECM and
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reduced remodelling, leading to progressive replacement of tissue structure,
which disrupts the function of the affected organs (Varga and Abraham,
2007). As the most abundant collagen produced by fibroblasts, collagen
type I is the main type of collagen found in scar tissue (Sgonc and Wick,
2008). In SSc, there is increased expression of the major fibrillar, collagens
type I and III, as well as collagens type V and VII, which are usually
expressed only in the dermal-epidermal junction, and collagen type XI.,
normally found in bone and cartilage (Hinz et al., 2012).
The current theories of fibrogenesis suggest a cascade of events which are
analogous to those in wound healing. Fibrosis may occur as a result of many
different pathological conditions, for example, after tissue damage such as
burns, after inflammatory conditions such as infections and connective tissue
diseases such as SSc (see section 1.2), around artificial body implants, in
tumours such as neurofibromatosis, or even spontaneously such as in
keloids (Denton et al., 2006). While reduced degradation and turnover of the
ECM is partially accountable for the accumulation of ECM, the
overproduction of matrix plays a major role in this process (Korn, 2004),
which is facilitated by expansion of the fibroblast pool.
1.3.3 Fibroblasts in fibrosis and SSc
As key players in fibrosis, fibroblasts are dynamic, connective tissue cells
responsible for the synthesis of interstitial collagens, fibronectins and other
matrix components (Abraham et al., 2007; Klingberg et al., 2013). In normal
tissue repair, fibroblasts are tightly regulated while in fibrosis, there is
persistent and amplified fibroblast activation (Klingberg et al., 2013).
Fibroblasts may be activated from their relatively quiescent state, slowly
turning over the ECM, to undergo proliferation and differentiation into
myofibroblasts - α-smooth muscle actin (α-SMA)-positive cells specialised for 
contractile functions during wound closure and tissue contraction (Varga and
Abraham, 2007). The activated fibroblasts secrete ECM components (Table
1.6) such as collagens for adhesion, contraction and remodelling of
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connective tissue, and also release growth factors and cytokines (Klingberg
et al., 2013).
1.3.3.1 Activated fibroblasts
Fibroblasts can be activated by soluble growth factors and cytokines
released by platelets, endothelial cells, epithelial cells, and inflammatory cells
such as FGF (-1, -2, -4, -5, -6), CTGF, PDGF and TGF-β in autocrine and 
paracrine fashions (Abraham et al., 2007; Willis et al., 2006; Yun et al., 2010).
The constitutive fibrotic phenotype of SSc fibroblasts may also be attributed
to aberrant expression or activity of intracellular signalling molecules and
pathways intrinsic to SSc fibroblasts (Table 1.7) such as altered integrin
(integrin αvβ5 and αvβ3) signalling from the adjacent ECM (Eckes et al., 2006;
Hoyles et al., 2011). Additionally, the activated phenotype of SSc fibroblasts
may reflect the epigenetic modulation such as histone acetylation (increased
acetylation and decreased inhibition by histone deacetylation enzymes), DNA
methylation, and downregulation of miRNAs (De Santis and Selmi, 2012;
Dieudé et al., 2011; Wang et al., 2006). Examples include the transcriptional
silencing of FLI1 and SMAD7, leading to derepression of profibrotic factors
(Wang et al., 2006). Inhibition of histone deacetylase (e.g. using trichostatin
A) has been shown to increase acetylation of certain proteins (e.g. Sp1),
which leads to attenuation of TGF-β-induced fibrotic responses such as 
collagen expression in skin fibroblasts (Guo et al., 2009) and epithelial-to-
mesenchymal transition (EMT) in hepatocytes (Kaimori, 2010). These
findings may be applied to SSc, suggesting that epigenetic modulators are
potential therapeutic targets. A recent study implicated downregulation of
miR-7 in the skin and serum as a contributor to the pathogenesis of lcSSc via
the overexpression of collagen type I (α2 chain) (Etoh et al., 2013).
It is noteworthy that fibroblasts from different locations of the body show
different gene expression profiles (Chang et al., 2002), which may contribute
to the abnormal fibroblast activation and fibrosis. This is consistent with a
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Components Distribution and function
Collagens
I Fibrillar; structural role in all tissues e.g. dermis, bone, vessel
walls, except cartilage
III Fibrillar; principal collagen type in granulation tissue, muscles,
artery wall; produced by fibroblasts before collagen type I
V Fibrillar; Structural role in basement membranes; interactions
with collagen type I; inhibits endothelial cell adhesion and
proliferation
IV Non-fibrillar; structural role in basement membrane; angiogenesis
VIII Non-fibrillar; structural role in ECM e.g. sclera, vasculature;
stabilisation of membranes; angiogenesis; interaction with ECM
molecules
VI An association type of collagen; structural role in connective
tissue e.g. in vessels, liver and muscle
XVIII A multiplexin type of collagen; structural role in basement
membrane; inhibition of angiogenesis and tumour growth
Microfibrillar proteins
Fibrillin-1 Principal component of microfibrils together with fibrillin-2;
structural support; tissue homeostasis
Proteoglycans and glycoasminoglycans
Hyaluronan Major structural carbohydrate component in ECM; angiogenesis;
cell migration; wound healing, cell adhesion
Versican Structural support in ECM e.g. blood vessels; cell adhesion and
migration
Lumican Structural role in e.g. cornea
PG-100 Proteoglycan form of colony-stimulating-factor-1
Non-collagenous ECM glycoproteins
Fibronectin Cell adhesion, fibril and ECM formation; tissue injury and
inflammatory response; modulation of vascular morphogenesis
e.g. angiogenesis
Tenascins Cell adhesion, migration and growth; wound healing;
neovascularisation
Thromobospondins Cell migration; platelet aggregation; inflammation; wound healing
Table 1.6 ECM components implicated in fibrosis
Table adapted from a review by Järveläinen et al. (Järveläinen et al., 2009).
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recent study showing differential expression of profibrotic factors in dermal
fibroblasts from the face and those from the torso (Kurita et al., 2012). In
contrast to normal wound healing, where myofibroblasts are present only
transiently in the granulation tissue before elimination by apoptosis, the pool
of ECM-producing cells is expanded (section 1.3.4) and myofibroblasts
persist in pathological fibrogenesis leading to excessively contracted ECM
(Desmouliere et al., 2005).
1.3.3.2 Termination of tissue repair
Endogenous mechanisms to downregulate the fibrotic response may be
suppressed in SSc.  The Th1 cytokine IFN-γ inhibits collagen expression, 
TGF-β signalling, fibroblast proliferation, ECM contraction and myofibroblast 
differentiation (Ghosh et al., 2001; Jimenez et al., 1984; Pannu and
Trojanowska, 2004). Myofibroblasts expressing ED-A fibronectin – a cofactor
for TGF-β-induced myofibroblast transdifferentiation – and Thy-1 are present 
in SSc but not normal skin (Jelaska et al., 1996; Rajkumar et al., 2005). In
early stage SSc, pericytes are activated and express receptors for PDGF and
Thy-1, which is characteristic of wound healing (Rajkumar et al., 2005). IFN-γ 
was shown to attenuate fibrotic responses in vivo and in vitro (Varga, 1997).
Also, IL-10 may act alone or together with IFN-γ, as a repressor of fibrosis in 
SSc (Arai et al., 2000). Phosphatase and tensin homolog (PTEN), which
promotes tissue repair via dephosphorylation of phosphatidyl-inositol,3,4,5
triphosphate (PI3K) and subsequent activation of v-Akt murine thymoma viral
oncogene (AKT, protein kinase B), is downregulated in SSc dermal
fibroblasts. Hence, loss of PTEN has been associated with development of
skin fibrosis and indeed, selective inhibition of the PI3K/AKT pathway
restored normal levels of collagen and CTGF by PTEN-deficient fibroblasts
(Parapuram et al., 2011). This is consistent with in vivo data showing that
PTEN-deficiency in mice results in sustained fibroproliferation.
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The downregulation or reduced function of repressors of collagen synthesis
such as the transcription factors SP3, Fli-1, p53, RAS, and the nuclear
hormone receptor PPAR-γ (Chen et al., 1998; Czuwara-Ladykowska et al.,
2001; Ghosh et al., 2004a; Ghosh et al., 2004b), may also contribute to
excessive ECM deposition. SSc fibroblasts express lower levels of SMAD7,
an inhibitory SMAD which can decrease the intensity and duration of TGF-β 
signalling and prevent extended induction of collagen synthesis (Chen et al.,
1999; Dong et al., 2002).
Fibroblasts from lesional skin or the fibrotic lungs of SSc patients
demonstrate an abnormal, autonomously (exogenous signal-independent)
activated phenotype, which can be maintained for several passages in vitro
(Leroy et al., 1988). The SSc fibroblast phenotype, as defined by gene
microarray studies, features enhanced ECM production, constitutive release
of cytokines and chemokines, and increased expression of profibrotic cell
surface receptors accompanied by aberrant intracellular signalling molecules
(Gardner et al., 2006; Pannu and Trojanowska, 2004; Tan et al., 2005;
Whitfield et al., 2003) (Table 1.7). SSc fibroblasts undergo myofibroblast
differentiation, facilitated by constitutive activation of focal adhesion kinase
(FAK) (Mimura et al., 2005) and are resistant to apoptosis, perhaps due to
increased expression of the pro-survival factors Bcl2 and AKT (Jelaska and
Korn, 2000; Jun et al., 2005; Santiago et al., 2001). Features of the SSc
fibroblast may be replicated in normal fibroblasts by incubating the cells with
TGF-β, which implicates autocrine TGF-β signalling as a contributor to the 
SSc phenotype (Pannu and Trojanowska, 2004).
There is much interest in the identification of the cellular sources of
fibroblasts involved in SSc, and also the factors that activate and recruit
these cells to lesions and promote their in situ differentiation into
myofibroblasts (Abraham et al., 2007).
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Molecule Elevated expression or
activity
Reduced expression or
activity
Transcription
factor / cofactor
SMAD2, SMAD3
SP-1
p300/CBP
EGR1, EGR2
SMAD7
Fli-1
PPAR-γ 
NAB2
Ski, Sno
miRNA - miR-29
miR-7
miR-196
Surface receptor TGFβRI, TGFβRII  
Integrin αvβ5, integrin αvβ3
PDGFR-α, PDGF-β 
-
Kinase /
phosphates
PTEN
TAK1
PKC-δ 
ERK1, ERK2
AKT, FAK1
-
Table 1.7. Dysregulated intracellular signalling molecules and receptors
in SSc fibroblasts
The table shows some of the signalling molecules and receptors which are
dysregulated in SSc fibroblasts. Table adapted from Bhattacharyya et al.
and from Varga and Abraham (Bhattacharyya et al., 2012; Varga and
Abraham, 2007). EGR, early growth response protein; Fli-1, friend leukemia
integration 1 transcription factor; NAB2, nerve growth factor-induced protein
A (NGFI-A) binding protein 2, EGR1 binding protein 2; Ski, Sloan-Kettering
Institute protei; Sno, Ski-like protein; TAK, transforming growth factor-b-
activated kinase; PKC, protein kinase C; ERK, extracellular signal-regulated
kinase.
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1.3.4 Sources of fibroblasts
Originally, fibroblasts in fibrotic lesions were thought to derive from resident
fibroblasts, which have been present in the mesenchyme since the time of
organ formation during foetal development (McAnulty, 2007). Resident
fibroblasts have been shown to play an essential role in lung fibrosis in a
TGF-β-dependent manner (Hoyles et al., 2011). As shown in Fig. 1.2,
activated fibroblasts may also originate from a number of alternative sources
including: tissue-specific precursors such as epithelial cells, pericytes,
vascular smooth muscle cells, endothelial cells, and circulating progenitors
such as fibrocytes, pluripotent stem cells, monocyte-derived mesenchymal
progenitors (MOMPs), and bone marrow-derived cells (Postlethwaite et al.,
2004; Quaggin and Kapus, 2011), although the relative contribution of each
source remains unresolved, and is likely to be tissue dependent.
1.3.4.1 Epithelial-to-mesenchymal transition (EMT)
Epithelial cells may contribute to the fibroblast pool by undergoing EMT, a
process by which epithelial cells lose cell-cell attachment, polarity and
epithelial-specific markers such as E-cadherin and acquire mesenchymal
markers such as fibroblast-specific protein-1 (FSP-1), α-SMA, collagen type I, 
and fibronectin (Willis et al., 2006; Willis and Borok, 2007). Rearrangement
of F-actin stress fibres occurs alongside formation of filopodia and
lamellipodia, presumably to facilitate cell migration. During embryonic
development of vertebrates, EMT enables epithelial cells to migrate to
different parts of the embryo and differentiate into other structures. EMT is
induced by cytokines such as TGF-β, FGF-2, EGF and insulin-like growth 
factor (IGF)-II, and proteases which degrade basement membranes (Chen et
al., 2005; Postlethwaite et al., 2004).
In adults, EMT may occur during tumourigenesis and fibrogenesis in organs
such as the lung (Chapman, 2011; Kim et al., 2006; Kim et al., 2009; Tanjore
et al., 2009), kidney (Iwano et al., 2002; Postlethwaite et al., 2004), liver and
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the gastrointestinal tract (Quaggin and Kapus, 2011). The presence of EMT
in lung fibrosis was implicated by the co-expression of epithelial and
mesenchymal markers in the cells of an idiopathic pulmonary fibrosis lung
(Chapman, 2011). The role of EMT in the pathogenesis of lung disease is
further supported by evidence of EMT markers such as the expression of
pro-collagen type I, α-SMA, vimentin and FSP-1, in multiple models of TGF-
β- and bleomycin-induced pulmonary fibrosis (Kim et al., 2006; Kim et al.,
2009; Tanjore et al., 2009). In vitro, TGF-β has been shown to induce EMT 
in cultured alveolar epithelial cells while bone morphogenetic protein inhibited
this process (Kasai et al., 2005; Lamouille et al., 2014; O'Connor and Gomez,
2014). Expression of CTGF in epithelial cell types such as hepatocytes in the
liver suggests that CTGF may play a role in mediating TGF-β-stimulated 
EMT (Gressner and Gressner, 2008).
However, the role of EMT in fibrosis has been increasingly challenged,
particularly in the context of kidney and liver fibrosis (Humphreys et al., 2010;
Koesters et al., 2010; Li et al., 2010b; Quaggin and Kapus, 2011). For
example, Koesters et al. reported that neither genetic tagging nor tracing of
injured tubular epithelial cells by electron microscopy showed cells moving
across the tubular basement membrane, questioning whether epithelial cells
do migrate and differentiate into fibroblast-like cells in fibrotic lesions
(Koesters et al., 2010). Similarly, Humphreys et al. concluded with their
lineage tracing studies, that myofibroblasts in kidney fibrosis originate from
pericytes rather than from epithelial cells (Mayes, 2003). The role and
significance of EMT in the pathogenesis of fibrosis in SSc remains to be
elucidated.
Previous work show that EMT is a reversible process whereby fibroblasts
derived from EMT are able to revert back to the epithelial cell type through
the process of mesenchymal-to-epithelial transition (Neilson, 2006). We
showed that mice overexpressing connective tissue growth factor (CTGF)
specifically in fibroblast cells (Col1a2-CTGF mice) displayed epithelial cell
Tissue fibrosis is a hallmark of connective tissue scarring and SSc and
involves the recruitment and activation of fibroblasts. Fibroblasts may
originate from various sources in addition to the d
resident in the interstitium, including from bone marrow
circulating cells, pericytes, vascular smooth muscle cells
cells through epithelial
cells through endothelial
extracellular matrix.
Figure 1.2 Schematic representation of the sources of fibroblasts
ifferentiation of fibroblasts
(BM)
(vSMC)
-to-mesenchymal transition (EMT), and endothelial
-to-mesenchymal transition (endo
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EMT-like changes in alveolar epithelial cells in vitro, suggesting that the
CTGF expressed by mesenchymal cells play a role in the differentiation of
neighbouring epithelial cells during fibrosis (Sonnylal et al., 2013).
Therapeutic strategies may be developed to promote reversal of EMT, which
may potentially attenuate or reverse EMT-mediated fibrotic changes.
1.3.4.2 Bone marrow-derived progenitors
It has been demonstrated in models of bleomycin-induced pulmonary fibrosis
that bone marrow-derived progenitor cells are a source of fibroblasts (Kim et
al., 2006). Hashimoto et al. used chimeric mice generated by engrafting
adult mice with bone marrow isolated from green fluorescent protein (GFP)-
expressing-transgenic mice to show that after bleomycin treatment, GFP-
tagged bone marrow cells were present in fibrotic lesions and expressed
collagen type I (Hashimoto et al., 2004). Similarly, using a bone marrow
chimera model expressing GFP under the control of the FSP-1 promoter,
Tanjore et al. also found GFP-tagged bone-marrow cells in areas of fibrosis
(Tanjore et al., 2009). However, they concluded that bone marrow
progenitors made only a minor contribution to the fibroblast pool, accounting
for one fifth of the FSP-1-positive fibroblasts in the lung.
1.3.4.3 Endothelial cells
During fibrosis, endothelial cells affect fibroblasts in a paracrine manner
mediated by Snail and CTGF (Lee et al., 2013b). Endothelial cells may also
contribute to the fibroblast pool through the process of endothelial-to-
mesenchymal transition (endoMT) which has been implicated in the
development of experimentally-induced cardiac, lung and kidney fibrosis
(Piera-Velazquez et al., 2011; Piera-Velazquez and Jimenez, 2012). Studies
to date suggest TGF-β as an important inducer of endoMT, which is 
supported by the observations that endoMT may be blocked by either the
TGF-β antagonist, BMP-7, (Zeisberg et al., 2008) or the SMAD3-specific
inhibitor, SIS3 (Li et al., 2010a). Assessing the expression profile of three
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mouse models of chronic kidney disease (unilateral ureteral obstructive
nephropathy, streptozotocin-induced diabetic nephropathy (DN), and a model
of Alport’s renal disease), it was revealed that 30 to 50% of fibroblasts co-
expressed endothelial (CD31), fibroblast (FSP-1), and myofibroblast (α-SMA) 
markers. Additionally, fibroblasts were shown to derive from endothelial cells
in the kidney using the technique of lineage tracing in Tie2-Cre;R26R-stop-
EYFP transgenic mice (Zeisberg et al., 2008). In contrast to the
experimentally-induced animal models, there are relatively few studies of
endoMT in human endothelial cells.  Recently, IFN-γ was shown to induce 
endoMT in human microvascular endothelial cells via ET-1 and TGF-β2 
signalling (Chrobak et al., 2013). Exposure of human microvascular
endothelial cells to proinflammatory cytokines such as TGF-β, IL-1β and 
TNF-α induced the cells to undergo endoMT, characterised by concomitant 
downregulation of endothelial cell markers such as CD-31 and VE-cadherin,
and acquisition of mesenchymal markers such as N-cadherin, vimentin, and
collagen type I (Rieder et al., 2011). Evidence of endo-MT has also been
reported in SSc, with the localisation of endothelial cell specific markers (CD-
31 and CD-34) in fibroblasts present in the subendothelial compartment of
small pulmonary arteries (Piera-Velazquez and Jimenez, 2012). Conversely,
a study excluded endothelial cells as precursors for myofibroblasts in dcSSc,
as the anti-endothelial cell marker, PAL-E did not co-localise with the pre-
myofibroblast marker Thy-1 (Rajkumar et al., 2005).
1.3.4.4 Pericytes
The potential of pericytes to differentiate into fibroblasts as well as other cell
types such as vascular smooth muscle cells, osteoblasts, chondrocytes and
adipocytes, implicates a prominent role of the vasculature in fibrosis (Lin et
al., 2008). Pericytes, like perivascular fibroblasts, basally express collagen
type I, and have been reported to transdifferentiate to become a major
source of myofibroblasts in a number of in vivo studies of kidney fibrosis
using fate mapping or immunofluorescence co-localisation methods (Lin et al.,
2008; Ren and Duffield, 2013). Notably, the study by Lin et al. found no
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evidence of EMT (Lin et al., 2008). Using proliferating cell nuclear antigen
staining, Rajkumar et al. showed that proliferating pericytes were absent from
control skin but present in dcSSc skin (Rajkumar et al., 2005). In the same
study, microvascular pericytes, identified by positive α-SMA staining, also
expressed the pre- / myofibroblast markers EDA-fibronectin and Thy-1. This
showed that pericytes are able to produce Thy-1 and EDA-fibronectin,
although this was not exclusive to dcSSc skin as these cells were also
present in control skin in fewer numbers. From this study, Rajkumar et al.
suggested that the proliferating pericytes found in SSc contribute to the
generation of myofibroblasts in the interstitium.
1.3.4.5 Fibrocytes and fibrocyte-like cells
Fibrocytes are bone marrow-derived (monocyte-derived mesenchymal
progenitors, MOMPs) fibroblast-like cells that have been identified in human
and murine peripheral blood where they are present in small numbers
(Bucala, 2012; Postlethwaite et al., 2004). Fibrocytes infiltrate tissues, serve
as mesenchymal progenitor cells and participate in wound healing (Abe et al.,
2001; Bucala, 2012). Using genetic mouse models and fate mapping
methods, 35% of myofibroblasts in the fibrotic kidney were found to originate
from bone marrow (50% from proliferating resident fibroblasts, 10% from
transdifferentiated endothelial cells, and 5% from transdifferentiated epithelial
cells) (LeBleu et al., 2013). T-cells may stimulate the generation of fibrocytes
from CD14+ human blood monocytes upon direct contact with T-cells.
CD14+ mononuclear cells cultured on collagen- or fibronectin-coated
surfaces and stimulated with soluble factors such as monocyte colony-
stimulating factor (MCSF) and monocyte inhibitory factor (MIF) have also
been shown to acquire a fibroblast-like, spindle-shaped morphology,
expressing monocyte, stem cell, endothelial, and mesenchymal markers
(type III collagen, fibronectin, vimentin) (Kuwana et al., 2003; Zhao et al.,
2003). These fibrocytes contain a mixture of structural components
prototypical of phagocytes, mesenchymal, and endothelial cells (Kuwana et
al., 2003).
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TGF-β can stimulate fibrocytes to become myofibroblast-like, expressing α-
SMA and contracting collagen gels (Kahaleh et al., 1979). As shown in
mouse lung, fibrocyte recruitment during pulmonary fibrosis is dependent on
TGF-β signalling through TβRII (Hoyles et al., 2011). A growing number of
studies provide support that fibrocytes are able to differentiate into
myofibroblasts, both in vivo (Bucala, 2008; Mori et al., 2005; Schmidt et al.,
2003) and in vitro (Abe et al., 2001). Evidence of fibrocytes as a source of
myofibroblasts has been provided by co-expression of haematopoietic stem
cell markers (such as CD14, CD45 and CD34) with myofibroblast markers
and/or collagen, in fibrotic lesions and pathologies such as human
hypertrophic scars, in the skin of nephrogenic systemic fibrosis patients, in
atherosclerosis, and in pulmonary diseases involving chronic inflammation
and remodelling, like asthma (Bellini and Mattoli, 2007; Maharaj et al., 2013;
Quan et al., 2004).
Fibrocytes have also been linked to SSc pathogenesis due to the
identification of factors in early SSc lesional skin which promote fibrocyte
trafficking and accumulation, such as chemokine stromal cell–derived factor-
1 (SDF-1, CXCL12) and its receptor, CXCR4 (Phillips et al., 2004). SSc
patients have low levels of serum amyloid protein (SAP), an inhibitor of
fibrocyte formation from CD14+ precursors, which may facilitate the
accumulation of fibrocytes in SSc (Postlethwaite et al., 2004). The
accumulation of fibrocytes in SSc-ILD has been associated with
downregulation of caveolin-1 in the monocyte precursors (Tourkina et al.,
2011). In mice, bone marrow-derived cells have been shown to provide a
source of myofibroblasts in bleomycin-induced lung fibrosis (Hashimoto et al.,
2004).
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1.3.5 Growth factors and cytokines in fibrosis
Growth factors and cytokines act in an endocrine, paracrine, autocrine,
intracrine or juxtacrine manner to modulate cellular activities and functions by
binding to cell surface receptors or ECM proteins. Upon ligand binding,
receptors activate a cascade of downstream signalling events, amalgamating
to induce expression of genes that regulate cell cycle, motility or
differentiation. Many cellular events which occur during fibrosis are
orchestrated by a host of growth factors and cytokines, analogous to wound
healing. Major growth factors important both in wound healing and in fibrosis
(Table 1.8) include PDGF, TGF-β, EGF, FGF, VEGF, granulocyte 
macrophage colony stimulating factor (GM-CSF), and TNF-α (Abraham et al.,
2007).  Recent studies have also implicated the signalling molecule TGF-β-
activated kinase 1 (TAK-1) as a mediator of α-SMA expression and ECM 
contraction in fibroblasts (Shi-Wen et al., 2009). The differing cellular
activities induced by various growth factors and cytokines suggest that
combination therapies targeting more than one of these molecules may be
the optimal treatment approach for fibrosis.
1.3.5.1 PDGF
The PDGF family consists of five ligand isoforms which form dimers (PDGF-
AA, -BB, -AB, -CC, -DD) that interact with the three combinations of homo- or
hetero-dimerised PDGF receptors (PDGFRα and PDGFRβ), with varying 
specificity and efficacy (Donovan et al., 2013). The PDGFs, released by
platelets, macrophages, endothelial cells and fibroblasts, promote
chemotaxis of neutrophils, macrophages, smooth muscle cells and
fibroblasts as well as the mitogenesis of the latter two cell types. PDGFs
induce fibroblast synthesis of collagen, fibronectin, and proteoglycans and
secretion of TGF-β1, MCP-1, and IL-6.  PDGF expression is elevated along 
with that of its receptors in cultured fibroblasts from SSc lesional tissue (Gay
et al., 1989), and in bronchoalveolar lavage (BAL) fluid of SSc patients
(Ludwicka et al., 1995). Autoantibodies specifically against PDGF receptors
have also been detected in SSc patient sera (Baroni et al., 2006). When
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applied in vitro to control human primary fibroblasts, these anti-PDGF
receptor autoantibodies stimulated PDGF receptor activation, triggering
ERK1/2 signalling-mediated generation of reactive oxygen species (Baroni et
al., 2006).
1.3.5.2 Interleukins
Interleukins are a family of cytokines which bind to specific receptors and
mediate signalling between leukocytes (Akdis et al., 2011). They are
secreted by various types of cells and also target numerous cell types
including immune cells such as macrophages, monocytes and lymphocytes,
and endothelial cells and fibroblasts (Akdis et al., 2011). The cytokines IL-4
and IL-13 have major roles the pathogenesis of fibrotic disorders (Wynn,
2004). In normal fibroblasts, IL-4 stimulates proliferation, chemotaxis, and
collagen synthesis and enhances the production of TGF-β and CTGF 
(Postlethwaite et al., 2004).
In SSc, serum IL-4 Levels are increased (Hasegawa et al., 1997), along with
the increased abundance of IL-4-producing T cells in the peripheral blood
(Sakkas et al., 2002; Tsuji-Yamada et al., 2001). This is consistent with
elevated expression of IL-4 protein and mRNA in SSc skin lesions and in
cultured SSc fibroblasts (Salmon-Ehr et al., 1996). Similarly, IL-13 is also
elevated in SSc patient sera and its ability to activate fibroblasts directly and
via TGF-β signalling suggest a potential role in initiating and sustaining 
fibrosis in SSc (Jinnin et al., 2004; Kaviratne et al., 2004).
1.3.5.3 Chemokines
There is growing interest in chemokines as mediators of fibrosis due to their
diverse cellular targets and biological activities (Pannu and Trojanowska,
2004). Chemokines act as mediators of leukocyte chemotaxis and migration
through the endothelial barrier into tissues, enabling leukocytes to interact
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with fibroblasts (Hasegawa and Sato, 2008). Pronounced expression of two
members of the subfamily of monocyte chemoattractant proteins, MCP-1
(CCL-2) and MCP-3 (CCL-7), and their receptors, have been noted in SSc
skin lesions and fibroblasts in vitro (Carulli et al., 2005; Distler et al., 2009;
Ong et al., 2003). MCP-1 has been shown in vitro to induce collagen
expression directly and indirectly via endogenous TGF-β or IL-4 signalling 
(Distler et al., 2006). In SSc, levels of MCP-1 and other chemokines are
elevated in the serum and BAL fluid, correlating with severity of fibrosis
(Galindo et al., 2001; Kodera et al., 2005). The chemokine receptors CCR2
and CX3CR1 are also reported to play a significant role in mediating skin
fibrosis in a mouse model of SSc (Arai et al., 2013).
1.3.5.4 Endothelin
ET-1, a strong inducer of vasoconstriction, is also implicated in tissue fibrosis
due its effects on inducing mitosis (Abraham et al., 2005) as well as the
biosynthesis of ECM components (Levin 1995 & Shi wen 2001). Additionally,
applying exogenous ET-1 to cultured fibroblasts induced expression of
collagen type I and III while inhibiting MMP-1, and promoting cell contraction
(Shi-Wen et al., 2004; Xu et al., 1998a; Xu et al., 1998b; Xu et al., 2004). In
SSc, ET-1 expression is augmented in the dermis (mainly in the superficial
papillary microvessels) and in particular cell types including fibroblasts,
endothelial cells, and smooth muscle cells (Kawaguchi et al., 1994;
Vancheeswaran et al., 1994). Indicators of a role for ET-1 in SSc
pathogenesis include increased total ET-1 receptors present in lesional areas
in the alveolar epithelium and pulmonary interstitium (Abraham 1997) and the
association of increased circulatory levels of ET-1 with severity of skin and
lung fibrosis in SSc (Yamane et al., 1992). In bleomycin-induced pulmonary
fibrosis, expression of ET-1 and the profibrotic ET-A receptor is increased
concomitantly with collagen deposition in fibrotic lesions (Mutsaers et al.,
1998; Shiwen et al., 2009). ET-1-overexpressing transgenic mice develop
inflammation and lung fibrosis, suggesting that chronic ET-1 expression is
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able to induce an inflammatory and fibrotic phenotype without additional
stimuli (Kalk et al., 2008).
1.3.5.5 TGF-β  
TGF-β is one of the most extensively studied profibrotic factors and is 
released by numerous cell types including platelets, macrophages, T
lymphocytes and fibroblasts. It is essential in various physiological
processes including wound healing, immune regulation, angiogenesis, cell
proliferation and differentiation and also in pathogenesis (Blobe et al., 2000).
TGF-β exists as several isoforms including TGF-β1 (TGF-β is used to refer to 
TGF-β1) and TGF-β2, which can induce profibrotic effects, and TGF-β3, 
which can play an anti-fibrotic role and downregulate the former isoforms. It
has therefore been suggested that neutralising TGF-β1 and TGF-β2 or by 
adding TGF-β3 (Shah et al., 1995). A study by Coker et al. showed co-
localisation of TGF-β1 and TGF-β3 in various cell types, suggesting these 
isoforms may act in an autocrine or paracrine manner in the lung (Coker et
al., 2001). Both TGF-β1 and TGF-β3 mRNA transcripts were localised to 
bronchiolar epithelium and alveolar macrophages while only TGF-β1 was 
detected in mesenchymal and endothelial cells.  In ﬁbrotic lung tissue, mRNA 
transcripts for both isoforms were also detected in type II alveolar epithelial
cells, but only the expression of TGF-β1, not TGF-β3 was elevated.  This 
provided support for TGF-β1 as the major profibrotic isoform, along with the 
observation of ubiquitous expression of TGF-β2 and TGF-β3 but little or no 
expression of TGF-β1 in another study of normal human lung (Khalil et al.,
1996).
Cellular responses induced by TGF-β activation differ depending on the 
context or target cell lineage, as most cell types express specific cell surface
receptors for TGF-β and secrete TGF-β as a latent complex that is anchored 
to the ECM, in a process involving fibrillin-1 (Annes et al., 2003), integrins,
thrombospondins, Thy-1, or plasmin (Moustakas and Heldin, 2005). In
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mesenchymal cells, TGF-β functions as a potent fibrogenic stimulus by 
enhancing collagen synthesis, proliferation, migration, adhesion, and
transdifferentiation into myofibroblasts (Blobe et al., 2000).
1.3.5.5.1 TGF-β signalling pathways
This diversity in function is reflected in the variety of downstream signalling
events triggered by TGF-β, including SMAD and non-SMAD (non-canonical) 
signalling pathways (Nakerakanti and Trojanowska, 2012).  Binding of TGF-β 
to the TGFβRII triggers an intracellular signal transduction cascade that 
leads to gene transcription (Massague, 1990). In the canonical TGF-β 
pathway, phosphorylation activates TGFβRI (ALK5), a transmembrane 
serine-threonine kinase, which then phosphorylates cytoplasmic SMAD
proteins. Phosphorylated SMAD2 and SMAD3 (pSMAD) form a
heterocomplex with SMAD4, which translocates into the nucleus. The
complex binds specifically to a cis-acting DNA sequence (CAGAC), the
conserved SMAD-binding element (SBE) – found in promoters of TGF-
inducible genes such as collagen type I, PAI-1, α-SMA and CTGF, and 
recruits transcriptional cofactors to activate gene transcription. SMAD
signalling is negatively regulated by endogenous inhibitors such as SMAD7.
Alternatively, TGF-β signalling via non-canonical pathways (Moustakas and 
Heldin, 2005) is also likely to play a role in fibrosis, either with or without
interaction with SMAD proteins. Non-canonical signalling molecules
activated by TGF-β include lipid kinases (such as PI3K/FAK and its 
downstream target, AKT), protein kinases (the MAPKs p38, ERK and JNK, c-
ABL (Daniels et al., 2004), and TAK-1, the calcium-dependent phosphatase
calcineurin, and EGR1 (Chen et al., 2006a).
1.3.5.5.2 TGF-β in pathology 
In pathology, TGF-β is considered to be a key regulator of fibrogenesis 
(Border and Ruoslahti, 1992; Pannu and Trojanowska, 2004), through its
abilities to induce expression of matrix genes such as collagen,
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proteoglycans and fibronectin (Steen and Medsger, 2007) and to regulate
various fibroblast functions including chemotaxis and myofibroblast
differentiation (Kurita et al., 2012).   TGF-β also regulates ECM accumulation 
by preventing matrix degradation through reducing secretion of proteases
such as collagenases and stimulating expression of TIMPs in fibroblasts and
smooth muscle cells (Desmouliere et al., 2005). Furthermore, TGF-β can 
attract and stimulate macrophages to secrete other cytokines such as PDGF,
TNF-α, FGF, and IL-1, which together, enhances ECM deposition by matrix-
producing cells.
1.3.5.5.3 TGF-β in SSc 
In SSc, dysregulated expression or activity of TGF-β-dependent signalling 
molecules (Abraham and Varga, 2005; Pannu and Trojanowska, 2004; Varga
and Bashey, 1995) is likely to contribute to the initiation or perpetuation of the
SSc fibroblast phenotype (Table 1.7).  While serum levels of TGF-β are not 
elevated in SSc, thrombospondin and αvβ3 integrins - activators of latent 
TGF-β, are increased in SSc fibroblasts (Asano et al., 2005; Mimura et al.,
2005).  Moreover, increased expression and altered ratio of TGF-β receptors 
(TGFRI, TGFRII) in SSc fibroblasts suggest a greater responsiveness of
fibroblasts to endogenous levels of TGF-β or increased sensitivity to sub-
threshold levels of exogenous TGF-β (Kawakami et al., 1998; Pannu et al.,
2006). Furthermore, transcriptional profiling studies have repeatedly
reported a TGF-β-responsive signature in SSc fibroblasts (Varga and Pasche, 
2008; Whitfield et al., 2003), which is consistent with increased levels of
TGF-β being detected in SSc BAL fluids (Ludwicka et al., 1995).  SSc 
fibroblasts also show constitutively increased expression and nuclear
localisation of pSMAD3 (Dong et al., 2002; Mori et al., 2003) and its
interaction with its co-activator p300/CBP (Bhattacharyya et al., 2005; Ihn et
al., 2006). This supports the idea that TGF-β acts in an autocrine loop in SSc.  
Certain characteristics such as the constitutive production of CTGF or ET-1
suggest that autocrine canonical TGF-β signalling is not the only mechanism 
responsible for the activated fibroblast phenotype (Shi-Wen et al., 2007). This
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is supported by observations that inhibition of TGFβRI-dependent SMAD 
signalling with small molecule inhibitors does not completely abrogate the
fibrotic phenotype in SSc fibroblasts (Chen et al., 2006a; Ishida et al., 2006;
Pannu et al., 2006). Collectively, these results suggest that both TGF-β-
dependent and TGF-β–independent signalling are at play in inducing the SSc 
phenotype.
Other studies have reported dysregulated expression of endogenous
suppressors of TGF-β signalling such as Fli-1 and SMAD7 in SSc (Chen et
al., 1999; Denton et al., 2005; Wang et al., 2006). The nuclear receptor
PPAR-γ, which blocks profibrotic TGF-β signalling, shows reduced 
expression and activity in SSc skin (Bhattacharyya et al., 2012; Lakota et al.,
2012; Wei et al., 2012), which is consistent with previous reports that TGF-β 
is able to downregulate expression of PPAR-γ in normal fibroblasts (Wei et
al., 2010).  Similarly, CTGF is also able to inhibit PPAR-γ expression or 
activity in adipocytes (Tan et al., 2008).
Despite the obvious involvement of TGF-β signalling in fibrosis, anti-TGF-β 
strategies to date have failed to achieve the desired anti-fibrotic effects
(Nakerakanti and Trojanowska, 2012). Whether this might be due to
incomplete inhibition of TGF-β, in which case increasing the dose of anti-
TGF-β treatment may be a solution at the risk of serious side-effects such as 
autoimmunity and epithelial hyperplasia (Varga and Pasche, 2008), it may be
more favourable to target signalling molecules that interact with TGF-β, alone 
or combined with TGF-β inhibition for a more effective anti-fibrotic treatment 
with lower risk of cellular toxicity.
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Factors Cellular source(s) Effect(s) in SSc Expression in SSc Reference
CTGF Platelets, pericytes,
chondrocytes, fibroblasts,
smooth muscle cells, endothelial
cells, mesangial cells, renal
podocytes, hepatocytes, hepatic
stellate cells, pancreatic ductile
cells, T cells
Regulates fibroblast proliferation,
migration, and TGF-β-dependent ECM 
synthesis; angiogenesis
Elevated (Leask and
Abraham, 2006)
EGF Platelets, macrophages,
fibroblasts
Regulates motility and proliferation of
keratinocytes
Elevated (Yamane et al.,
2003)
ET-1 Endothelial cells, epithelial cells,
mast cells, macrophages,
polymorphonuclear leukocytes,
cardiomyocytes, fibroblasts
Regulates synthesis and contraction of
ECM
Elevated (Abraham et al.,
2005; Mayes,
2003)
bFGF Macrophages, endothelial cells Regulates fibroblast proliferation and
angiogenesis
Elevated (Takehara, 2000)
IGF-1 Fibroblasts, keratinocytes Regulates re-epithelialisation and
formation of granulation tissue
Elevated (Hamaguchi Y. et
al., 2008)
IL-1 Neutrophils, monocytes,
macrophages, keratinocytes
Mediates Inflammation Elevated (White, 1996)
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IL-4 T-cells, mast cells Regulates collagen synthesis Elevated (Banning et al.,
2006)
IL-6 Monocytes, fibroblasts,
endothelial cells, neutrophils,
macrophages
Regulates myofibroblast expression of
α-SMA 
Elevated (Gallucci et al.,
2006)
IL-12 B-cells, T cells Regulates collagen synthesis Elevated (Banning et al.,
2006)
IL-13 T cells Induces TGF-β expression  Elevated (Fichtner-Feigl et
al., 2008;
Hasegawa et al.,
1997)
IL-17 T cells Regulates fibroblast proliferation,
mediates angiogenesis
Elevated (Kurasawa et al.,
2000)
MCP-1 Monocytes, macrophages,
dendritic cells, endothelial cells,
smooth muscle cells, pulmonary
type 2 like epithelial cells
Mediates inflammation and regulates
collagen synthesis.
Elevated (Yamamoto, 2008)
MCP-3 Macrophages Regulates collagen synthesis Elevated (Ong et al., 2003)
PDGF Platelets, macrophages,
endothelial cells, fibroblasts,
keratinocytes, myoblasts,
Regulates TGF receptor expression and
recruitment of fibroblasts and progenitor
Elevated (Heldin et al., 2002;
Trojanowska,
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smooth muscle cell cells 2008)
TGF-β1, 
TGF-β2 
Platelets, macrophages,
keratinocytes, lymphocytes,
fibroblasts
Regulation of fibroblast proliferation,
differentiation and chemotaxis, ECM
synthesis and remodelling; keratinocyte
migration, macrophage chemotaxis
Elevated (Leask, 2009)
TGF-β3 Macrophages, keratinocytes,
lymphocytes, fibroblasts
Anti-scarring Decreased (Leask, 2009;
Leask and
Abraham, 2004)
TNF-α Neutrophils, macrophages, T
cells, B-cells, natural killer (NK)
cells, smooth muscle cells,
endothelial cells, and fibroblasts
Induces expression of growth factors in
macrophages, keratinocytes and
fibroblasts
Elevated (Abraham and
Varga, 2005)
Table 1.8 Growth factors and cytokines implicated in fibrogenesis in SSc.
Growth factors and cytokines which are abnormally expressed in SSc and their effects on SSc. Adapted from Abraham et al. 2007.
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1.4 Connective tissue growth factor (CTGF, CCN2) in tissue
fibrosis
1.4.1 Discovery of CTGF
The multitude of names which exist for CTGF is a testament to its discovery
by independent groups around the same time, each assigning its own
nomenclature. In 1988, the cDNA of the mouse orthologue of CTGF was
isolated by differential screening of a cDNA library from serum-stimulated
NIH/3T3 mouse embryonic fibroblasts (Almendral et al., 1988). The protein
was named Fisp-12 (fibroblast-inducible secreted protein-12) and in 1991,
the gene and predicted amino acid sequences were identified (Ryseck et al.,
1991). Meanwhile, Fisp-12 cDNA was discovered independently by Brunner
et al. (Brunner et al., 1991) using a similar screening method and was
assigned the name of βIG-M2 (TGF-β-induced gene 2) after isolating the 
cDNA from TGF-β-stimulated AKR-2B mouse embryonic fibroblasts. Human 
CTGF was also discovered in 1991 when PDGF anti-serum was found to
cross-react with a 36 kDa protein secreted by cultured human vein umbilical
endothelial cells (HUVECs) (Bradham et al., 1991). CTGF was therefore
sometimes referred to as 36-kD PDGF-like protein in publications. Human
CTGF cDNA was subsequently isolated by screening of a HUVEC cDNA
expression library with an anti-PDGF antibody. The protein consisted of 349
amino acids and was 91% homologous to Fisp-12. It was named CTGF due
to its mitogenic and chemotactic properties for fibroblast-like cells in vitro
(Steffen et al., 1998). Another name for CTGF is hypertrophic chondrocyte-
specific protein 24 (HCS-24) as osteoblasts produce CTGF for maintaining
skeletal homeostasis (Canalis et al., 2014).
1.4.2 The CCN family – agonists and antagonists
The term CCN2 was introduced in an attempt to overcome the confusion
caused by the multiple names for CTGF, although the term CTGF is still
popular in current publications as the general audience is more familiar with
this historical term. The systematic CCN nomenclature avoids the
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presumption that CTGF function is limited to that of a growth factor, which
induces mitogenesis and chemotaxis. CTGF belongs to the CCN protein
family, a group of immediate-early response genes that encode secreted,
regulatory proteins associated with the ECM. CCN is derived from the
abbreviation of the first three members of the protein family, which includes
cysteine-rich-61 (Cys-61, CCN1), connective tissue growth factor (CTGF,
CCN2) and nephroblastoma over-expressed protein (Nov, CCN3) (Perbal et
al., 2014). The proteins share a conserved modular secondary structure
that consists of up to four domains including an insulin-like growth factor
binding protein (IGFBP) domain, a von Willebrand type C (VWC) domain, a
thrombospondin-1 (TSP-1) domain and a cysteine knot domain (Bork, 1993;
Perbal, 2004) (Figure 1.3). As matricellular molecules, the CCN family play
an important role acting as adaptor molecules between the cell surface and
ECM (Bornstein, 1995).
It is of interest currently to investigate whether members of the CCN family
cooperate or antagonise each other in physiological and pathological states.
CCN1, CTGF and CCN3 are induced during tissue repair in adults (Igarashi
et al., 1993; Latinkic et al., 2001; Lin et al., 2005). CTGF and CCN4 are
upregulated in fibrosis (Jian et al., 2014). Interestingly, CCN1 appears to act
as an anti-fibrotic factor while CTGF is associated with profibrotic responses
(Jun and Lau, 2011). A recent study also implicated opposing roles for
CTGF and CCN3 in fibrosis as CCN3 showed anti-scarring properties
including inhibition of palatal fibroblast proliferation, apoptosis and ECM
production (Ren et al., 2014). Although CCN proteins have some
independent activity such as promoting adhesion through integrins and
HSPGs, they primarily function by modifying the signalling of a range of other
extracellular ligands such as ECM components and growth factors (Leask
and Abraham, 2006). CCN1, CTGF and CCN6 have been linked to
development of cancer while CCN5 inhibits cancer cell migration (Ji et al.,
2014; Saglam et al., 2014).
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1.4.3 The structure of CTGF
Distinct from other CCN proteins, CTGF is highly conserved across species
(over 90% sequence identity between human and mouse CTGF) (Brigstock,
1999). Human CTGF protein is 80% identical with mouse; the first 43 amino
acids are the least conserved with only 60-65% sequence identity. CTGF is
composed of five exons and four introns and maps to chromosome 10 in
mouse, and chromosome 6q23.1 in human – other genes implicated in
autoimmunity as well as cancer and other diseases are also on chromosome
6 (Mungall et al., 2003). Human and mouse CTGF span 3.2 and 3.1 kb,
respectively, while human CTGF protein consists of 349 amino acids and
mouse CTGF has 348 amino acids (Brunner et al., 1991; Ryseck et al., 1991).
Human CTGF has a molecular weight (MW) of 36-38 kDa, as shown by SDS-
PAGE, with variations in MW arising due to different degrees of glycosylation
(N-linked glycosylation is predicted to occur at amino acid residues Asp28
and Asp225) and the protein is susceptible to cleavage by endoglycosidase F,
which can decrease its mass by 2 – 8 kDa. Mouse and pig CTGF are not
glycosylated, which suggests either that the glycan groups in human CTGF
may provide some advantageous property or, alternatively, may be
functionally redundant (Brigstock, 1999).
Like other members of the CCN family, CTGF is rich in cysteine residues,
with 38 residues in human CTGF at conserved positions. Modules II and III
of the CTGF protein are linked by a cysteine-free hinge region (between
residues Asp167 and Asn198 in human CTGF) which is susceptible to
cleavage by proteases such as chymotrypsin (Bork, 1993). The abundance
of disulphide bridges renders the rest of the protein resistant to digestion by
most proteases except plasmin, which can cleave the protein into separate
modules (Figure 1.3). In biological fluids, CTGF exists as fragments
containing either the N-terminal or the C- terminal modules of the protein or
module IV alone (Brigstock et al., 1997). The tertiary protein structure of
CTGF remains elusive. The modular structure permits CTGF and other CCN
proteins to be involved in a range of signalling and physiological functions,
Figure 1.3 Schematic showing the CTGF gene and protein structure
In the representation of the DNA, coloured bars are exons, grey lines
represent introns and white bars are untranslated regions (UTR). TGF-β and
endothelin-1 (ET-1)-induced CTGF transcription is mediated by enhancer
elements in the proximal promoter (red arrows): SMAD binding element
(SBE), tandem repeat of ETS element (Ets-1), basal control element-1 (BCE-
1) and specificity protein 1 (Sp1) binding site. Hypoxia may induce CTGF
expression via the hypoxia-inducible factor (HIF) binding site further
upstream of the transcription start site (not shown) or by increasing the
stability of CTGF mRNA via the 3'UTR of the mRNA transcript. Transcription
of the CTGF gene yields an mRNA transcript of 2.3 kb in length. Exon 5
yields a long 3'UTR containing a cis-acting element of structure-anchored
repression (CAESAR) sequence, which is involved in downregulation of
CTGF expression post-transcriptionally. CTGF protein comprises of an N-
terminal signal peptide (SP) that directs CTGF secretion, and four functional
modules including the insulin-like growth factor binding protein domain
(IGFBP), von-Willebrand factor type C (VWC) / cysteine-rich (CR) domain,
thrombospondin domain 1 (TSP1), and carboxy (C) terminal domain
containing a cysteine knot (CT). Numbers indicate amino acid residue
number in the protein sequence. Modules II and III of the CTGF protein are
linked by a cysteine-free hinge region, which is susceptible to cleavage by
proteases such as chymotrypsin. Sites susceptible to protease and plasmin
cleavage are indicated by dashed lines. Various N-terminal or C-terminal
fragments are found in biological fluids. Figure adapted from de Winter et al.Introduction | 68
2008.
Figure 1.4 Schematic representation of putative mechanisms of
CTGF-stimulated scarring and
CTGF module I binds IGF; module II binds TGF
III binds integrins α4, 5, 6, β1,αvβ3, LRP
adhesion; module IV may bind LRP5 and LRP6, VEGF, HSPGs including
syndecan-4 and perlecan, may
and proliferation that enhances responses to TGF
may also bind the receptor tyrosine kinase A and p75 complex (TrkA).
Interactions of CTGF with the various binding
may act through signalling pathways such as the SMAD, MAPK, Wnt and
FAK pathways and stimulate a variety of cellular responses. ECM
fibrosis
-β, BMP, integrins; module
-1, VEGF and promotes cell
be involved in dimerisation, cell adhesion,
-β or fibronectin. CTGF 
partners suggest that CTGF(extracellular matrix).
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and hence involvement in a range of pathological conditions (Oemar and
Luscher, 1997).
1.4.4 Regulation of CTGF expression
CTGF is absent or expressed at basal levels in normal adult cells, but is
induced during normal wound repair (Igarashi et al., 1993). Studies to date
show that CTGF gene expression is regulated principally at the level of
transcription (Abraham, 2008), although post-transcriptional and epigenetic
regulation may also play important roles, as shown by emerging reports on
miRNA-mediated regulation of CCN proteins (Vettori et al., 2012).
1.4.4.1 Transcriptional regulation
CTGF transcription may be induced by: growth factors and cytokines such as
TGF-β, ET-1, VEGF, PDGF, IGF-1, TGF-α, EGF and HGF; mechanical force 
such as shear stress and cell stretch; hypoxia; angiotensin II; thrombin; high
glucose; serotonin; lyphosphatidic acid; and ROS (Gao et al., 2014; Leask
and Abraham, 2006).  TGF-β can specifically induce CTGF expression in 
fibroblasts (Grotendorst et al., 1996; Igarashi et al., 1993; Soma and
Grotendorst, 1989) via the canonical SMAD pathway using the SMAD-
binding element (SBE) or the tandem repeat of a v-ets erythroblastosis virus
E26 oncogene homolog 1 (Ets-1) element in the proximal promoter of the
CTGF gene (Abraham et al., 2000; de Winter et al., 2008; Ding et al., 2013;
Holmes et al., 2001; Shi-Wen et al., 2000; Yang et al., 2013). In contrast to
the SBE in the CTGF promoter, which is not essential for CTGF expression,
a binding site for the Sp1 transcription factor is indispensible for the
constitutive overexpression of CTGF in SSc fibroblasts (Holmes et al., 2003).
This was implicated by the increase in levels of Sp1-bound DNA in nuclear
extracts from SSc fibroblasts, and proven by the observation that blocking
Sp1 activity resulted in reduced expression of CTGF. TGF-β is reported to
induce CTGF expression in hepatic stellate cells through Stat3 signalling (Liu
et al., 2013c).  The presence of independent response elements to TGF-β 
and ET-1 in the CTGF promoter suggests that CTGF may be a common
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mediator of fibrosis downstream of these proteins, and may therefore be a
more attractive therapeutic target than either alone. A recent study showed
that activation of the adenosine A(2A) receptor, which is associated with
dermal fibrosis, also induces CTGF expression by dermal fibroblasts (Chan
et al., 2013).
Negative regulators of CTGF expression have been reported and include
TNF-α, cyclic adenosine monophosphate (cAMP), nitric oxide (NO), and 
PPAR-γ.  TNF-α has been shown to block TGF-β-induced CTGF expression 
in healthy control and SSc fibroblasts, demonstrating TNF-α as a regulator of 
TGF-β-dependent CTGF expression (Abraham et al., 2000). Modulators of
CTGF expression can have different effects in different cell types. In
mesangial cells, TNF-α, but not IFN- γ, has a positive regulatory effect on 
CTGF expression (Cooker et al., 2007), while in lung endothelial cells, TNF-α 
has an inhibitory effect, which is enhanced by synergistic action with IFN-γ 
(Laug et al., 2012).   HGF is able to inhibit TGF-β-induced fibrotic responses 
by downregulating CTGF in a model of kidney fibrosis (Inoue et al., 2003)
and in human primary tubular epithelial cells (Kroening et al., 2009), which
may in turn abrogate CTGF-dependent fibrotic processes such as collagen
expression in fibroblasts (Wahab and Mason, 2006). Ceramide inhibition of
CTGF in human retinal pigment epithelial cells has also been reported with
implications for targeting retinal fibrosis (Sonoda et al., 2014). Oncostatin M
(OSM), a member of the IL-6 family, which can be profibrotic or pro-healing
depending on the type of injury or cellular environment, also inhibits TGF-β-
stimulated expression of CTGF in human proximal tubular epithelial cells
(Pollack et al., 2007), and the effect of OSM on CTGF expression in other
tissues and cell types requires further investigation.
Owing to the presence of several transcription factor binding sites in the
promoter of CTGF, it follows that a number of signalling pathways regulate
CTGF expression.  In addition to the TGF-β/SMAD pathway, CTGF induction 
is also mediated by non-canonical signalling pathways including
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Ras/mitogen-activated protein kinase kinase (MEK)/ MAPK, PKC, nuclear
factor-κB (NF-κB), FAK, Janus-family tyrosine kinase (JAK)/STAT, cAMP, 
Ras homolog gene family, member A (RhoA), serum response factor (SRF),
Src, JNK and PI3K are involved (Chen et al., 2002; Ding et al., 2013; Leask
et al., 2003; Leask et al., 2009; Rueda et al., 2009; Yang et al., 2013). CTGF
is induced by BMPs, Wnt and Notch in osteoblasts (Canalis et al., 2014).
There are certain single nucleotide polymorphisms or mutations associated
with differential CTGF expression in human diseases. A large genetic study
of SSc in the UK found that the GG genotype of the G-45C occurs more
frequently in SSc, suggesting substitution to the C allele is protective in SSc
(see section 1.2.5 and 1.4.9.4) (Fonseca et al., 2007). Similarly, the
rs9399005, rs6918698 SNPs in the CTGF promoter have also been
associated with SSc. SNPs in CTGF have also been associated with other
human conditions including hepatic fibrosis (rs9402373, rs12526196)
(Dessein et al., 2009), cardiovascular conditions such as stroke and
myocardial infarction (-945 GG genotype) (Cozzolino et al., 2010), increased
calcification in individuals with symptomatic aortic stenosis (-447 C) (Ortlepp
et al., 2004), and nephropathy in type I diabetes (-20 GG genotype) (Wang et
al., 2010a).
1.4.4.2 Post-transcriptional and epigenetic regulation
While the early studies have focussed primarily on transcriptional regulation
of CTGF, more recent studies have shifted to investigating the role of post-
transcriptional regulators such as miRNAs. The miRNA cluster 17-92
(miR17-92), which has been implicated in epigenetic regulation in several
disease states, including oncogenesis, has been suggested to regulate CCN
proteins including CCN2 and CCN5, as well as CCN1 indirectly through
modulating components of TGF-β signalling (Dews et al., 2010). Notably,
miR18a of the miR17-92 cluster has a functional site in the 3’ untranslated
region (UTR) of CTGF mRNA. A decrease in expression of miR17-92,
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particularly miR18a, as demonstrated by a recent study in glioblastoma
multiforme (GBM) cell lines, is concomitant with an increase in CTGF
expression (Fox et al., 2013). Conversely, in a mouse colon cancer model,
increase in expression of pro-angiogenic oncogenes (e.g. myelocytomatosis,
Myc) is accompanied by a decrease in the anti-angiogenic CCN2 and CCN5,
and concomitant increase in miR17-92 (Dews et al., 2006). This is consistent
with the negative correlation between these two CCN proteins and the
miRNA17-92 primary transcript (MIR17HG) in human cancer cell lines (Dews
et al., 2010). Furthermore, transduction of cells with miR17-92 reduces
CTGF levels while blocking miR17-92 with antisense oligonucleotides is able
to restore CTGF expression (Dews et al., 2006). MiR-133 and miR-30c also
regulate CTGF expression by binding to the 3’UTR of CTGF, in rodent and
human cardiac fibrosis and left ventricular hypertrophy (Duisters, 2009). In
cardiomyocytes but not cardiac fibroblasts, miR-18 and miR19 of the miR17-
92 cluster, which are decreased in cardiac ageing, negatively correlate with
CTGF expression (van Almen et al., 2011). Furthermore, miR-18a was
shown to directly regulate CTGF in chondrocytic cells (Ohgawara et al.,
2009). CTGF is also reported to regulate TGFBRII expression by increasing
expression of miR-302 miRNAs in mesangial cells (Faherty et al., 2012).
These results suggest that miRNA regulation of CTGF expression may also
play an important role in the development of tissue fibrosis in SSc.
Treatment of several hepatoma cell lines with an HDAC inhibitor (trichostatin
A) increases CTGF expression over 5-fold, suggesting a role for histone
acetylation-related regulation of the CTGF gene (Chiba et al., 2004). In the
same study, abnormal methylation in the 5’CpG islands of the CTGF gene
suppressed CTGF expression, which was derepressed by treatment of the
cells with a DNA methyltransferase inhibitor (5Aza-dC). A recent study
showed that decreased DNA methylation of the CTGF gene promoter is
associated with increased expression of CTGF in type 2 diabetes (Zhang et
al., 2014). These results suggest a potential for inhibitors of DNA
methylation and histone acetylation to be developed as novel clinical targets
in diseases where CTGF expression is upregulated, including SSc.
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1.4.5 CTGF binding proteins and cell surface receptors
CTGF is documented to activate various signalling pathways via one or more
signalling receptors (Figure 1.4), although no specific high affinity cell surface
receptor has yet been identified (de Winter et al., 2008; Lau and Lam, 1999;
Winterhager and Gellhaus, 2014). CTGF is also able to modulate the
activities of TGF-β and other cytokines and growth factors such as FGF, 
BMP and VEGF (Abreu et al., 2002; Chujo et al., 2009; Inoki et al., 2001).
1.4.5.1 Adhesion receptors
CTGF is anchored at the cell surface through binding to integrins (Lau and
Lam, 1999) and HSPGs such as perlecan and sydecan-4 (Chen et al., 2004;
Nishida et al., 2003). CTGF induces angiogenesis and endothelial cell
migration and adhesion through integrin ανβ3 as well as adhesion to human 
foreskin fibroblasts, human platelets, endothelial cells, and blood monocytes
by binding integrins α6β1 (via the thrombospondin motif), αIIβ3, ανβ3 or 
αMβ2, respectively (Chen et al., 2001a; Jedsadayanmata et al., 1999; 
Schober et al., 2002).  In mesangial cells, CTGF interacts with integrin β3 to 
activate the MAPK and PI3K/PKB signalling pathways (Mason, 2009). CTGF
interacts with integrins α1, α2 or ανβ3 to induce ERK1/2 and AKT-dependent 
mesangial cell migration (Crean et al., 2002). It is important to note however,
that integrin and proteoglycan binding is non-specific as they also bind
substrates other than CTGF. The heparin-binding domain of CTGF appears
to be essential for CTGF activity, including the induction of fibroblast
proliferation, attachment and adhesion (Babic et al., 1999; Ball et al., 2003;
Brigstock et al., 1997). For example, CTGF induces chondrocyte
proliferation and migration through the HSPG, perlecan (Nishida et al., 2003).
In addition to activation of tyrosine receptor kinase (TrkA) at the plasma
membrane, CTGF has also been proposed to be involved in intracellular
signalling in the endosome and nucleus, as CTGF can be endocytosed and
internalised, in a similar mechanism to endosome signalling induced by
internalised nerve growth factor (NGF)/TrkA (Mason, 2013).
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1.4.5.2 TGF-β and TGF-β receptor III 
The association of CTGF with TGF-β signalling has led to the speculation 
that CTGF may activate SMAD signalling indirectly either by interacting with
TGF-β (via the VWC domain of CTGF) to increase the binding affinity of 
TGF-β for its receptors or by changing levels of inhibitory SMAD proteins and 
thus prolonging TGF-β signalling (Abreu et al., 2002; de Winter et al., 2008).  
However, this mechanism has only been shown in Xenopus, where module II
of CTGF bound to TGF-β (Kd 30 nM), facilitating TGF-β to bind to its 
receptors (Abreu et al., 2002).  The underlying mechanism of this TGF-β and 
CTGF interaction remains elusive.  Unlike CTGF, CCN3 inhibits TGF-β- and 
Wnt-induced fibrillogenesis in SSc and Marfan syndrome (Lemaire et al.,
2010), which demonstrates that different members of the CCN family can
display opposing cellular functions, despite their conserved modular structure.
Controversially, CTGF has been shown to interact with TGF-β to shift 
signalling from SMAD-dependent to non-canonical signalling, in a
mechanism involving CTGF binding with TGFβRIII in mesangial cells 
(O'Donovan et al., 2012). This study found that CTGF decreased expression
of pSMAD2 and pSMAD3 but increased levels of non-canonical signalling via
ERK1/2, an effect reversed by the knockdown of TGFβRIII expression.  The 
authors also showed that CTGF decreased TGF-β transcription in a cancer 
cell line (HeLa) and that CTGF reduced binding of TGF-β to its receptor in a 
human renal proximal tubule cell line (HK2). These findings are contradictory
to other reports such as that showing simultaneous treatment of mesangial
cells with CTGF and TGF-β inducing pSMAD2, pSMAD3 and transcription of 
TGF-β responsive genes (Wahab and Mason, 2006).  One reason suggested 
for these contradictory results is that the study by O’Donovan et al. was
carried on whole cell lysate while the latter was on nuclear cell extracts only.
However, in another study using whole cell extracts, TGF-β treatment of 
fibroblasts from mice over-expressing CTGF (Col1a2-CTGF), also induced
expression of pSMAD2 and pSMAD3 (Sonnylal et al., 2010). Furthermore,
Introduction | 76
CTGF-mediated TGF-β/SMAD signalling has also been implicated in kidney 
fibrosis and in vivo, in models of fibrosis such as the UUO model (Yokoi et al.,
2004) and subtotal nephroctomy model (Okada et al., 2002).
1.4.5.3 Low density lipoprotein receptor-related proteins
In addition to adhesion receptors, CTGF may also function via the low
density lipoprotein receptor-related proteins (LRP) -1 (Chen et al., 2001b;
Segarini et al., 2001) and LRP-6 (Mercurio et al., 2004). LRP-1 is involved in
endocytosis of many proteins, and was shown to bind to CTGF in a bone
marrow stem cell line (BMS2) and rat kidney fibroblasts (NRK-49F) (Yang et
al., 2004). CTGF activation of the Wnt co-receptor LRP-6 in mesangial cells
suggests that CTGF may signal via the Wnt pathway, which has been
implicated in fibrosis and wound healing. Conversely, interaction of LRP6
with CTGF in developing Xenopus blocked Wnt signalling (Mercurio et al.,
2004).
1.4.5.4 Tyrosine receptor kinase
CTGF has also been reported to bind the dual receptor complex formed by
Trk and the neurotrophin receptor p75NTR (Wahab et al., 2005b). The
interaction was disrupted by the Trk antagonist K252a and was shown to
enhance TGF-β signalling by mediating expression of TGF-β immediate early 
gene-1 (TIEG-1), a repressor of the TGF-β negative regulator SMAD7.  
CTGF has also been shown to interact with bone morphogenetic protein 7
(BMP7), an antagonist of TGF-β signalling and organ fibrosis, BMP4, VEGF 
and integrins (Gressner et al., 2007; Mason, 2009). It may also be possible
that CTGF-TrkA signalling requires the cooperation of other cell surface
proteins such as integrins and HSPGs. For example, CTGF binding to
integrin β1/TrkA was shown to activate NF-κB signalling in glioma tumour-
initiating or tumour stem cells, and a CTGF/TrkA/HSPG receptor complex
was suggested to account for CTGF-induced ERK1/2 and PI3K/PKB/NF-κB 
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signalling in mesangial cells, which led to expression of chemokines including
CX3CL1, MCP-1, RANTES (Wu et al., 2008).
1.4.5.5 Bone morphogenetic proteins
In addition to TGF-β, CTGF also interacts with other members of the TGF-β 
superfamily, BMP-4 and BMP7. Indeed, CTGF has a higher affinity for BMP4
(Kd 5 nM) and BMP7 (Kd 14 nM) than TGF-β (Kd 30 nM).  As with binding to 
TGF-β, CTGF interacts with BMP4 via the VWC domain of CTGF, but 
instead of enhancing signalling, CTGF antagonises actions of BMP4 such as
SMAD1 phosphorylation in Xenopus embryos (Abreu et al., 2002). In
support of this, a more recent study showed that BMP4, but not BMP7,
reduced TGF-β-induced proliferation and ECM synthesis of normal human 
lung fibroblasts (Pegorier et al., 2010). In contrast, in mouse models and
fibrotic disorders such as diabetic nephropathy (Wahab et al., 2005a),
increased CTGF is concomitant with increased BMP4 levels, suggesting that
CTGF inhibition of BMP4 in kidney fibrosis is unlikely, and that the effect of
CTGF and BMP4 interaction is likely to be cell-type/tissue dependent.
Reduced expression of BMP7 is linked to fibrogenesis as BMP-7 can
normalise TGF-β-induced fibrotic responses in vitro, and abrogate fibrosis in
the heart, kidney and colon (Gonzalez et al., 2002; Izumi et al., 2006; Klahr,
2003; Klahr and Morrissey, 2003; Maric et al., 2003; Zeisberg et al., 2003;
Zeisberg et al., 2005). However, it seems that BMP-7 has no effect on skin
fibrosis, bleomycin-induced lung fibrosis, or rescuing renal proximal tubule
cells from EMT.  Both BMP4 and BMP7 inhibited TGF-β-induced 
myofibroblast differentiation, and release of MMP-13 but only BMP7 blocked
MMP-2 activity in human lung fibroblasts (Pegorier et al., 2010).
1.4.6 Biological function of CTGF
CTGF expression and function (Table 1.9) are dependent on cellular context
and interactions with regulatory factors in the environment (Figure 1.4).
CTGF is mainly secreted into the extracellular space and has been detected
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Function Target cells Reference
ECM synthesis Mesangial cells, fibroblasts (Crean et al., 2002; Grotendorst
and Duncan, 2005)
Chemotaxis,
Proliferation
Mesangial cells, fibroblasts
chrondrocytes,
osteoblasts, endothelial,
smooth muscle
(Bradham et al., 1991; Crean et
al., 2002; Fan et al., 2000;
Nakanishi et al., 2000; Shimo et
al., 1999)
Cell
differentiation
Chrondrocytes,
osteoblasts, fibroblasts
(Grotendorst and Duncan, 2005)
Cytoskeletal
rearrangement
Mesangial cells, fibroblasts (Chen et al., 2004; Crean et al.,
2002)
Cell cycle Mesangial cells,
fibroblasts, epithelial cells
(normal rat kidney cell line)
(Abdel-Wahab et al., 2002;
Kothapalli and Grotendorst, 2000)
Apoptosis Endothelial, mesangial,
smooth muscle, epithelial
(MCF-7 cancer cell line)
cells
(Babic et al., 1999; Brigstock,
2003; Hishikawa et al., 1999b;
Hishikawa et al., 2000)
Table 1.9. Effects of CTGF on cellular functions
The various effects of CTGF on cellular functions and the cell types on which
CTGF act on.
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in various biological fluids including serum, amniotic, cerebrospinal and
wound fluid (Gressner and Gressner, 2008). CTGF is stored in platelets and
released during blood clotting and at the site of injury in atherosclerosis and
fibrotic tissue lesions to increase the local CTGF concentration (Cicha et al.,
2004). Removal of CTGF from the interstitium and circulation is thought to
involve binding of CTGF via module III to low density lipoprotein receptor-
related protein (LRP), followed by CTGF internalisation and subsequent
degradation (Chen et al., 2001b; Segarini et al., 2001). Although the
extracellular half-life of CTGF in the interstitium and circulation is unknown,
the N–terminal fragment of CTGF is suggested to have a longer half-life than
the C-terminal fragment since module III of CTGF, which is essential for its
cellular uptake, is on the C-terminal fragment (Gressner and Gressner, 2008).
Interestingly, in mesangial cells, it has been reported that internalisation of
CTGF is followed by transport via endosomes to juxtanuclear organelles.
CTGF is subsequently translocated to the cytosol where phosphorylation by
PKC enables CTGF to translocate into the nucleus and perhaps act on
transcription (Wahab et al., 2001). Another consequence of CTGF binding to
LRP is the inhibition of the Wnt signalling pathway. In this case, CTGF
competes with Wnt to bind the Wnt co-receptor LRP6 (Mercurio et al., 2004).
During development, CTGF is essential for formation of connective tissues
during chrondrogenesis and osteogenesis, and in angiogenesis (de Winter et
al., 2008; Ivkovic et al., 2003; Perbal, 2004). CTGF expression has been
detected in skeletal and vascular tissue including hypertrophic chondrocytes
in the growth plate of cartilage, in smooth muscle cells and connective tissue
around developing muscle, and in renal podocytes in the developing
glomerulus (Friedrichsen et al., 2003; Yamamoto et al., 2002). In adults,
CTGF expression is restricted to the placenta during embryo implantation,
ovarian follicles, testicular tubes, the cardiovascular mesenchyme, or during
response to injury (Leask et al., 2004; Winterhager and Gellhaus, 2014).
Consistent with the described CTGF functions, homozygous CTGF knockout
mice are neonatal lethal due to impaired chondrogenesis and ECM
abnormalities (Ivkovic et al., 2003). Furthermore, recombinant CTGF has
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been shown to induce differentiation and proliferation of chondrocytes
through the MAPK pathway in vitro (Nakanishi et al., 2000a; Yosimichi et al.,
2001) and angiogenesis in a breast cancer cell line and in skin fibroblasts
(Babic et al., 1999; Shimo et al., 2001a; Shimo et al., 2001b). CTGF is also
involved in protecting and regenerating cartilage - in chondrocytes and
models of osteoarthritis (Abd El et al., 2014; Zhu et al., 2014).
1.4.7 CTGF signalling
CTGF is reported to modulate various signalling pathways (Lipson et al.,
2012). At the cellular level, CTGF may regulate cell growth, migration,
proliferation, ECM synthesis, adhesion that is linked to cell attachment (e.g.
to fibronectin), differentiation, survival and apoptosis (Chen et al., 2004;
Leask and Abraham, 2006; Shi-Wen et al., 2008) (Figure 1.4). In addition to
acting as an adapter molecule that modulates signalling via other cytokines
or growth factors (see section 1.4.5), CTGF can also directly stimulate
numerous signalling pathways and transcription factors including p38,
ERK1/2 MAPK, AKT/PKB, JNK, SMAD and NF-κB pathways, as 
demonstrated in mesenchymal cells (Sonnylal et al., 2010). Activation of the
ERK1/2 pathway is important in mediating cell adhesion and ECM production
(Chen et al., 2001a).  Activation of NF-κB is followed by nuclear localisation 
of the protein to activate transcription of genes promoting cell survival, which
includes enhancing cell growth and preventing apoptosis.  Like TGF-β, CTGF 
can induce either proliferation or differentiation depending on its interaction
with other growth factors and cytokines. For example, when fibroblasts are
stimulated with CTGF, DNA synthesis and cell proliferation are induced in the
majority of the cells while the presence of IGF-2 with CTGF induces
fibroblasts to differentiate into myofibroblasts (Grotendorst et al., 2004).
Seemingly opposing functions of CTGF have been reported, for example, as
an inhibitor of smooth muscle cell proliferation and inducer of apoptosis
(Hishikawa et al., 1999a), and as a potent mitogen for fibroblasts and smooth
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muscle cells (Fan et al., 2000). This may reflect the fact that individual
domains of the protein have different biological activities. CTGF has been
likened to a prokaryotic polycistronic message, as separate exons code for
the individual modules of CTGF, which have different biological functions. For
example, the N-terminal portion, including modules I and II, of CTGF
mediates cell differentiation and collagen synthesis while the C-terminal
fragment consisting of modules III and IV, supports proliferation (Grotendorst
and Duncan, 2005). In vitro, the full-length protein seems to be the most
potent form of biologically-active CTGF (Grotendorst and Duncan, 2005). In
biological fluids such as uterine flushings, endogenous proteases cleave
CTGF into its constituent N- and C-terminal fragments (Ball et al., 1998).
1.4.8 CTGF in wound healing
CTGF expression is elevated following injury, and as a strong inducer of
ECM proteins such as collagen type I and fibronectin and integrin receptors,
it is involved in various stages of wound healing including granulation tissue
formation, re-epithelialisation, matrix formation and remodelling (Abraham et
al., 2007). It is not surprising then that CTGF is the most abundant growth
factor stored in platelets, and is released upon coagulation, alongside TGF-β, 
to initiate wound healing (Kubota et al., 2004; Liu et al., 2003). Although the
potential significance of CTGF in wound healing is well known (Duncan et al.,
1999; Igarashi et al., 1993; Stratton et al., 2002), the precise in vivo role of
CTGF and mechanisms of CTGF action however, remain to be elucidated.
Demonstration of CTGF-induced endothelial cell proliferation, migration,
survival, and adhesion in vitro suggests CTGF plays a role in angiogenesis
while the pro-migratory function of CTGF indicates its role in re-
epithelialisation. A recent study showed that conditionally knocking out
CTGF in mice significantly impaired re-epithelialisation of wounds in the
cornea (Gibson et al., 2014). Interestingly, fibroblast-specific knockout of
CTGF did not affect the rate of repair in mouse dermal punch wounds nor
fibroblast activation and proliferation, but did influence pericyte recruitment
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(Liu et al., 2014). This suggested that CTGF is not essential for cutaneous
tissue repair, but enhances TGF-β-induced wound healing.
After coagulation, while TGF-β is thought to be involved in the initiation of 
repair, CTGF plays a more important role in the later stages of repair
(Igarashi et al., 1993). Injury to the skin has been shown to induce
expression of TGF-β and CTGF RNA (Igarashi et al., 1993). Interestingly,
expression of these proteins appeared to be time-dependent with peak levels
of TGF-β appearing at three days post-injury, which is a contrast to the peak 
levels of CTGF detected on day 9 post-injury. The main cell types to express
CTGF included connective tissue and vascular endothelial cells. Once the
stages of repair were complete, levels of CTGF mRNA returned to basal
levels (Igarashi et al., 1993), which support the concept that only low levels
or CTGF are expressed basally in adult cells, apart from during wound
healing, and that expression is controlled largely at the level of transcription.
1.4.9 CTGF in disease
A pathological role has been implicated for CTGF in a number of human
diseases and mouse models of disease, mainly in cancer, chronic kidney
disease and fibrotic disorders, making CTGF a potential target in developing
effective therapies against these diseases (Chen and Lau, 2009; van Geest
et al., 2014). Indeed, approaches that block CTGF signalling such as
through the use of anti-CTGF neutralising antibodies or RNAi in clinical trials
or non-clinical models of diseases such as hypertension, pancreatic cancer,
liver and lung fibrosis, and chronic kidney disease, has already been reported
(Adler et al., 2010; Aikawa et al., 2006; Dornhofer et al., 2006; Li et al., 2006;
Szabo et al., 2014).
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1.4.9.1 CTGF in cancer
CTGF involvement has been described in metastatic cancers such as
pancreatic cancer, glioblastoma, acute lymphoblastic leukemic and bone
metastasis of breast cancer but its role in tumourigenesis is not completely
understood (Charrier and Brigstock, 2013; Jacobson and Cunningham, 2012).
The effects of CTGF in cancer appear to be cell-type dependent. In this
context, CTGF is reported to modulated cell cycle progression by increasing
levels of cyclin A and downregulating p27kip1, a positive regulator and an
inhibitor of cell cycle progression, respectively (Kothapalli and Grotendorst,
2000). In proliferating endothelial cells and glioma cells, CTGF levels are
elevated (Pan et al., 2002) while in the breast cancer epithelial cell line, MCF-
1, the observed deficiency in CTGF expression is likely to prevent CTGF-
induced apoptosis and contribute to the immortal property of these cells. This
is consistent with the observation that overexpression of CTGF, as found in
oral squamous cells and carcinoma-derived cell lines, is associated with
attenuation of cell growth and tumour development (Hishikawa et al., 1999b;
Moritani et al., 2003).
In prostate cancers, CTGF expression, prominent in the surrounding stroma,
is thought to positively condition the tumour microenvironment (Yang et al.,
2005). In paediatric nephroblastomas, the dysregulated expression of CTGF
is attributed to mutations in the tumour suppressor gene, WT-1, which is a
repressor of CTGF (Stanhope-Baker and Williams, 2000).
1.4.9.2 CTGF in fibrosis
Consistent links between CTGF and fibrotic disorders including SSc,
atherosclerosis, cardiac fibrosis, diabetic nephropathy, keloids and
hypertrophic scars, liver cirrhosis, skeletal muscle fibrosis, eosinophilic
fasciitis, nodular fasciitis, Dupuytren's contracture and pulmonary
hypertension suggest that CTGF is an important participant in fibrosis in
various organs (Abraham, 2008; Charrier et al., 2014; Gressner et al., 2007;
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Gressner et al., 2013; Igarashi et al., 1995; Igarashi et al., 1996; Jun and Lau,
2011; Metalidis et al., 2013; Morales et al., 2013; Rosin et al., 2013).
Experiments such as those blocking CTGF expression in vitro or in animal
models are required to provide proof of concept that CTGF is an essential
mediator of fibrosis. Many studies have shown CTGF-mediated production
of ECM proteins and alteration of fibroblast proliferation or activation status
(Sakai et al., 2013). A recent report showed that in human lung fibroblasts,
CTGF is able to induce collagen type I expression via the Rac1/mixed-
lineage kinase 3 (MLK3)/JNK/AP-1 signalling pathway (Lin et al., 2013). In
the pancreas, CTGF is produced by pancreatic acinar cells and stellate cells
to drive inflammation and fibrosis, respectively (Charrier et al., 2014). CTGF
and Snail are reported to mediate paracrine signalling of endothelial cells on
fibroblasts in cardiac fibrosis (Lee et al., 2013b).
In idiopathic pulmonary fibrosis (IPF), CTGF expression is increased and is
localised to proliferating type II alveolar epithelial cells (T2) and
myofibroblasts in the interstitium (including the alveolar walls and
perivascular and peribronchial tissues), which play a central role in
pulmonary fibrosis. Both apoptosis and hyperplasia of T2 cells have been
detected in IPF tissue, which reflects the presence of proliferative alveolar
epithelial cells directly adjacent to injured epithelial cells, leading to aberrant
epithelial-mesenchymal cross-talk (Konigshoff et al., 2009). Amongst other
growth factors and cytokines, T2 cells may secrete CTGF to enhance
fibroblast activation and ECM production during pulmonary fibrosis (Shi-Wen
et al., 2008). Like myofibroblast differentiation, CTGF upregulation is
dependent on RhoA signalling, an important pathway in cell cycle regulation,
suggesting CTGF plays an important role in Rho-A mediated fibroblast
turnover in the lung (Watts et al., 2006). In IPF, Thy-1(-) myofibroblasts,
which have greater expression of myofibroblast and myogenic regulatory
factors (MRF) than Thy-1(+) cells, predominate in fibroblastic foci, whereas
normal lung fibroblasts are mainly Thy-1(+) (Sanders et al., 2007). As
discussed below, upregulation of CTGF is also observed in SSc. Anti-CTGF
strategies are potential anti-fibrotic therapies as studies are emerging
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reporting anti-CTGF antibodies or CTGF-specific shRNA are able to the
inhibit or reverse fibrosis in the liver and lungs of mice (Lipson et al., 2012).
The anti-fibrotic properties of statins (3-hydroxy-3-methylglutaryl-coenzyme A
reductase inhibitors) in keloid fibroblasts and bleomycin-induced lung fibrosis
in rats have been associated with their ability to inhibit CTGF expression
(Mun et al., 2014; Zhu et al., 2013). Inhibition of CTGF has also been
reported to effectively prevent liver fibrosis in vivo and diminish hepatic
stellate cell activation (Hao et al., 2014).
1.4.9.3 CTGF in SSC
Hints of a connection between CTGF and SSc were first described in 1995
by Takehara’s group (Kikuchi et al., 1995). Firstly, they reported that
compared to healthy controls, scleroderma fibroblasts showed enhanced
responses to TGF-β, which were mediated by CTGF. Consistent with this
finding, they also reported in situ hybridisation experiments which showed
elevated CTGF mRNA level in SSc lesional tissue, particularly in fibroblasts
in the deep dermis. A key finding was the positive correlation of CTGF
expression with the progression and severity of fibrosis in SSc. Furthermore,
CTGF-expressing fibroblasts were more abundant in skin tissue in the fibrotic
stage than inflammatory stage, which, collectively, supports the hypothesis
that CTGF contributes to fibrosis in SSc (Igarashi et al., 1995). The
conclusion drawn from these early experiments is supported by the work of
several other groups noting increased CTGF expression in SSc, and has led
to the current perspective of CTGF upregulation as a characteristic feature of
SSc (Igarashi et al., 1995; Igarashi et al., 1996; Shi-Wen et al., 2000; Zhou
et al., 2005). SSc is also associated with the loss of the tumour-suppressing
phsophatase PTEN, and a recent study using CTGF and PTEN gene
knockout mice showed that CTGF is essential for collagen production and
myofibroblast recruitment induced by the loss of PTEN (Liu et al., 2013b).
The A(2a) receptors of the profibrotic factor adenosine are upregulated in
SSc dermal fibrosis and CTGF plays a role in mediating collagen production
downstream of A(2a) receptor activation (Chan et al., 2013). CTGF
overexpression is associated with myofibroblast differentiation and has also
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been detected in SSc microvascular endothelial cells and (Serrati et al.,
2013).
As a multi-organ disease, increased levels of CTGF have also been detected
in the SSc lung as well as the skin (Lindahl G.E. et al., 2013). As CTGF is a
secreted protein, studies have also investigated its levels in various body
fluids, which found that CTGF levels in sera and plasma, blister (dermal
interstitial) fluids and bronchoalveolar lavage (BAL) fluids from SSc patients
were elevated compared to those from healthy controls (Dziadzio et al.,
2005b; Sato et al., 2000; Shi-Wen et al., 2000). Consistent with the notion
that CTGF becomes cleaved following secretion, differing levels of the N-
terminal and C-terminal products, and intact CTGF were found in SSc
patients (Dziadzio et al., 2005b). In the study on levels of CTGF in plasma
and blister fluids, only the N-terminal fragments of CTGF were elevated in
SSc patients compared to healthy controls and postively correlated with
severity of skin disease and negatively with disease duration. This is
consistent with clinical observations that skin fibrosis begins to regress 2–3
years after SSc initiates (Steen and Medsger, 2001). In contrast, levels of
intact and C-terminal CTGF fragments remained consistently low in SSc.
Combining this finding with other studies which have reported increased
CTGF expression in various tissues in SSc, provides support that it is the C-
terminal portion of CTGF which can modulate cellular functions by attaching
to the ECM. This is consistent with the C-terminal end of CTGF being
associated with integrin binding and heparin-dependent cell adhesion, while
the N-terminal end acts by modulating the activities of other soluble
mediators in the ECM (Bork, 1993; Mori et al., 1999; Perbal, 2004). These
observations support CTGF as a mediator of the fibrotic response in SSc and
as a marker of SSc fibrosis.
As it might be expected that levels of profibrotic factors accumulate in fibrotic
lesions, the highest levels of CTGF protein were detected in cultured dermal
fibroblasts explanted from areas of skin ‘involved’ in fibrosis in SSc patients
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(Shi-Wen et al., 2000). Surprisingly, cultured dermal fibroblasts grown from
SSc patient biopsies showed increased CTGF expression compared to those
from healthy controls, regardless of whether the biopsy was taken from
‘involved’ or ‘uninvolved’ areas (Shi-Wen et al., 2000). This apparent
anomalous expression of CTGF in uninvolved areas suggested that
abnormal CTGF expression may act as a predisposition to the development
of fibrosis in SSc patients. This hypothesis is consistent with a later
microarray study which showed that lesional and non-lesional fibroblasts
from SSc patients showed no significant differences in gene expression, yet
they presented a different gene profile to fibroblasts from healthy control skin
(Zhou et al., 2005).
1.4.9.4 Genetics of CTGF in SSc
The theory that the CTGF gene may increase the susceptibilty of individuals
to develop SSc was strengthened by the introduction of genome-wide
association studies (GWAS). By screening the genome of the Choctaw
Indians, a population with a high prevelance of SSc, a significant association
was found between disease and the region 6q23-27 which contains the
CTGF gene (Zhou et al., 2003). A study by Fonseca et al. on polymorphisms
in the promoter region of the CTGF gene found that the G-945C
polymorphism, which is more common in healthy controls than individuals
with SSc, may provide protective effects by repressing CTGF transcription
via a mechanism which exploits the higher affinity of the C allele for Sp3, the
transcription factor which is linked to repression of CTGF (see section 1.4.4.1)
(Fonseca et al., 2007; Holmes et al., 2003). Patients with the homozygous
GG genotype occurred more frequently in SSc patients than in healthy
controls. This genotype was associated with the presence of anti-
topoisomerase I antibodies and fibrosing alveolitis in the patients. The
association of this polymorphism may explain in part, the increased
expression of CTGF. Additionally, in support of CTGF as a contributer to
SSc genetic susceptibility, polymorphisms in the CTGF gene have also been
identified in a Japanese and a French cohort (Granel et al., 2010; Kawaguchi
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et al., 2009). However, as is often the case with genetic associations, the G-
945C polymorphism association has not been replicated, perhaps due to
geographical variation or differences in sample size, in all patient cohorts,
including a North American, a Thai and a pan-European set of patients
(Dendooven et al., 2011b; Louthrenoo et al., 2011; Rueda et al., 2009).
Perhaps analogous to the similar gene expression of CTGF in lesional and
non-lesional areas of SSc skin, a genetic study of twins showed increased
CTGF expression in dermal fibroblasts from both SSc patients and their
healthy monozygotic twin (Zhou et al., 2005). These observations support
the idea that increased CTGF expression alone is insufficient for fibrogenesis
and implies that other factors must be present and work together with CTGF
to induce and promote fibrosis. The most obvious is perhaps the
relationship between CTGF and TGF-β function, although a study by Gore-
Hyer et al. showed that SSc fibroblasts were more sensitive to CTGF-
induced collagen expression, mediated by CTGF working in concert with a
co-activator such as insulin (Gore-Hyer et al., 2003).
Culturing normal dermal fibroblasts in the presence of serum from an SSc
patient or her clinically unaffected monozygotic twin induced expression of
CTGF – as well as Col1a2 and SPARC, which suggests a secreted factor,
which could be CTGF itself, regulates CTGF expression (Zhou et al., 2005).
This supports the notion that the autocrine effect of CTGF may represent a
key mechanism by which CTGF expression is persistently elevated in SSc
(Riser et al., 2000; Wang et al., 2003). It can be seen from the wealth of
studies on dysregulated signalling pathways in SSc that increased collagen
expression is an important characteristic of SSc and end-point in fibrotic
experiments (Dziadzio et al., 2004). It is noteworthy that numerous
regulators of collagen expression and their signalling pathways have also
been implicated in regulation of CTGF expression. Therefore, determining
the signalling pathways that mediate CTGF expression and function may
elucidate the mechanisms which underlie the development of fibrosis in SSc.
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1.4.10 The TGF-β and CTGF axis in fibrosis 
Expression of CTGF is concomitantly increased with that of TGF-β in wound 
healing, and fibrotic conditions such as keloid and hypertrophic scars
(Barrientos et al., 2008).  This is perhaps not surprising since TGF-β is able 
to induce expression of CTGF (Igarashi et al., 1993). Intriguingly, in SSc,
while circulatory levels of CTGF (N-terminal fragment) are elevated, total
levels of TGF-β in the sera of SSc patients did not show significant difference 
to those in healthy controls.  In fact, levels of active TGF-β were decreased in 
dcSSc compared to lcSSc and healthy controls, demonstrating that in
contrast to the positive correlation between CTGF and disease duration and
skin fibrosis, TGF-β shows negative correlation with these variables of 
disease activity (Dziadzio et al., 2005a).  In SSc, the highest levels of TGF-β 
expression occur in skin tissue that is in the inflammatory stage, whereas
peak CTGF expression is found in skin that has entered the fibrotic stage
(Igarashi et al., 1995; Querfeld et al., 1999). This is consistent with the
theory that CTGF plays a more central role in sustaining fibrosis as opposed
to initiating fibrosis, a process more strongly influenced by TGF-β.  
Altered expression of CTGF contributes to abnormal wound healing and
fibrosis (Liu et al., 2014). Evidence exists both for CTGF acting downstream
of TGF-β, and for CTGF working synergistically with TGF-β. One school of
thought suggests that endogenous CTGF acts as a downstream mediator of
TGF-β because many activities of CTGF parallel those induced by TGF-β 
(Leask and Abraham, 2006). It has been reported that CTGF is essential for
TGF-β to activate SMAD1-ERK1/2 signalling (but it is not required for the 
phosphorylation of Smad3) (Nakerakanti et al., 2011). This idea of CTGF as
a downstream mediator is supported by another study by Okada et al., which
demonstrated that treatment of animals with CTGF antisense oligonucleotide
attenuated fibrosis while having no effect on levels of TGF-β (Okada et al.,
2005). This is consistent with other studies showing a requirement for CTGF
for the induction of a subset of transcriptional responses to TGF-β such as 
Introduction | 90
fibroblast proliferation, collagen synthesis, adhesion and myofibroblast
differentiation (Duncan et al., 1999; Frazier et al., 1996; Grotendorst, 1997;
Grotendorst et al., 2004; Kothapalli et al., 1997; Lau and Lam, 1999; Shi-wen
et al., 2006); processes that are inhibited when CTGF synthesis or action is
blocked.
Other studies support the alternative view that TGF-β works in synergy with 
CTGF to sustain fibrosis.  For example, the injection of TGF-β or CTGF alone 
into the dermis of naive mice results in the formation of transient granulation
tissue only, while serial injections of CTGF following that of TGF-β lead to 
development of persistent dermal fibrosis (Bonniaud et al., 2003; Mori et al.,
1999). Another piece of evidence against CTGF as a downstream mediator
of TGF-β is presented in a recent study showing that fibroblasts from CTGF-
deficient mice remained responsive to TGF-β-stimulation leading to collagen 
and α-SMA expression (Liu et al., 2011).  Recent studies showed a joint role 
for TGF-β2, CTGF and gremlin (an antagonist of BMPs) in the induction of 
EMT and ECM synthesis in lens epithelial cells (Ma et al., 2014). Ma et al.
demonstrated that the three proteins were individually sufficient to induce
EMT and expression of ECM proteins and that CTGF and gremlin mediated
TGF-β2-induced EMT in vitro.
1.4.11 Altering CTGF expression in animals as models of disease
Consistent with the well known functions of CTGF being tissue- and cell type-
specific, it follows that overexpression or deletion of CTGF in different
anatomic locations or types of cells produces different phenotypes in mice.
The phenotype of various transgenic animal models combined with
experimental intervention (as outlined in Table 1.10) demonstrates that
CTGF can be pathogenic, but it can also have a beneficial and protective
effect in some cases, via mechanisms of action which are not yet completely
understood.
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Homozygous CTGF knockout animals are perinatally lethal with severe
skeletal dysplasia, enlarged hypertrophic zones, impaired endochondral
ossification, a reduced β-islet cell population and more glucagon-positive 
cells in the pancreas, pulmonary hypoplasia (Ivkovic et al., 2003; Jun and
Lau, 2011). Cell-type specific deletion in early limb or osteoblasts results in
osteopaenia (Canalis et al., 2010) while deletion in ovary and uterus impairs
follicle development, steroidogenesis and ovulation (Nagashima et al., 2011).
Deletion in fibroblasts induces resistance to bleomycin-induced skin fibrosis
in mice (Liu et al., 2011).
Doherty et al. reported a model where basal CTGF expression could be
altered from low to high. Overexpression (9-fold) of CTGF caused death at
embryonic day 10 to day 12 while mice expressing only 30% of the normal
level of CTGF are viable and healthy (Doherty et al., 2010). The effects of
fibroblast-specific overexpression of CTGF in mice are covered in the
Chapter 3 Introduction.
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Animal model Treatment and/or phenotype Reference
Fibrosis
Hepatocyte-specific CTGF overexpression in mice Increased severity of CCl4- or bile duct
ligation-induced liver fibrosis
(Tong et al., 2009)
CCl4-induced liver fibrosis CTGF siRNA reduced fibrosis (Li et al., 2006)
N-nitrosodimethylamine-induced liver fibrosis CTGF siRNA reduced fibrosis (George and
Tsutsumi, 2007)
Streptozotocin-induced diabetes in podocyte-specific
CTGF overexpression in mice
Increased renal hypertrophy, proteinuria and
mesangial matrix expansion
(Yokoi et al., 2008)
Tubulointerstitial fibrosis induced by unilateral uretal
obstruction in rats
Injection of CTGF antisense oligonucleotide
into rat tail veins reduced ECM production
(Yokoi et al., 2004)
Subtotal nephroctomy in active TGF-β overexpression 
in mice
Intravenous injection of CTGF antisense
nucleotide blocked interstitial fibrosis in
remnant kidney
(Okada et al., 2005)
Angiotensin II-induced pressure overload and heart
failure in cardiomyocyte-specific CTGF overexpression
in rodents
CTGF promoted cardiac hypertrophy, and
protection against pressure-induced heart
failure and cardiac fibrosis
(Panek et al., 2009)
Bleomycin-induced skin fibrosis in fibroblast and
smooth muscle cell-specific CTGF knockout mice
Deletion of CTGF gives resistance to
bleomycin-induced skin fibrosis
(Liu et al., 2011)
Fibroblast-specific CTGF overexpression in mice Fibrosis in skin, lungs, kidneys and
vasculature
(Sonnylal et al., 2010)
Cancer
Pancreatic cancer xenografts CTGF shRNAs attenuated tumour growth (Bennewith et al.,
2009)
Orthotopic and xenografted pancreatic cancer in mice FG-3019 neutralising anti-CTGF antibody
reduced tumour growth and metastasis
(Aikawa et al., 2006;
Dornhofer et al.,
2006)
Cardiovascular disease
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Carotid artery angioplasty with viral perfusion in rats Application of recombinant CTGF promoted
neointimal thickening
(Kundi et al., 2009)
Nephropathy
Streptozotocin-induced diabetes in mice Subcutaneous injection of CTGF antisense
nucleotide reduced levels of proteinuria and
albuminuria
(Guha et al., 2007;
Kuiper et al., 2006)
Reduction of CTGF in CTGF+/- mice reduced
streptozotocin-induced pathology by
attenuating thickening of retinal capillaries
Wound healing
Rabbit punch wound (on the ears) Intradermal injection of CTGF antisense
oligonucleotide attenuates hypertrophic
scarring
(Sisco et al., 2008)
Table 1.10 Modulating CTGF expression in animal models of disease
Examples of animal models of human diseases and wound healing with altered CTGF expression. Table adapted from
Jun et al. 2011
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1.5 Hypothesis and aims
Several lines of evidence highlight a role for CTGF in tissue fibrosis, including:
the increase of CTGF observed in fibrotic diseases; the role of CTGF in ECM
production and fibroblast activation; the binding of CTGF to receptors on the
mesengial cell surface; and the fibrotic phenotype induced by CTGF
overexpression in transgenic mice. This thesis addresses the hypothesis
that one of the ways that CTGF mediates fibrosis is through induction of
EMT-like changes in epithelial cells and that interruption to CTGF activity
may provide a specific, TGF-β-independent method of treating tissue fibrosis
in SSc. In order to further understand the functional role of CTGF in the
pathological process of tissue fibrosis, the aims of the study are:
1. To examine in mice, the effects of overexpressing CTGF specifically in
fibroblasts using fibroblasts, and skin and lung sections (Col1A2-
CTGF transgenic mice).
2. To investigate EMT as a potential source of fibroblasts and the role of
CTGF in EMT in lung fibrosis, using type II alveolar epithelial cells,
recombinant TGF-β and CTGF to induce cells and identify EMT 
markers in cells.
3. To investigate if attenuating CTGF expression is able to abrogate
fibrosis.
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Chapter 2. Materials and methods
2.1 Patient samples
Samples were taken from healthy volunteers and scleroderma patients that
fulfilled the American College of Rheumatology (ACR) preliminary criteria for
disease (Leroy et al., 1988) (refer to table in Introduction). For cell culture or
histological analysis of human skin, 3-6 mm3 punch biopsies were taken from
the skin on the forearm or dorsal surface of the hand. For human lung
samples, specimens were obtained from open lung biopsies. Informed
consent and ethical approval was obtained in all cases. For histological
analysis, lung samples were obtained from: a female patient, age 66,
diagnosed with diffuse SSc (dcSSc), SCL70 positivity and lung fibrosis; a 76-
year old male with dcSSc, lung fibrosis, previous renal crisis, and was
positive for anti- RNA polymerase antibodies.
2.2 Cell culture
2.2.1 Primary cell culture
Mouse embryonic fibroblasts were isolated from embryos (E14.5) of Col1A2-
CTGF transgenic mice using a standard explant technique (Abraham et al.,
1991). Briefly, each biopsy was washed in Dulbecco's Modified Eagle
Medium (DMEM; Invitrogen) supplemented with antibiotics - 100 U/ml
penicillin, 100 mg/ml streptomycin - and 3% anti-fungal agent (Invitrogen) for
20 minutes at room temperature, and finely chopped using a scalpel into
1mm3 fragments. Fragments were spread on the bottom of cell culture flasks
using a cell spreader (BD Falcon) and left to adhere for 20 minutes. Tissue
fragments were covered with complete medium - DMEM containing 10%
foetal bovine serum (FBS; Invitrogen), and antibiotics at 37°C in a humidified
5% CO2 atmosphere until outgrowths of fibroblast-shaped, elongated cells
emerged from the fragments. The resulting cell colonies were passaged
after 2 weeks to new culture flasks to expand the cell population. The same
method was also used for the isolation of fibroblasts from human or mouse
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skin and lung tissues. Fibroblasts were used between passages 2 and 8,
unless otherwise stated.
Fibroblasts were treated with the TGF-β-neutralising antibody 1D11 (10 
µg/ml), or TGF-β receptor I inhibitor, SD208 (1 µM) at concentrations used 
previously on fibroblasts (Chen et al., 2006b; Holmes et al., 2011).
2.2.2 Cell lines
The rat SV40-transformed type II alveolar epithelial cell line (T2 AEC) was a
gift from Clement et al. (Clement et al., 1991). The cells were maintained in
DMEM containing 10% FBS at 37°C in a humidified 5% CO2 atmosphere.
2.2.3 Cell counting, passaging and cryopreservation
Adherent cell monolayers were released from tissue culture flasks for
passaging or cryopreservation by trypsinisation. Briefly, culture media was
aspirated from the flask, cells were washed in phosphate-buffered saline
(PBS, Invitrogen) before being incubated with trypsin-EDTA (TE, 0.5 g
porcine trypsin and 0.2 g EDTA • 4Na per litre of Hanks Balanced Salt
Solution with phenol red, Sigma) at 37°C for 2-10 minutes until cells
detached from the bottom of the flask. An equal volume of complete medium
was added to the trypsinised cells as the FBS in the medium inactivates the
trypsin enzyme. Cells were centrifuged at 300 x g for 5 min and the
supernatant was discarded to remove the trypsin-EDTA. For cell counting,
the cell pellet was resuspended in complete medium and 10 μL was 
aspirated and mixed with an equal volume of the non-viable cell stain, trypan
blue (Sigma). The mixture was pipetted onto a cover-slipped
haemocytometer and the cells (circular objects) were counted under the
microscope. Dead cells appeared blue due to the trypan blue while the
viable cells remain white.
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Confluent cells were given a fresh medium change 1 day before the expected
day of freezing. To freeze the cells, the monolayer was washed in PBS and
cells detached using TE, as described above. Detached cells were washed in
an equal volume of complete DMEM medium and centrifuged at 300 x g for 5
min. The cell pellet was resuspended in freeze medium, composed of
complete medium supplemented with 10% dimethylsulfoxide (Sigma), to give
a final concentration of 1-2x106 cells/ ml. The cells were transferred to
cryopreservation vials, and placed in a Mr Frosty insulation container
(Nalgene) to be stored in a -80°C freezer overnight, before long term storage
in liquid nitrogen.
2.2.4 Scratch wound healing assay
A scratch wound assay to assess the migration ability of cells was performed
as described previously (Xu et al., 2009). Briefly, fibroblasts were cultured
until confluent in 12-well plates. The cell monolayers were rinsed with PBS
before being cultured for another 24 hours in DMEM with 0.5% BSA. A linear
scratch was then made across the diameter of each well with a P-200 pipette
tip (Gilson). The monolayers were washed twice in PBS to remove any cell
debris, and cells were cultured in DMEM with 0.5% BSA with or without
CTGF (200 ng/ml), in the presence of mitomycin C (10 µg/ml, Sigma) as an
inhibitor of cell proliferation. Migration was assessed by measuring the
change in scratch area over time.
2.3 Generation of transgenic mice
The generation of Col1A2-CTGF transgenic mice was described previously
(Sonnylal et al., 2006; Sonnylal et al., 2010). Briefly, Fisp-12, the mouse
homolog of CTGF, was cloned into a vector containing the 6-kb enhancer
and minimal promoter sequences of the mouse Col1a2 gene, an IRES-lacZ
reporter sequence, and the mouse poly-A signal. Transgenic mice were
produced by the standard method of pronuclear injection of linear DNA into a
fertilized mouse egg.
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Mouse CTGF-Flox lung fibroblasts: mice containing the floxed CTGF gene
were crossed with mice harbouring the ROSA-Cre construct. Homozygous
mice were selected by genotyping and CTGF gene deletion via cre-
recombinase expression, which was induced by intraperitoneal injection with
tamoxifen (Sigma, 1 mg in 50µL saline per mouse, daily for 5 days) (Liu et al.,
2013a).
2.4 Genotyping
2.4.1 DNA from tissues
Genomic DNA was extracted from ear biopsies (2 mm diameter) or tail tips
(0.5 – 1cm) within 24 hours of snipping or ear clipping, and stored at 4°C,
using the REDExtract N-Amp Tissue PCR kit (Sigma). In brief, each tissue
was suspended cut-end down in 100 µL extraction solution and 25 µL tissue
extraction solution, and vortexed to mix. Samples were incubated at room
temperature for 10 minutes, followed by that at 95°C for 3 minutes, before
100 µL neutralisation buffer B was added per sample. Extracts were stored
at 4°C until used in PCR. Tissue was removed from extracts for long term
storage.
2.4.2 DNA from cell monolayers
Cells were washed twice in PBS, trypsinised (see section 2.2.3) and pelleted
by centrifugation. Cell pellets were washed by resuspending in PBS followed
by centrifugation. The resulting cell pellets were subjected to the same DNA
extraction and amplification protocol as for mouse tail tips in the REDExtract-
N-Amp Tissue PCR kit (Sigma), as described above. In brief, each cell pellet
was resuspended in 100 µL extraction solution and 25 µL tissue extraction
solution, and vortexed to mix. Samples were incubated at room temperature
for 10 minutes, followed by 95°C for 3 minutes, before 100 µL neutralisation
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buffer B was added per sample. Extracts were stored at 4°C until used in
PCR.
2.4.3 PCR Amplification
Briefly, the tissue or cell DNA extract (4 μL) was mixed with Taq polymerase-
containing REDExtract PCR reaction mix (10 μL, Sigma), primers (Invitrogen) 
for specific genes such as the Lac Z gene (20pmol each of forward and
reverse primers) and the endogenous mouse intestinal fatty acid binding
protein gene (Fabpi-200; 10 pmol each for forward and reverse primers) as
an internal control in a final volume of 20 μL/PCR reaction.  The PCR was 
performed on a PTC-100 Programmable Thermal Controller (MJ Research)
set for initialisation at 93°C for 1 minute, followed by 30 cycles of
denaturation at 93°C for 20 seconds, annealing and extension at 68°C for 3
minutes, and final hold at 4°C. A list of the primer sequences used is
provided in the Appendix.
The PCR products (10 μL/lane) were separated on a 2% agarose gel in 0.5% 
TBE (44.5 mM Tris base, 44.5 mM boric acid, 1.0 mM EDTA) by
electrophoresis (60V, 30mA, 2W) for approximately 2 hours, and visualised
with SYBR Safe DNA gel stain (Invitrogen). Sizes of the PCR products were
measured against a 100 BP ladder (New England Bio Labs).
2.5 Real-time quantitative PCR (qPCR)
To prevent RNA degradation, RNase was eliminated using nuclease-free
plastics and water and by treating glassware and reagents with diethyl
pyrocarbonate (DEPC, 0.1% v/v) - an alkylating agent which inhibits RNAses
- overnight and autoclaving to break down and inactivate the DEPC. qPCR
was used to measure changes in mRNA expression. A two-step method was
used to allow analysis of multiple genes from the same sample.
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2.5.1 RNA Isolation
Total RNA for qPCR was isolated using RNeasy MiniKit (Qiagen), following
the manufacturer’s protocol for extraction of RNA from adherent mammalian
cells. RNA from T2 cells was treated with DNase (Promega RQ1 RNase-free
DNase) to eliminate DNA contamination. The absorbances of RNA at 260
nm and 280 nm were measured using a NanoDrop spectrophotometer to
determine the resulting concentration and purity of isolated RNA. Before
continuing to the reverse transcription step, the integrity of each RNA sample
was determined by checking the presence of an A260/A280 ratio of 1.9 to 2.1
(maximum 2.3) - a lower ratio indicates the presence of contaminating
proteins, A260:A230 ratios between 1.9 and 2.2, indicate the purity of the RNA.
The RNA was also subjected to analysis on the Bioanalyzer (Agilent) and
confirmed to have a 28S/18S ribosomal RNA ratio greater than or equal to 2,
and an RNA integrity number (RIN) of 8-10 (10 being pure RNA).
2.5.2 Reverse transcription
For two step qPCR, reverse transcription (RT) of RNA into complementary
DNA (cDNA) was performed using reverse transcriptase enzyme, as the
PCR in the second step requires a DNA template. Avian Myeloblastosis
Virus – Reverse Transcriptase (AMV-RT; Promega) was used according to
the manufacturer’s instructions to reverse transcribe the RNA (800 ng of RNA
was used for each set of samples) into cDNA using oligo-d(T)15 and random
hexamers in a reaction volume of 20 μL.  The stock reverse transcription 
reaction was diluted (1:20 in water) to minimise inhibitory effects of excess
reverse transcriptase and RNase inhibitors on the PCR enzyme in
subsequent steps.
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2.5.3 qPCR amplification
A Rotorgene-6000 (Qiagen) was used for real-time PCR amplification.
Specific oligonucleotide primers (Invitrogen) were added to SensiMix SYBR
No-ROX (Quantace) and mixed with cDNA (2 μL).  A standard curve was 
generated by amplifying the specific amplicon at known concentrations of 10-
fold dilutions from 108 to 10 copies of cDNA/μL. The enzyme was activated 
with an initial incubation at 95°C for 10 minutes, followed by 40-50
amplification cycles, each cycle involving cDNA denaturation at 95°C for 15
seconds, annealing at 57°C for 20 seconds and extension at 72°C for 10
seconds. Four reference genes were tested initially: 60S ribosomal protein
L13a (RLP13A), 18S ribosomal RNA (18S), β2 microglobulin (B2M), and
succinate dehydrogenase complex subunit A (SDHA). Of these, 18S, B2M
and SHDA were selected based on the average expression stability (M)
derived using the GeNorm program (Vandesompele et al., 2002).
Measurements of target genes were normalised to the geometric mean of the
expression of the three selected reference genes using the GeNorm program.
A list of the primer sequences used is provided in the Appendix.
2.6 Western blot
2.6.1 Sample preparation
Conditioned media were aspirated from cell cultures and centrifuged for 5
minutes at 600 x g to remove any dead cells and debris. The cell layers were
washed twice in ice-cold PBS, scraped and lysed in RIPA buffer (Sigma)
containing a protease inhibitor cocktail (Roche) and phosphatase inhibitors
(Sigma). Total protein concentrations in cell lysates were quantified by the
BCA protein assay using BSA as the standard (Pierce). Lysates were stored
at -20°C.
In each experiment, equal amounts of protein (10 – 50 µg) were diluted to the
same volume by addition of lysis buffer and loaded in each lane of the gels.
Cell lysates were dissolved in 4x Laemmli sample buffer (0.25M Tris-HCL,
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40% glycerol, 8% SDS, 0.04% bromophenol blue) for Tris-glycine gels or 4X
NuPAGE sample buffer for NuPAGE gels (Invitrogen). For reduced samples,
lysates were also mixed with 2-β-mercaptoethanol (BioRad; final 
concentration 20%) or NuPAGE reducing agent (Invitrogen). Samples were
heat denatured at 95°C for 5 minutes for Tris-glycine gels and at 70°C for 10
minutes for NuPAGE gels. SeeBlue (Invitrogen) or Novex Sharp (Invitrogen;
for NuPAGE gels) molecular weight standards were also loaded on each gel.
2.6.2 BCA Assay
The protein concentration of lysates was measured using the BCA assay
(Pierce). Briefly, standards and samples were diluted, if required, in the lysis
buffer used to lyse cells (RIPA buffer, Invitrogen) to a final volume of 10 μL,
and added to a 96 well plate. Colourless BCA solutions A and B were mixed
at a ratio of 50:1 to give a green working reagent (WR). WR (200 μL) was
added to each well and incubated at 37°C for 30 min. The plate was cooled
to room temperature and the absorbance of the wells measured at 560 nm
on a plate reader (Dynex Technologies or MikroWin). The total protein
concentration in each sample was calculated by comparison with the
regression line of the standard curve and multiplying by the dilution factor of
the samples.
2.6.3 Gel electrophoresis
Either pre-cast NuPAGE or Tris-glycine gradient gels were used, or gels
were prepared from ProtoGel 30% (National Diagnostics), 4x Resolving
Buffer (National Diagnostics), distilled water, 10% ammonium persulphate
(Sigma) and N,N,N′,N′-Tetramethylethylenediamine (TEMED; Sigma).  
Various % acrylamide gels were used according to expected target protein
size; lower percentage gels for higher MW proteins and higher percentage
gels for lower MW proteins. Electrophoresis was performed at 125V for 90
minutes in Tris-glycine gels or 180V for 1 hour in NuPAGE gels (or longer for
larger MW proteins), until the dye-front reached the bottom of the gel.
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2.6.4 Transfer of proteins and staining
Proteins were transferred from the polyacrylamide gels to nitrocellulose or
PVDF membranes (GE Healthcare Amersham) by sandwiching each gel
between a membrane, filter paper and sponges soaked in transfer buffer
(Invitrogen), in a transfer block for either 1 hour or 1.5 hours, in transfer
buffer (diluted from 20X stock, Invitrogen) with 20% methanol.
Following transfer, proteins on the membrane were visualised using Ponceau
S Staining Solution (Sigma) to check for successful transfer. Ponceau S (20
ml) was applied to completely cover the membrane. Protein (minimum 250
ng) was detected as pink/red bands on the membrane. As a reversible stain,
it was removed by washing the membrane with 0.1% Tween 20/PBS (v/v) for
5 minutes with agitation, before proceeding to the blocking step.
2.6.4.1 Blocking the membrane and antibody incubation
To minimise non-specific binding of antibodies to the membrane, membranes
were blocked in 5% milk (Marvel) (w/v) dissolved in 0.1% Tween 20 (Sigma)
/PBS (v/v) with agitation, before incubation with primary antibodies overnight
at 4°C. Tween 20, as a detergent, also prevents non-specific antibody
binding to the membrane. Antibody dilution was optimised for the strongest
signal by testing 2 to 4 dilutions, beginning with the manufacturer’s
recommended dilution or dilution range. Primary antibodies used included:
α-SMA (Dako), vimentin (Santa Cruz), collagen type I (Millipore), E-cadherin 
(BD Biosciences), CTGF (Santa Cruz), β-tubulin (Abcam), and GAPDH 
(Abcam). All primary antibodies were diluted 1/1000 in blocking solution
except β-tubulin and GAPDH, which were diluted 1/5000.  After 3 x 10 minute 
washes in 0.1% Tween 20/PBS, the membranes were incubated at room
temperature for 1 hour with the corresponding horseradish peroxidase
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(HRP)-conjugated secondary antibodies diluted 1/5000 in 5% milk: anti-rabbit
(Cell Signalling), anti-mouse (Cell Signalling) and anti-goat (Dako).
2.6.4.2 Detection
After 3 x 10 minute washes, the bound antibodies were visualised by ECL
(Pierce). After incubation with ECL, blots were exposed on X-ray film (GE
Healthcare) and were either developed manually or by machine (Xograph
Imaging Systems, Compact X4). The intensities of the bands on the
developed film were quantified using Visionwork LS and normalised against
values for the β-tubulin or GAPDH loading controls.  Where possible, fold-
change was calculated relative to the control, which is assigned an arbitrary
value of 1.
2.7 Histochemistry
2.7.1 Embedding of tissue samples
Mouse dorsal skin and lung, and human lung specimens were collected and
preserved in formalin (10%, CellStor) until they were processed by the
Department of Histopathology and Cytopathology, Royal Free Hampstead
NHS Trust. Tissues were embedded in paraffin and the hardened paraffin
block was cut to give sections (4-6 μm), which were mounted on glass slides
for staining.
2.7.2 Haematoxylin and eosin staining
Sections were stained with haematoxylin and eosin (H&E; Surgipath and
Sigma) for general morphological analysis. Sections were dewaxed for 10
minutes in xylene, transferred through xylenes to ethanol and then water.
Slides were transferred to Harris Haematoxylin (Sigma) for 1 minute, rinsed
under running tap water and differentiated in acid alcohol. After another rinse
in running water, the slides were dipped several times in bluing solution
(0.2% ammonia solution in water; 2 ml concentrated ammonium hydroxide
Materials and methods | 105
added to 1000 ml distilled water), rinsed in running water for 5 minutes and
stained in eosin for 5 minutes. After rinsing, the slides were dehydrated
through ethanol and xylenes, and finally, mounted in DPX mountant
(distyrene, a plasticizer, and xylene; VWR) and coverslipped. Dermal
thickness was measured in AxioVision Rel. 4.8 and presented as mean
±SEM. Statistical analysis was performed using Student's one-tailed t-test at
a significance level of P<0.05.
2.7.3 PicroSirius Red staining
PicroSirius Red (VWR and Raymond Lamb) was used to stain collagen.
Sections were dewaxed in xylene for 10 minutes, hydrated in water, and
stained with a 1:1 mix of Weigert’s iron haematoxylin solution A and B (VWR)
for 8 minutes, followed by washing for 5 minutes in running tap water. Slides
were then stained in filtered PicroSirius Red for 8 minutes, rinsed in freshly
dispensed ethanol, dehydrated and cleared through ethanol and xylenes,
mounted in DPX and coverslipped.
2.7.4 Immunohistochemistry
For rabbit primary antibodies, the Impress Kit for Rabbit Antibody Staining
was used (Vector Laboratories), following the manufacturer’s instructions.
For mouse antibodies used on mouse tissues, the MOM kit (Vector
Laboratories) was used for staining according to the manufacturer’s protocol.
2.7.4.1 Immunoperoxidase staining
Sections were dewaxed for 10 minutes in xylene, transferred through xylenes
to graded ethanols and then water. Endogenous peroxidase activity was
quenched by incubation with 0.5% (v/v) hydrogen peroxide in methanol
(VWR) at room temperature for 15 minutes. Where an avidin-biotin detection
system was used, an avidin-biotin block (Vector Laboratories) was also
performed according to the manufacturer’s instructions. After washing in
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running water, antigen retrieval pre-treatment was carried out by heating the
slides in pre-warmed citrate buffer pH 6.0 (10 mM citric acid, 0.05% Tween
20) in a microwave on full power for 10 minutes.
Sections were cooled and washed in water (~20 minutes) then equilibrated in
PBS and non-specific binding of immunoglobulins (Ig) was blocked by
treatment for 30 minutes with 2.5% (v/v) normal serum (Vector Laboratories)
from the same species as the secondary antibody used, after which sections
were incubated with primary antibodies for 1 hour at room temperature or
overnight at 4°C. Antibody dilution was optimised for the strongest signal
and lowest background staining by testing 3 to 4 dilutions, beginning with the
manufacturer’s recommended dilution or dilution range. Primary antibodies
were diluted in antibody diluent (Dako) and include CTGF (Abcam, 1/100),
TTF-1 (Novocastra, 1/100), α-SMA (Dako, 1/100), CD-31 (Abcam, 1/100), 
Snail (Abcam, 1/100) and S100A4 (Abcam, 1/100). Isotype-matched IgG
controls were used to demonstrate specificity of primary antibodies used
(same species - mouse or rabbit IgG, and same concentration as primary
antibody; Vector Laboratories).
After 3 x 5 min washes in PBS, sections were incubated with the appropriate
secondary antibody (Vector Laboratories) to the primary antibody used for 30
minutes. For example, an anti-goat-HRP antibody was used against a goat
primary antibody. For avidin-biotin detection, slides were incubated with a
species-specific biotinylated secondary antibody (Vector Laboratories) for 30
minutes, rinsed 3 x 5 min in 0.1% Tween 20/PBS and incubated with
Vectastain avidin biotin complex (ABC)-peroxidase conjugate (Vector
Laboratories) for 30 minutes. After 3 x 5 min washes in 0.1% Tween 20/PBS,
sections were visualised using DAB (Vector Laboratories). Sections were
counterstained with Meyer’s haematoxylin and washed in water, then
dehydrated through ethanol solutions and dipped in xylenes before being
mounted in DPX (VWR). Sections were viewed and photographed on an
Axio Scope microscope (Zeiss).
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2.7.4.2 Immunofluorescence staining
For paraffin-embedded tissue sections, slides were deparaffinised in xylene
and rehydrated through ethanol. Antigen retrieval was performed by heating
slides in citrate buffer (as described for immunoperoxidase staining), cooled
and washed in water (~20 minutes), and equilibrated with PBS 3 times for 2
minutes each.  For α-SMA staining, slides were blocked in 10% normal 
serum (species the same as the secondary antibody used) in PBS and
incubated with α-SMA antibody (1/100, diluted in 10% normal goat serum; 
Sigma and Dako) overnight at 4°C in a humidified chamber. The appropriate
IgG control (same species and concentration as primary antibody; mouse or
rabbit IgG; Vector Laboratories) was used to show specificity of primary
antibody. Slides were washed in PBS and incubated in the appropriate
secondary antibody e.g. goat anti-mouse Alexa Fluor 488 (1:200 in 10%
normal goat serum; Invitrogen) for 1 hour at room temperature. Slides were
washed and following nuclear counterstaining with TOPRO or Meyer’s
haematoxylin, mounted in ProLong Gold (Molecular Probes).
For immunofluorescence staining of cells, cells were seeded at 1.46 x105
cells/well of an 8-well chamber slide (BD-Falcon), cultured for 24 hours in
complete medium with antibiotics and quiesced in serum-free DMEM for 24
hours. For cytokine treatment, the conditioned medium was replaced by fresh
serum-free DMEM containing CTGF (10-200 ng/ml) or TGF-β (4 ng/ml).  
Cells were fixed according to methods recommended on the antibody
specification sheet and/or determined by optimisation experiments. Cells
were fixed for 5 – 15 minutes in formalin (10%, CellStor) at room temperature
or methanol or methanol/acetone (1:1) at -20°C. Antibody dilution was
optimised for the strongest signal and lowest background staining by testing
3 to 4 dilutions, beginning with the manufacturer’s recommended dilution or
dilution range. Antibodies used include: E-cadherin (1/200, BD Biosciences),
CTGF (1/200, Abcam), vimentin (1/200, Cell signalling), α-SMA (1/100 Dako).   
Materials and methods | 108
2.8 Enzyme-linked immunosorbent assay (ELISA)
Fibronectin in cell conditioned medium was quantitated by ELISA (AssayPro)
according to the manufacturer’s protocol. In brief, fibronectin in the sample
was sandwiched between a polyclonal antibody against fibronectin that was
immobilised on a microplate, and a biotinylated polyclonal antibody specific
for fibronectin, which was recognised by an antibody conjugated to
streptavidin-peroxidase. The signal was developed with a peroxidase
substrate, stopped by adding a stop solution (provided in kit) and the
absorbance was measured at 450 nm.
For the CTGF ELISA (Peprotec), 96-well ELISA plates were coated with anti-
human CTGF antibody overnight. Blood samples were collected from the
heart and aorta of mice using a 1 ml heparinised syringe attached to a 23G
needle, stored at room temperature, before centrifuging for 20 minutes at
2000 x g. The serum (the supernatant) was aspirated and stored at -20 or -
80°C until ready to assay. All incubation steps were carried out at room
temperature. Briefly, the capture antibody was diluted to 1 µg/ml in PBS and
used to coat a 96-well ELISA plate overnight. The capture antibody solution
was aspirated and the plate washed 4 times in wash buffer (0.05% tween-20
in PBS). Human CTGF standards (1-4 ng/ml) and samples were diluted in
diluent (0.05% Tween-20, 0.1% BSA in PBS). Standards and samples were
added to the wells and incubated for 2 hours. Wells were washed four times
before incubation with detection antibody (0.5 µg/ml) for 2 hours. Plates
were washed four times and wells were incubated with avidin-HRP, diluted
according to manufacturer’s protocol, for 30 minutes. Solutions A and B from
the tetramethylbenzidine (TMB)/peroxide liquid substrate set (R&D Systems)
were mixed at a ratio of 1:1 and added to the wells and incubated while
protected from light. Colour development was monitored every 5 minutes for
20 minutes to 1 hour until a blue colour developed. Stop solution (Sigma)
was added to stop colour development. Addition of stop solution caused a
colour change from blue to yellow. The absorbance (450 nm) was read on a
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microplate reader (MikroWin). The total CTGF concentration in each sample
was calculated by comparison with the 4-parameter fit standard curve and
multiplying by the dilution factor of the samples.
2.9 Ammonium sulphate precipitation of collagen
Serum-free conditioned media (24 – 72 hours) were aspirated from the cells
and centrifuged at 300 x g for 5 minutes to pellet any cell debris. The
supernatant was either stored at -80°C or directly used for precipitation.
Saturated ammonium sulphate was added to the supernatant to a final
concentration of 40% (0.6 ml medium / 0.4 ml ammonium sulphate) and
samples incubated on a roller overnight at 4°C. Samples were centrifuged at
16,000 x g for 60 minutes. The supernatant was discarded and the pellet
dissolved in sample buffer (as described in 2.6.1 Western blot – Sample
preparation). After heating at 95oC for 2 – 5 minutes, samples were
centrifuged to remove any remaining insoluble material (cell debris) that
would interfere with the SDS PAGE.
2.10 Lentiviral-mediated small hairpin RNA gene knockdown
Lung fibroblasts isolated from healthy control and SSc patient lungs were
cultured to 50 – 60% confluence (recommended by manufacturers for
optimum transduction). A range of lentiviral particle concentrations were
tested in preliminary experiments to determine the optimum concentration for
knockdown and cell viability. Cells were treated with non-target control
shRNA (shNTC) or shRNA lentiviral particles specifically targeting CTGF
(5.616x105 Tu/ml) and TGF-β (4 ng/ml), in the presence of the lipid-based 
transduction reagent polybrene (10 µg/ml). For assessing effects of shRNA
gene knockdown on protein expression, cells were treated for 96 hours with
shRNA before being quiesced in 0.5% BSA-supplemented, serum-free
DMEM for 24 hours, and harvested for Western blotting analysis. See
Appendix for shRNA sequences.
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2.11 Small interfering RNA gene knockdown
A pool of siRNA sequences against CTGF (siCTGF; Appendix) and a pool of
non-targeting control siRNA sequences (siNTC) (Dharmacon) were used
following the manufacturer’s protocol. Briefly, primary human lung fibroblasts
were cultured to 60 – 70% confluence in antibiotic-free complete medium.
siRNA (50nm) with Dharmafect transfection reagent (Dharmacon) were
added to cells and cultured for 72 hours. On day 3, TGF-β (4ng/ml) was 
added. After 24h, cells were lysed for extraction of RNA and protein.
2.12 Statistical analysis
For quantitative variables, the mean ± SEM results from replicate samples
calculated (at least 2 independent experiments and three replicates).
Statistical analysis was performed using Microsoft Excel or GraphPad Prism.
Student's two-tailed t-test at a significance level of P<0.05. Standard curves
were generated using a 4-parameter curve fit or linear regression.
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Chapter 3. In vivo effects of CTGF
overexpression and knockout on fibrosis
3.1 Introduction
There is no shortage of literature citing links between CTGF and various
fibrotic disorders including SSc and pulmonary hypertension (Abraham, 2008;
Adler et al., 2010; Szabo et al., 2014). Upregulated CTGF is considered a
characteristic feature of SSc, with elevated levels detected in patient blister
fluids, sera, bronchoalveolar lavage fluids (Dziadzio et al., 2005b; Sato et al.,
2000; Shi-Wen et al., 2000) as well as in fibrotic lesions, especially in
fibroblast cells (Igarashi et al., 1995; Igarashi et al., 1996; Shi-Wen et al.,
2000; Zhou et al., 2005).  CTGF may act as a cofactor of TGF-β, a key 
molecule in the stimulation of fibrotic and inflammatory responses, as
suggested by evidence for direct interaction of CTGF and TGF-β in Xenopus
(Abreu et al., 2002).  TGF-β may work in partnership with CTGF, perhaps in 
an autocrine loop system since TGF-β is able to induce CTGF expression, 
and CTGF is also able to enhance the TGF-β-induced fibrotic responses in 
SSc fibroblasts (Kikuchi et al., 1995).
Although SSc dermal fibroblasts from areas of fibrotic involvement showed
six-fold more CTGF expression than those from uninvolved areas, SSc
fibroblasts originating from both areas showed marked increase in CTGF
expression compared to those from healthy controls (Shi-Wen et al., 2000).
This suggested that abnormal CTGF expression may confer a predisposition
to fibrosis in SSc patients. In an attempt to explain the increased CTGF
expression observed in some SSc patients, Fonseca et al. discovered an
increased abundance in SSc patients of the G-945C polymorphism in the
promoter region of the CTGF gene (Fonseca et al., 2007).
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While observational studies support CTGF as a mediator and marker of the
fibrotic response in SSc, they do not provide proof-of-concept. The
molecular mechanisms that bring about the overexpression of CTGF in SSc,
and other diseases, remain unknown. Experiments such as those blocking
CTGF expression in vitro or in animal models are necessary to confirm that
CTGF is an essential mediator.
To investigate the role of CTGF in fibrosis directly, a transgenic mouse that
constitutively expresses CTGF in fibroblasts was developed. This chapter
aims to investigate some of the characteristics of the Col1a2-CTGF mice
using histological techniques and cell culture of the fibroblasts isolated from
these mice. CTGF overexpression is most commonly described in adult
human fibrotic disorders and hence an inducible transgenic mouse
overexpressing CTGF was also developed, in addition to the Col1a2-CTGF
mice. Homozygous CTGF knockout mice are neonatal lethal due to impaired
chondrogenesis and ECM abnormalities (Ivkovic et al., 2003), and hence an
inducible CTGF knockout (KO) mouse may be useful for studying the effects
of CTGF gene KO on bleomycin-induced pulmonary fibrosis.
3.2 Specific methods
3.3 Modified Ashcroft Scale
The modified Ashcroft score was used for the quantification of pulmonary
fibrosis in histological sections stained with H&E. Images were captured
using the NanoZoomer (Hamamatsu) and analysed using 10X magnification
in the NDP View software (a 10-fold magnification was used to provide
sufficient overview and discrimination of fine structures). The modified scale
was defined according to the criteria outlined in Table 3.1. For each section,
multiple fields were scored following a raster-like pattern throughout the
entire section. The sum of the grades was divided by the number of fields to
obtain a fibrotic index. In every field, the predominant degree of fibrosis was
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recorded as that occupying more than half of the field area while areas
dominated by bronchial or tracheal tissue were omitted (Hubner et al., 2008).
Grade Alveolar septa Lung structure
0 No fibrosis at the small
fibres in some alveolar walls
Normal
1 Isolated, mild fibrotic changes
(septum ≤3× thicker than normal)
Alveoli partly enlarged and
rarefied, but no fibrotic masses
present
2 Prominent fibrotic changes
(septum >3× thicker than normal)
with knot-like formation but not
connected to each other
Alveoli partly enlarged and
rarefied, but no fibrotic masses
3 Contiguous fibrotic walls (septum
>3× thicker than normal)
predominantly in whole
microscopic field
Alveoli partly enlarged and
rarefied, but no fibrotic masses
4 Variable Single fibrotic masses (≤10% of 
microscopic field)
5 Variable Confluent fibrotic masses (>10%
and ≤50% of microscopic field). 
Lung structure severely
damaged but still preserved
6 Variable, mostly absent Large contiguous fibrotic masses
(>50% of microscopic field).
Lung architecture mostly
destroyed
7 Non-existent Alveoli nearly obliterated with
fibrous masses but still up to five
air bubbles
8 Non-existent Complete obliteration of lung
architecture with fibrotic masses
Table 3.1. Modified Ashcroft Score
The characteristics of each grade in the Modified Ashcroft Score. Table
adapted from Hubner et al. 2008 (Hubner et al., 2008).
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3.3.1 Bleomycin-induced injury
To study the effect of CTGF gene knockout on experimentally induced
fibrosis, conditional KO mice were administered with either bleomycin (0.12
units in 50 µL sterile saline) or saline via oropharyngeal instillation (Lagares
et al., 2012). Bleomycin induces cleavage of DNA strands, resulting in
pulmonary inflammation, injury, and subsequent interstitial fibrosis (Walters
and Kleeberger, 2008). Bleomycin treatment was given after completion of
the course of tamoxifen injections to induce gene deletion (Chapter 2). At 21
days post-bleomycin treatment, pulmonary pressures were measured by Dr
Sarah Trinder using a catheter and PowerLab system (AdInstruments)
(Baliga et al., 2008) before the mice were sacrificed and the lung and skin
tissues were harvested for histological analysis or micro-CT scanning.
3.3.2 Ex-vivo micro-CT imaging of mouse lungs
Lungs were inflated via intra-tracheal administration of 4% formaldehyde.
Lung inflation was carried out by Dr Sarah Trinder and Rob Good while
micro-CT scanning and generation of representative images were performed
by Dr Helen Jones and Wasabha Ramanayake. Inflated lungs were fixed in
neutral-buffered formalin (10%, CellStor) for 1 hour and then washed in PBS
and stored in 70% ethanol at 4°C until ready for dehydration through a series
of graded alcohols (2 hours each in 35%, 70%, 80%, 90%, then overnight in
100% ethanol) and 2 hours incubation in bis(trimethylsilyl)amine
(hexamethyldisilazane, HMDS) followed by air drying (HMDS steps in fume
cupboard) overnight until tissue became white. The micro-CT x-ray source
was set to 40 kV and 100 μA tube current.  The rotation step, or angle the 
sample was rotated between each image capture, was set to 0.2°, and the
system was configured to acquire two images at each given position, and
average them in order to increase the signal to noise ratio. The pixel size of
the camera was set to 11.31 μm and the size of the pixels within each image 
was set to 10.12 μm.  For histological analysis after micro-CT scanning, lung 
tissue was prepared by rehydrating in HMDS for 2 hours, followed by
incubation in 100% ethanol and then 90% ethanol for 2 hours each. Finally,
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tissues were stored in 70% ethanol until ready to process into wax. All
rehydration steps were performed at room temperature.
3.4 Results
3.4.1 Fibroblast-specific expression of the CTGF gene is directed by
the collagen type I alpha 2 (Col1a2) promoter
To specifically express CTGF constitutively in fibroblast cells, the CTGF gene
is present downstream of the Col1a2 minimal promoter and enhancer
sequences (Figure 3.1 A) as the Col1a2 gene is usually expressed in
mesenchymal type cells in most organs (Bou-Gharios et al., 1996). To
distinguish between WT and Col1a2-CTGF mice, DNA was extracted from
mouse tails for genotyping by PCR. Internal control primers, amplifying a
194 base pair (bp) sequence (see Appendix for primer sequences) from the
intestinal fatty acid binding protein gene, were used to confirm successful
amplification, that the PCR enzyme was functional and that the DNA was
suitable for the reaction. The lacZ transgene sequence was amplified as a
389 bp fragment and detected only in the DNA of Col1a2-CTGF transgenic
mice as the transgene construct (Fig. 3.1 B), which is absent from the WT
mice, consists of an internal ribosome entry site (IRES) sequence-linked lacZ
reporter gene downstream of the CTGF gene and Col1a2 promoter and
enhancer sequences (Sonnylal et al., 2010).
3.4.2 Fibroblast-specific overexpression of CTGF induces skin fibrosis
To examine the skin phenotype of the transgenic mice, dermal biopsy
specimens from 4- and 8-week-old Col1a2-CTGF transgenic mice and WT
littermates were obtained, on which H&E staining (Fig. 3.2 A, top panel) were
performed. The staining showed no obvious difference between the
epidermal layers of the WT and transgenic mice. In contrast, the dermis of
the Col1a2-CTGF mice appeared to be markedly thickened compared to that
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Figure 3.1 Fibroblast
by the collagen typ
A) Col1a2-CTGF transgene construct. Fibroblast
the mouse homolog of the
minimal promoter and enhancer sequences. Figur
et al., 2010). (B) Mice were genotyped by performing PCR on DNA extracted
from mouse tails. Target gene primers amplified a 389 base pair (bp)
sequence from the
mice while the internal control primers amplified a 194 bp sequence from the
intestinal fatty acid binding protein
mice. Sizes of the PCR products were measured against a 100 bp DNA
ladder.
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Figure 3.2 Fibroblast
in the skin
Haematoxylin and eosin (H&E; A) and PicroSirius Red (B) staining of. (A)
Nuclei are stained purple and the cytoplasm pink. (B) Collagen fibres are
stained red/pink. The epidermal layer is shown by the top purple/blue layer,
which is above the dermis and subcutaneous fat (hypodermis, subdermis) in
pink. (C) For each section, measurements of the depth were made at three
different points along the dermis (as indicated
(A)). Unpaired student’s t
3), ** p < 0.01.
-specific overexpression of CTGF induces fibrosis
by double headed arrows in
-test between WT (n = 3) and Col1a2
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-CTGF (n =
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of the WT mice (Figure 3.2 B). Triplicate measurements of the dermis
revealed the Col1a2-CTGF dermis (249.7 ± 9.65 μm) to be significantly
thicker (p = 0.001, significance level p<0.05) than the WT dermis (132.3 ±
14.63 μm). In addition, the subcutaneous fat layer in Col1a2-CTGF mouse
skin was thinner than that in WT mice, perhaps due to the presence of a
thicker dermal layer. The morphology of the muscle layer also seemed to
differ between the Col1a2-CTGF and WT mice, with the muscle blocks in
Col1a2-CTGF skin appearing to be larger and more disordered than in the
WT skin. Additionally, PicroSirius Red staining showed increased collagen
deposition in the dermis of Col1a2-CTGF mice compared to WT (Fig. 3.2 A,
bottom panel) and also increased staining in the subcutaneous fat layer of
the Col1a2-CTGF skin than WT. Taken together these observations suggest
that fibroblast-specific CTGF overexpression up-regulates ECM synthesis
and/or downregulates ECM turnover, resulting in accumulation of matrix and
dermal fibrosis.
3.4.3 Fibroblast-specific overexpression of CTGF induces a fibrotic
phenotype in the lung parenchyma and abnormalities in alveolar
epithelium.
To examine the effect of fibroblast-specific CTGF overexpression on the lung,
lung samples for histological analysis were obtained from the Col1a2-CTGF
mice at the same time the skin biopsies were collected. H&E staining
indicated extensive fibrosis and focal fibrotic lesions within the lung
parenchyma, evident from the alveoli being frequently obliterated with fibrotic
masses - alveolar spaces (shown as light grey/white spaces in Fig. 3.3 A and
B) in the area of the lesions were reduced, disrupting the normal architecture
of the lung. Echoing findings in the skin, increased PicroSirius Red staining
was also detected in the Col1a2-CTGF lung, suggesting elevated collagen
deposition (Fig. 3.3 C and D). Immunostaining and imaging of Co1a2-CTGF
lungs were carried out by Dr Shonali Sonnylal.  Staining of α-SMA was 
absent in the lungs of WT mice (Fig. 3.4 A) but was markedly increased in
the lesions of the lung in Col1a2-CTGF mice (Fig. 3.4 B), indicative of an
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Figure 3.3 Pulmonary fibrosis in adult Col1A2
H&E (A and B; images in black and white) amd
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lung sections. Nuclei
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PicroSirius Red (C and D)
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Figure 3.4 Increased abundance of myofibroblasts and presence of
abnormal alveolar epithelia in Col1A2
WT (left panels) and Co
for α-SMA (green; A
large numbers of
Col1a2-CTGF mice (B),
from WT lungs (A). Inset in (B) shows higher magnification o
cells. Scale bar represents 50
were kindly provided by Dr Shonali Sonnylal.
-CTGF mice
l1a2-CTGF (right panels) lung sections
-D) and TTF-1 (red; C and D). White arrows indicate
α-SMA-positive myofibroblasts (green) in
some of which co-express TTF-1 (D), and
μm.  DAPI-stained nuclei are blue. Images
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abundance of myofibroblasts and active fibrosis. Intriguingly, there were
also cells present in the fibrotic lesions of Col1a2-CTGF lung only, which co-
expressed α-SMA and the type II alveolar cell marker, TTF-1 (Fig. 3.4 D), 
suggesting that these cells may be in a process of transition from an
epithelial to a mesenchymal cell type. These results prompted further
investigation into the potential role of CTGF-mediated EMT as a contributor
to the expanding pool of fibroblasts during fibrosis.
3.4.4 In vitro constitutive expression of CTGF by Col1a2-CTGF
fibroblasts enhanced by TGF-β treatment 
To assess the level of CTGF expression in Col1a2-CTGF fibroblasts
compared to WT fibroblasts, mouse embryonic fibroblast (MEF) cells were
isolated and cultured as described in Chapter 2. Phase contrast microscopy
was used to examine the morphology of the cells and demonstrated that both
the WT and Col1A2-CTGF MEFs assume an elongated, spindle shape
morphology that is typical of fibroblastic cells (Fig. 3.5). When cells were
plated at the same density, the Col1A2-CTGF cells reached confluence more
rapidly than the WT cells, suggesting that fibroblast-specific CTGF
overexpression may drive fibroblast proliferation (data not shown).  As TGF-β 
is a transcriptional activator of CTGF (Leask and Abraham, 2006), it was
interesting to find out whether exogenous TGF-β would have any effect on 
CTGF expression in Col1a2-CTGF fibroblasts. MEFs were quiesced for 24
hours in 0.5% BSA-supplemented serum-free medium prior to stimulation
with TGF-β (4 ng / ml) for a further 24 hours.  CTGF expression in the MEFs 
of WT and Col1a2-CTGF mice (n=3) was examined by lysing the cultured
MEF cells to harvest the protein for Western blotting (Fig. 3.6 A). Using an
anti-CTGF antibody, a single band of protein with a MW of 36 kDa detected
in the Col1a2-CTGF cells was either relatively weak or absent in WT cells (p
= 0.0154).  As a positive control for TGF-β treatment, a significant difference 
was found between the TGF-β-treated MEFs compared to those untreated 
(Fig. 3.6 B; p = 0.0149). Furthermore, the high basal level of CTGF in the
Col1a2-CTGF MEFs was not maximal as expression could be further
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Figure 3.5 Mouse embryonic fibroblast (MEF) cells isolated from
Col1a2-CTGF transgenic mice show typical fibroblast morphology
By phase contrast microscopy cells appear spindle shaped and elongated
(original magnification 100X). Inset shows higher magnification of image.
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elevated by treatment with TGF-β (p = 0.0105).  This suggested that TGF-β 
was able to induce expression of endogenous CTGF and perhaps also
enhance the transgene expression controlled by the Col1a2 promoter, which
is also responsive to TGF-β signalling. 
Since CTGF is a secreted protein (Gressner and Gressner, 2008), the levels
of secreted CTGF present in the conditioned media of MEFs were also
assessed by Western blotting (Fig. 3.6 A). A protein of 36 kDa was detected
in the medium of Col1A2-CTGF cells while there was no detectable CTGF in
the conditioned medium from WT MEFs, similar to observations with the cell
lysates. In contrast to the change in cellular CTGF levels, the change in
secreted CTGF is more modest after TGF-β treatment in WT cells and does 
not match levels released by Col1a2-CTGF MEFs. A possible reason for this
is that after being secreted, some of the CTGF may become anchored at the
cell surface, perhaps via its C-terminal domains, rather than freely
accumulating in the conditioned medium.
Although canonical TGF-β signalling has been shown to be dispensable in 
the induction of basal CTGF in Col1a2-CTFG MEFs (Sonnylal et al., 2010),
when MEFs were incubated with the TGF-β neutralising antibody, 1D11 (p = 
0.0024), or TGF-β receptor I inhibitor, SD208 (p = 0.0027) for 24 hours, both 
inhibitor pre-treatments attenuated expression of CTGF by the Col1a2-CTGF
MEFs significantly compared to that in the absence of inhibitor treatment
(Fig. 3.7).  This suggested that there is some TGF-β component to CTGF 
expression involving TGF-β receptor I.  CTGF induction may also be 
mediated by non-SMAD signalling such as through the pERK, p38 or JNK
pathways, as reported previously (Ponticos et al., 2009; Sonnylal et al.,
2010) .
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Figure 3.6 CTGF expression is increased in Col1a2
embryonic fibroblasts (MEF) and enhanced by TGF
MEFs from WT and Col1A2
confluent and then maintained in serum
BSA for 24 hours prior to stimulation with TGF
hours. (A) Western blotting of who
detect cell-associated and secreted CTGF protein, respectively. Whole cell
lysate from cultured SSc skin fibroblasts was used as a positive control for
CTGF detection. The two bands detected correspond to the 36 k
and its glycosylated form at 38 kDa. (B) Densitometric analysis of band
intensities presented as relative density (arbitrary units). CTGF expression
was normalised to the β
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Figure 3.7 CTGF expression is attenuated by inhibitors TGF
in Col1a2-CTGF mouse embryonic fibroblasts (MEFs)
MEFs from WT and Col1A2
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hours. (A) Western blotting of whole cell lysates. (B
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3.4.5 Attenuated lung fibrotic response to bleomycin in CTGF
knockout mice
Since overexpression of CTGF appeared to give rise to a fibrotic phenotype
in the Col1a2-CTGF mice, it was interesting to find out whether knocking out
CTGF was able to attenuate fibrosis such as that induced by bleomycin.
Conditional CTGF knockout mice (GF/CY/Renull/null Col1a2 Cre-ER+) were
generated as shown in the schematic in Fig. 3.8. Deletion of exon 2 from the
CTGF gene was induced by treatment of mice with tamoxifen (as described
in Chapter 2).
To assess the extent of pulmonary fibrosis in the bleomycin-treated mice,
mouse lungs were subjected to micro-CT scanning (Fig. 3.9). H&E staining
of the lungs obtained from mice 21 days after bleomycin treatment showed
that the walls of the alveoli were thickened (Fig. 3.10 C), a feature which was
absent from the saline treated subjects (Fig. 3.10 A and B). In bleomycin-
treated mice, alveolar spaces were reduced as the alveoli were obliterated by
the presence of florid fibrosis (Fig. 3.10 C). The bleomycin-induced fibrotic
phenotype was attenuated in the CTGF KO mouse lung (Fig. 3.10 D).
PicroSirius red staining showed that compared to WT (Fig. 3.11 A) and
CTGF KO mice treated with saline (Fig. 3.11 B), collagen deposition in the
lungs of bleomycin-treated WT mice (Fig. 3.11 C) were significantly
increased. However, in the CTGF knockout lung (Fig. 3.11D), bleomycin
induced less collagen deposition compared to that in WT mice (Fig. 3.11 C).
This finding is in line with previous reports of CTGF as a mediator of
bleomycin-induced fibrosis in the lung (Ponticos et al., 2009) and the skin
(Liu et al., 2011).
For semi-quantitative analysis, a fibrotic index was calculated for each H&E
stained mouse lung section by applying a score from the Modified Ashcroft
Scale to each field of view, which was then added and divided by the total
number of fields. As expected, following exposure to bleomycin, the fibrotic
In vivo effects of CTGFoverexpression and knockout on fibrosis |
Figure 3.8 A schematic of the generation
mice
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to remain in the cytoplasm until the administration of tamoxifen, which
releases the Cre from this inhibition so it is able to enter the nucleus and
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CTGF flanked by loxP sites) mice and the
ROSA-CreERT2 (B; Cre recombinase
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Figure 3.9 Bleomycin
Representative micro
mice treated with saline control (A), bleomycin (C) or bleomycin and anti
CTGF antibody (D). (B) shows
images from the side, front and top elevations are shown.
-induced pulmonary fibrotic lesions in mice
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Figure 3.10 Knockout of CTGF abrogated bleom
pulmonary fibrosis
(A – D) Representative imag
lung sections. In contrast to saline
bleomycin-treated WT lung (C) showed florid fibrosis. Alveolar spaces were
reduced as the alveoli were obliterated by fibrotic masses. Lungs
deficient mice (D) showed a significant reduction in bleomycin
fibrosis compared to those of WT mice which had
bleomycin (C). (E) Modified Ashcroft
test, * denotes p < 0.05).
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Figure 3.11 Knockout of CTGF reduced bleomycin
deposition in mouse lungs
(A – D) Representative images (magnification 100X) of PSR stained mouse
lung sections. Compared to
bleomycin-treated WT lung (C) showed
deposition (red staining)
bleomycin-induced collagen expression that was observed in (C).
-induced coll
saline-treated WT (A) and KO (B) lungs,
markedly increased collagen
. Knockout of CTGF in mice (D) alleviated the
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index was significantly increased in WT mice compared to those dosed with
saline control (p < 0.05). No significant difference was found between the
fibrotic index of saline treated WT and KO mice (p = 0.1576). In bleomycin
treated animals, a reduction in the fibrotic index was observed in KO
compared to WT (p = 0.0277).
As well as increased H&E staining after bleomycin treatment,
immunostaining of the mouse lungs also showed increased CTGF staining
with bleomycin treatment, particularly around the blood vessels (not shown)
and at the alveolar epithelial lining (Fig. 3.12). The cells expressing CTGF
are likely to be fibroblasts, smooth muscle cells and type II alveolar epithelial
cells. In contrast, although CTGF expression is not completely blocked in
CTGF KO mouse lungs treated with bleomycin, it is markedly reduced
compared to bleomycin-treated WT mice.
CTGF KO did not abrogate completely the fibrotic phenotype, suggesting
other factors in addition to CTGF played a part in this model of fibrosis.
However, given the role of CTGF in sustaining fibrosis, it would perhaps be
interesting to elucidate observe these mice at a later time point and longer
exposure to bleomycin injury to investigate whether maintenance of fibrosis
might be affected by CTGF KO. The modest reduction between the CTGF
KO and WT bleomycin-treated animals may be due to the bleomycin-induced
fibrosis not occurring uniformly and widespread through the lung.
3.4.6 Generation of inducible CTGF overexpression mice
In addition to the Col1a2-CTGF transgenic mice, which constitutively express
CTGF, an inducible CTGF transgenic mouse has also been developed for
overexpression of CTGF in the adult mouse. This model can perhaps
recapitulate more accurately the CTGF upregulation observed in SSc
patients as adults. Mice containing the floxed CTGF gene were crossed with
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mice harbouring the ROSA-Cre construct (animals were generated by Dr
George Bou Gharios; Figure 3.13). Homozygous mice were selected by
genotyping and CTGF expression was induced by deletion of the STOP
codon via cre-recombinase expression induced by injection with tamoxifen (1
mg/50µL saline/mouse, daily for 5 days). H&E (Fig. 3.14 A and B) revealed
thickened alveolar septa (purple) and reduced alveolar spaces (white,
unstained areas) in the lung of CTGF overexpressing mice, indicative of a
fibrotic phenotype. This correlates with the observations of fibrotic lesions on
the skin of the face and back of the overexpression mice (data not shown).
Immunostaining showed increased expression of CTGF in the cytoplasm and
at the plasma membrane of cells in the lung parenchyma (Fig. 3.14 C and D).
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Figure 3.12 Reduced CTGF expression in the bleomycin
pulmonary fibrotic lesions of CTGF knockout mice compared to
Representative images of CTGF immunostaining of mouse lung sections.
(A) WT + saline, (B) CTGF KO + saline, (C) WT + bleomycin, (D) CTGF KO +
bleomycin, (E) Rabbit IgG negative control. Images captured using NDP
View at magnification 20X and inset shows overview of whole section.
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Figure 3.13 Schematic of the generation of conditional CTGF
overexpression mice
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Figure 3.14 Increased CTGF expression in lung parenchyma of
inducible CTGF overexpression
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Representative H&E staining (top panel) and CTGF immunostaining (bottom
panel; brown) of lung sections from WT (A and C) and transgenic mice
induced by tamoxifen (B and C).
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3.5 Discussion
Fibroblast-specific overexpression of CTGF in the Col1a2-CTGF transgenic
mice resulted in a fibrotic phenotype marked by excessive collagen
production leading to a thickened dermis in the skin as well as obliteration of
the normal alveolar architecture in the lung parenchyma as compared to WT
mice. These findings were in agreement with those of our collaborator who
showed evidence of fibrosis in the lungs, skin and kidney of the Col1a2-
CTGF mice as well as vascular abnormalities (Sonnylal et al., 2010). The
Col1a2-CTGF mouse phenotype supports the role of CTGF overexpression
in promoting ECM production and/or downregulating ECM degradation.
This observation of CTGF-driven fibrosis is consistent with the association of
CTGF with multiple fibrotic diseases including atherosclerosis, cardiac
fibrosis, diabetic nephropathy, keloids and hypertrophic scars, liver cirrhosis,
skeletal muscle fibrosis, IPF and SSc (Charrier et al., 2014; Kono et al.,
2011; Metalidis et al., 2013; Rosin et al., 2013; Serrati et al., 2013). The
Col1a2-CTGF mouse provides a useful model for studying the fibrosis facet
of SSc as the upregulated CTGF in fibroblasts is reminiscent of the autocrine
overexpression of CTGF observed in SSc dermal and lung fibroblasts
(Leask, 2012b). As well as in the lysates of the Col1a2-CTGF fibroblasts,
elevated levels of secreted CTGF were also detected in the conditioned
medium of the fibroblasts, which is coherent with the characteristic of CTGF
as a secreted protein (Alfaro et al., 2013).
TGF-β further stimulated the expression of CTGF in fibroblasts from Col1a2-
CTGF mice, which relates well with TGF-β as a potent inducer of CTGF
(Leask and Abraham, 2006). Although activation of SMAD1 has been shown
to activate the CTGF promoter, this TGF-β induction of CTGF is likely to
involve activation of the ALK5 receptor/SMAD2/3 pathway as the Col1a2 and
CTGF promoters contain SMAD3 binding sequences (Munoz-Felix et al.,
2014). This would also support previous demonstrations of an association
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between SMAD2 and CTGF (Gressner et al., 2009). Although canonical
TGF-β signalling has been shown to be dispensable in the induction of basal 
CTGF in Col1a2-CTFG MEFs (Sonnylal et al., 2010), CTGF expression was
attenuated by treatment with TGF-β-neutralising antibody or TGF-β receptor I 
inhibitor, providing support of TGF-β-induced CTGF expression via TGF-β 
signalling. CTGF induction may also be mediated by non-SMAD signalling
such as through the pERK, p38 or JNK pathways, as reported previously
(Ponticos et al., 2009; Sonnylal et al., 2010) .
In order to elucidate the mechanism underlying the fibrotic phenotype
observed in the lung tissue of Col1a2-CTGF mice, lung sections were
examined by histological analysis, as with the mouse skin. In addition to the
presence of fibrotic lesions, abnormalities in the alveolar epithelium, which
were lacking in WT mice, were discovered in the lungs of Col1a2-CTGF
mice.  The co-localisation of the prototypical myofibroblast marker α-SMA 
with the type II alveolar epithelial cell marker TTF-1 in the lung of the Col1a2-
CTGF mice suggested that CTGF may act via a paracrine mechanism on
adjacent epithelial cells, possibly promoting them to undergo transition into a
mesenchymal cell type. This implicated a role for CTGF in mediating
epithelial-to-mesenchymal transition (EMT) in lung fibrosis (Chapter 4).
A drawback to using Col1a2-CTGF mouse to study human SSc is perhaps
that SSc onset often occurs later in life, and when the CTGF gene is
upregulated constitutively in Col1a2-CTGF mice, profound changes are likely
to have already occurred from birth given the role of CTGF in development
(Canalis et al., 2010; Nagashima et al., 2011). Therefore, the conditional
CTGF overexpression mice were generated. This transgenic mouse
demonstrated a fibrotic phenotype in the lungs, like that observed in the
Col1a2-CTGF mice, marked by increased H&E staining and collagen
deposition. This model may be a useful tool for future studies into the
mechanisms of CTGF action in the adult mouse.
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Since CTGF upregulation in human and mouse correlated with development
of fibrosis, we were interested to elucidate whether CTGF downregulation or
deletion would attenuate fibrosis. Early studies investigating the effect of
knocking out CTGF in vivo demonstrated that homyzygous deletion of CTGF
yielded mice which were perinatally lethal with notable skeletal defects
(Doherty et al., 2010; Ivkovic et al., 2003). There have also been studies of
osteoblast-specific and ovarian/uterine-specific CTGF deletion demonstrating
the importance of CTGF in skeletal development and homeostasis, and
female reproduction (Canalis et al., 2010; Nagashima et al., 2011). A more
recent study showed that conditional deletion of CTGF specifically in smooth
muscle cells/fibroblasts in mice conferred resistance to bleomycin-induced
skin fibrosis (Liu et al., 2011). In these mice, CTGF deletion hindered
myofibroblast recruitment to lesional areas as well as dermal thickening and
collagen deposition in response to bleomycin insult. However, the effect of
CTGF knockout on bleomycin-induced lung fibrosis was unknown. In order
to assess this, conditional deletion of CTGF was performed in adult mice.
Bleomycin treatment induced pulmonary fibrosis more prominently in the WT
mice than in the CTGF-KO mice, in support of previous reports of CTGF
playing a role in mediating bleomycin-induced fibrosis in the lung and skin in
vivo (Liu et al., 2011; Ponticos et al., 2009). Modified Ashcroft scoring
showed a modest but significant reduction in bleomycin-induced fibrosis in
bleomycin-treated CTGF-KO lungs compared to WT counterparts.
Conventional studies of tissue fibrosis using histological analysis alone can
be difficult to assess the extent of fibrosis across the whole organ as tissue
samples may be taken by chance in lesional or non-lesional areas of the lung.
The advantage of using micro CT analysis was that it allowed the lung
volume to be assessed across both lungs ex vivo. Combining histological
and micro-CT analysis, it was clear that fibrotic masses were not uniformly
dispersed throughout the bleomycin-treated lung sections, perhaps due to
the uneven distribution of bleomycin instillation. Overall, blocking CTGF
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expression attenuates some of the fibrotic effects induced by bleomycin
treatment suggesting that CTGF mediates, at least partially, bleomycin-
induced fibrosis in the lung. In support of these findings, CTGF expression
was alternatively blocked with the use of an anti-CTGF antibody. The anti-
CTGF antibody also reduced bleomycin-induced fibrosis in the lungs. A
larger study with a greater number of mice n each experimental group will be
required to confirm these results. Co-localisation immunostaining of CTGF
with other cell type markers will help to show which cell types might be
expressing CTGF and whether deletion of CTGF might affect the process of
EMT. Future work to characterise the phenotype of the lung fibroblasts
would aid in elucidating the feasibility of CTGF deletion in reducing ECM
production and development of fibrosis.
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Chapter 4. A role for CTGF in alveolar
epithelial-to-mesenchymal transition
4.1 Introduction
While activated fibroblasts accumulate, they can drive fibrosis by directly
enhancing matrix deposition. Additionally, this key cell type may exert
profibrotic effects indirectly through modification of adjacent epithelial cells.
As shown in Chapter 3, in the Col1a2-CTGF transgenic mice (Sonnylal et al.,
2010), overexpression of CTGF specifically in fibroblasts, appeared to induce
profibrotic changes not only in fibroblast cells, but also in the alveolar
epithelium, including co-expression of TTF-1 and α-SMA in the alveolar lining.  
The focus of this chapter stems from the observations made on this abnormal
epithelium and aims to investigate the potential role that CTGF might play in
the process of epithelial-to-mesenchymal transition (EMT), an event during
which lung epithelial cells become more mesenchymal cell-like, adopting a
pro-migratory and proliferative phenotype, which in turn might provide an
additional source of matrix-depositing fibroblasts besides resident fibroblasts
(Iwano et al., 2002). Notably, out of the two types of alveolar epithelial cells
or pneumocytes present in lung tissue, type II alveolar epithelial cells, which
produce surfactant protein, are the ones of interest in this study as they are a
plastic cell type, able to undergo transition to become the more abundant
type I alveolar epithelial cells during tissue repair and also in EMT during
metastasis and fibrosis (Kasai et al., 2005; Lee et al., 2013a; Saika et al.,
2004; Willis et al., 2005). This would be consistent with numerous studies,
which have suggested that the activated fibroblast population is derived from
a heterogeneous source of cell types in addition to resident fibroblasts,
including epithelial cells, vascular smooth muscle cells, endothelial cells and
fibrocytes (Abraham et al., 2007; Krieg et al., 2007; Postlethwaite et al., 2004;
Quaggin and Kapus, 2011). However, the relative contribution of each
source remains unresolved, and may vary in different tissues and in different
diseases.
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EMT involves epithelial cells losing cell-cell attachment, polarity and
epithelial-specific markers such as E-cadherin (switching to N-cadherin
expression) and acquiring mesenchymal markers such as α-SMA, collagen 
type I, fibronectin and fibroblast-specific protein-1 (FSP-1) (Willis et al., 2006;
Willis and Borok, 2007). As a result, experimental EMT is often defined by
the expression of a panel of these protein markers. While EMT may be
induced by various cytokines, a classic example being TGF-β (Chen et al.,
2005; Postlethwaite et al., 2004), the role of CTGF in this process remains to
be elucidated. The altered phenotype of the alveolar epithelium in the
Col1a2-CTGF mice suggests that CTGF may also influence EMT
independently. Previous studies have reported elevated CTGF in response
to TGF-β-induced EMT in a human type II alveolar epithelial (A549) cell line 
(Kasai et al., 2005; Shi-Wen et al., 2008), so it may be possible that CTGF
mediates some of the EMT-promoting effects of TGF-β, and in turn enhances 
fibroblast activation and overall ECM accumulation in fibrosis. Furthermore,
in the idiopathic pulmonary fibrosis (IPF) lung, it has been demonstrated that
as well as myofibroblast cell expression, CTGF is also elevated in type II
alveolar cells alongside observations of epithelial-mesenchymal cross-talk
marked by the presence of proliferative alveolar epithelial cells adjacent to
injured epithelial cells (Konigshoff et al., 2009). In this chapter, the potential
role of CTGF in mediating EMT in a rat alveolar cell line (referred to as T2
cells in this chapter) will be explored.
4.2 Results
4.2.1 TGF-β and CTGF induce morphological changes in type II 
alveolar epithelial cells (T2)
It is well documented that TGF-β can induce EMT in lung epithelial cells in
vitro (Lamouille et al., 2014; O'Connor and Gomez, 2014; Willis and Borok,
2007). In order to determine whether the T2 cells can undergo EMT in vitro,
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Figure 4.1 TGF-β and CTGF induce morphological change
epithelial cells (AEC)
Phase-contrast microscopy (top) and schematic (bottom) of SV40
transformed T2 AECs cultured with DMEM / 0.5 % BSA alone (control) or
DMEM / 0.5 % BSA containing TGF
hours. TGF-β stimulated cells adopt an elongated morphology (right panel)
while control cells retain the typical cuboidal shape of type II alveolar cells
(left panel). An increased number of apoptotic or floating cells were also
observed in the TGF
-to-mesenchymal transition
-β (4 ng/ml) or CTGF (100 ng/ml) for 48
-β-treated cells.  Magnification 400X. 
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these cells were treated with recombinant TGF-β (4 ng/ml) for 48 hours.  
Changes in cell morphology were observed (Fig. 4.1 A), as the T2 cells
shifted from a prototypical cobble-stone epithelial cell structure to a more
elongated, spindle-shaped fibroblast-like morphology (as depicted in the
schematic in Fig. 4.1 B). There were also more floating, detached cells in the
TGF-β-treated cell culture, indicative of apoptosis.  On exposure to 
recombinant CTGF (100 ng/ml) in vitro, the T2 cells developed a similar
morphological change to that observed after TGF-β treatment (Fig. 4.1 A), 
suggesting CTGF alone may also induce the epithelial cells to diverge from
its normal phenotype.
4.2.2 TGF-β induces expression of mesenchymal protein markers in T2 
cells
To further examine whether T2 cells are able to undergo EMT-like changes,
T2 cells were cultured with TGF-β (4 ng/ml) for 24 – 72 hours (h).  Whole cell 
lysates were assessed for expression of EMT markers by Western blotting.
Although no significant changes were detected in levels of expression of the
epithelial marker E-cadherin, TGF-β treatment was associated with 
significant increases in the expression of the mesenchymal cell markers
CTGF at 24 hours (p = 0.0153), and α-SMA at 24 hours (p = 0.0003), 48 
hours (p < 0.0001) and 72 hours (p = 0.0188). These results indicated that
TGF-β treatment led to some EMT-like changes, although no significant 
changes were observed in the expression of the other EMT markers
investigated, including the intermediate filament protein vimentin and
transcription factor SOX-9 (Fig. 4.2).
As CTGF functions as a secreted protein, the levels of CTGF in the
conditioned media of the T2 cells were also examined by Western blotting.
TGF-β treatment was associated with significantly higher expression of 
secreted CTGF at 24 hours (p = 0.0004), 48 hours (p = 0.0173) and 72 hours
(p = 0.0353) (Fig. 4.3 A). As collagen type I is also considered a
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Figure 4.3 TGF-β induced expression of secreted mesenchymal protein 
markers in T2 cells
T2 cells were cultured with TGF
blot analysis of (A, left)
the conditioned media. Western blots were quantified by densitometry (right).
Expression of target proteins (CTGF, collagen type I) was normalised against
β-tubulin in corresponding whole cell lysates
Histograms in A show mean (n=3 from 3
p < 0.05, *** p < 0.0005. Histogram in B is from a representative Western
blotting image (n=1).
-to-mesenchymal transition
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secreted CTGF and (B, left) collagen type I levels in
(as shown in Fig. 4.2).
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mesenchymal marker of EMT associated with tissue fibrosis (Kalluri, 2009),
the levels of collagen type I in the conditioned media were also measured by
Western blotting (Fig. 4.3 B). Fibronectin is another mesenchymal marker,
but due to the variability experienced with Western blotting of this protein,
(mainly because of its large molecular weight of 240 kDa, making it difficult to
transfer from gel to membrane), fibronectin levels in the conditioned media
were measured by enzyme linked immunosorbent assay (ELISA).
Significantly higher levels of fibronectin expression was observed in TGF-β-
treated cells at 24 hours (p = 0.0004) and 48 hours (p = 0.0442) compared to
untreated cells (Fig. 4.4). These results are consistent with previous studies
reporting the involvement of TGF-β in the process of EMT in a human 
alveolar epithelial cell line, A549, characterised by expression of the same
mesenchymal markers (Kasai et al., 2005). An important finding in the
current study, which is supported by observations made by Kasai et al.
(Kasai et al., 2005), was the enhanced expression of CTGF identified as one
of the features in a series of EMT-like changes induced by TGF-β treatment 
(Fig. 4.2).
4.2.3 TGF-β induced mRNA expression of CTGF and α-SMA in T2 cells 
without altering E-cadherin levels
To assess whether there were any changes in mRNA expression of EMT-
related genes, T2 cells treated with TGF-β (4 ng/ml) subjected to qPCR 
analysis. Since results of the Western blot analysis indicated alterations in
protein expression could already be detected at 24 hours, treatment of cells
for qPCR analysis was also performed for 24 hours. Gene expression (copy
number) was normalised against the geometric mean of the expression of
three reference genes. As shown in Fig. 4.5, T2 cells treated with TGF-β 
expressed significantly higher levels of CTGF (p < 0.0001) and α-SMA (p = 
0.0094). However, consistent with findings from the Western blot analysis
showing that protein levels of E-cadherin were unchanged by TGF-β 
treatment (Fig. 4.2), no significant difference was found in expression of E-
cadherin mRNA (p = 0.9545) between TGF-β-treated and control cells (Fig.  
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4.5 A).  Increased expression of CTGF and α-SMA mRNA (Fig. 4.5 B and C) 
detected in TGF-β treated T2 cells compared to untreated cells suggest the 
increase in CTGF and α-SMA protein may be related to altered 
transcriptional regulation of these genes favouring de novo protein synthesis.
These alterations in mRNA expression levels suggest that TGF-β and CTGF 
may both play a role in EMT-like changes of alveolar epithelial cells.
4.2.4 TGF-β induces redistribution of E-cadherin and expression of 
mesenchymal cell proteins
In order to examine the expression and intracellular distribution of EMT
proteins following TGF-β treatment, T2 cells were cultured on glass chamber 
slides and treated with TGF-β for 24 (data not shown) and 48 hours and 
assessed by immunofluorescence for expression of E-cadherin, α-SMA, 
CTGF and vimentin (Fig 4.6).  Elevated expression of CTGF, α-SMA and 
vimentin were observed in the T2 cells treated with TGF-β compared to 
untreated controls.  The staining also shows that α-SMA is incorporated into 
stress fibres after TGF-β treatment.  Interestingly, although total protein and 
RNA levels, as shown by Western blotting and qPCR analysis (Fig. 4.2 and
4.5), was not significantly altered by TGF-β treatment, the intracellular 
distribution of E-cadherin seemed to be changed; a decrease in E-cadherin
staining was observed at the plasma membrane of the TGF-β treated cells. 
4.2.5 Knockdown of CTGF attenuates TGF-β-induced α-SMA in T2 cells 
CTGF has been reported to act as a downstream mediator of TGF-β action in 
fibroblasts (Grotendorst, 1997) but the relationship of CTGF and TGF-β 
signalling in T2 cells remains largely unknown.  In this study, TGF-β is shown 
to induce α-SMA expression and in order to investigate directly whether 
CTGF may be involved in this induction, T2 cells were treated with non-
targeted control siRNA (siNTC) or CTGF-specific siRNA (siCTGF, 20 nM)
prior to TGF-β (4 ng/ml) treatment for 24 hours (Fig. 4.7).  Changes in CTGF 
and α-SMA mRNA expression were assessed by qPCR.  Treatment with  
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CTGF-specific siRNA (siCTGF) significantly reduced TGF-β-induced CTGF 
mRNA expression by 20 ± 0.1 % (p = 0.043) compared to control cells
exposed to non-targeting control siRNA (siNTC). Concomitant with this
knockdown in CTGF expression, a significant decrease of 43 ± 0.1 % (p =
0.0042) in TGF-β-induced α-SMA mRNA was observed in siCTGF-treated T2 
cells compared to siNTC control. This shows that a partial knockdown of
CTGF is able to reduce α-SMA expression induced by TGF-β treatment in T2 
cells.
4.2.6 CTGF induces expression of mesenchymal cell proteins in T2
cells
As TGF-β treatment induced EMT-like changes in T2 cells, in a process 
which seemed to be at least partially dependent on CTGF, the question of
whether CTGF alone may mediate EMT was investigated. In order to mimic
the situation in which CTGF released by adjacent fibroblasts influences
epithelial cells, as in the Col1a2-CTGF transgenic mice (Chapter 3), T2 cells
were treated with recombinant CTGF. Initially, a range of recombinant CTGF
concentrations (10 – 200 ng/ml) were tested with treatment times of 24 or 48
hours to determine the optimum dose and time of treatment.
Expression of the EMT markers, E-cadherin and α-SMA were assessed by 
Western blotting (Fig. 4.8). At 24 hours after the addition of exogenous
CTGF to the T2 cell culture, a significant increase in α-SMA expression was 
already observed at the lowest concentration of CTGF at 10 ng/ml (p =
0.0039) compared to untreated cells.  Peak α-SMA induction at 24 hours was 
achieved by treatment of the cells with 50 ng/ml of CTGF (p = 0.0037).
Treatment with higher concentrations of CTGF did not induce significantly
higher levels of α-SMA compared to CTGF at 50 ng/ml (Fig. 4.8 A).  Elevated 
α-SMA expression was also observed after 48 hours of CTGF treatment, 
although in this case, the dose-dependent increase in α-SMA levels peaked 
at 100 ng/ml of CTGF (Fig. 4.8 B).  Despite a rise in α-SMA expression, E-  
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cadherin expression did not drop, as would be expected in EMT. Conversely,
E-cadherin protein was significantly increased at the highest concentration of
CTGF treatment at 24 hours and also at several concentrations at 48 hours
(Fig. 4.8 A and B). The elevation of E-cadherin by CTGF may involve a
mechanism other than EMT, which CTGF may be involved in (Tan et al.,
2008).
The mesenchymal protein fibronectin was also induced by CTGF stimulation
of T2 cells. Fibronectin levels in the conditioned media, measured by ELISA,
were found to be significantly elevated after treatment of cells with 10 ng/ml
(p = 0.0385) and 50 ng/ml (p = 0.0186) of CTGF for 48 hours (Fig. 4.9).
However, induction of fibronectin by CTGF was lower compared to induction
by TGF-β; 48 hours after treatment with TGF-β, fibronectin levels increased 
by 26.9 ± 3.12 % while CTGF treatment resulted in a more modest 14.0 ±
3.49 % increase compared to control.
Immunofluorescent staining demonstrated that addition of exogenous CTGF
alone induced expression of α-SMA incorporated into stress fibres (Fig. 4.10) 
with no expression seen in untreated cells, confirming the results of the
Western blotting analysis (Fig. 4.8). Detection of vimentin filaments were
also increased in CTGF-treated T2 cells compared to control, reminiscent of
the enhanced vimentin expression after TGF-β treatment of T2 cells (Fig 
4.6). Although total E-cadherin levels as shown by Western blot were
increased after CTGF treatment (Fig. 4.8), immunofluorescence showed a
decrease in E-cadherin at the plasma membrane suggesting a disruption to
E-cadherin function in maintaining cell-cell adhesion junctions.
4.2.7 CTGF induces a partial EMT phenotype in NMuMG cells
Like T2 cells, NMuMG cells are also epithelial cells, but are non-transformed
mammary epithelial cells. In fact, NMuMG cells were the first cell type
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reported to undergo EMT after TGF-β treatment (Maeda et al., 2005). Since
NMuMG cells provide a classic in vitro system for studying EMT, to verify
whether CTGF was able to induce EMT in vitro, NMuMG cells treated with
CTGF (200 ng/ml) for 24 – 72 hours.  Expression of E-cadherin, and α-SMA 
protein were assessed by Western blotting (Fig. 4.11 A) and quantified by
densitometry (Fig. 4.11 B and C). Treatment with the prototypical inducer of
EMT, TGF-β (4 ng/ml), was associated with a time-dependent decrease in E-
cadherin levels, as well as a time-dependent accumulation of α-SMA.  The 
change in E-cadherin expression was -0.5529 ± 0.1362 arbitrary units (p =
0.0154) at 24 hours, with expression diminishing to a change of -0.9758 ±
0.1593 arbitrary units (p = 0.0036) at 48 hours, and -0.5516 ± 0.1300
arbitrary units (p = 0.0132) at 72 hours compared to controls at each time-
point.  No significant change was observed with α-SMA expression until 48 
hours of TGF-β treatment compared with control (0.5177 ± 0.1487 arbitrary 
units (p = 0.0253), which increased further at 72 hours (1.155 ± 0.3299
arbitrary units ( 0.0249).
In contrast to treatment with T2 cells, CTGF induced a significant decrease in
E-cadherin expression by NMuMG cells, albeit a more modest change
compared to the effects of TGF-β.  At 24 hours, the difference in E-cadherin 
expression between control and CTGF-treated NMuMG cells was -0.7450 ±
0.1818 arbitrary units (p = 0.0149). Similarly at 48 hours, the difference was
-0.8058 ± 0.2023 arbitrary units (p = 0.0163). However, no significant
differences were observed in α-SMA protein levels in CTGF-treated NMuMG 
cells compared to control, in contrast to that observed in CTGF-treated T2
cells, which resulted in the induction of α-SMA.   
4.2.8 Activation of p38, ERK1/2 and SMAD2/3 by CTGF in T2 cells
In vivo overexpression of CTGF in the Col1a2-CTGF mice demonstrated
enhanced phosphorylation of p38, ERK1/2 and AKT but not SMAD2/3
compared to wild-type control lung fibroblasts (Sonnylal et al., 2010),
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Figure 4.11 CTGF induces EMT
epithelial cells
To verify whether CTGF is able to induce EMT
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implying that CTGF acts via the MAPK and PI3K pathways rather than the
canonical TGF-β pathway.  In order to elucidate which signalling pathways 
may be activated in T2 cells by CTGF, the expression of p-p38, pERK1/2 and
pSMAD2/3 and AKT were assessed. Confluent T2 cells were treated with
CTGF (200 ng/ml) for 15 – 30 minutes. By 15 minutes, CTGF already
stimulated the expression of p-p38 (p = 0.0406), pERK1/2 (p = 0.0006) and
pSMAD2/3 (p = 0.0294) but not p-AKT in T2 cells. At 30 minutes after
treatment, p-p38, pERK1/2 and pSMAD2/3 expression returned to basal
levels, suggesting a transient activation of these phosphoproteins in T2 cells
following CTGF treatment (Fig. 4.12). CTGF stimulation may activate SMAD
signalling by modulating TGF-β activity (Abreu et al., 2002).  These results 
imply that the CTGF-induced expression of mesenchymal proteins in T2 cells
may be mediated by p-p38, pERK1/2 and pSMAD3 signalling, but not by
pAKT signalling. Induction of the first two of these signalling molecules
accords with the in vivo activation of p38 and pERK1/2 in the skin of Col1a2-
CTGF mice (Sonnylal et al., 2013). However, the signals activated differ
from Col1a2-MEF cells which showed CTGF overexpression resulted in
activation of p38, ERK1/2 and AKT but not SMAD (Sonnylal et al., 2010).
The differences in AKT and SMAD activation may be due to the difference in
cell type being studied; MEFs and alveolar epithelial cells.
4.2.9 CTGF induced-α-SMA is dependent on p-p38, pSMAD2/3 and 
pERK1/2 signalling but not pAKT in T2 cells
Based on the previous results demonstrating a robust and repeatable α-SMA 
induction following CTGF treatment (Fig. 4.8 and 4.10), experiments using α-
SMA expression as an end-point were used to gain insight into the
mechanism that could underlie this CTGF-induced result. Since p38,
SMAD2/3 and ERK1/2 activation were detected in T2 cells (Fig. 4.12), we
wanted to directly investigate whether the increase in α-SMA expression by 
CTGF is associated with any of these signalling pathways (Fig. 4.13). T2
cells were treated with inhibitors targeting p38 (SB203580, 10 µM - a
concentration shown to block TGF-β induced α-SMA expression in fibroblast 
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cells (Meyer-ter-Vehn et al., 2006)), ERK1/2 (U0126, 10 µM, - a
concentration shown to inhibit ERK1/2 phosphorylation in vitro (Favata et al.,
1998)), and TGFβRI/ALK5 (LY364947, 10 µM - a potent ATP-competitive 
inhibitor shown to block TGF-β-induced EMT in NMuMG cells at 2 μM (Peng 
et al., 2005)) for 1 hour prior to treatment with CTGF (200 ng/ml) for 24 hours
(Fig. 4.13). The representative Western blotting identified a decrease in
CTGF-induced α-SMA expression in the presence of SB203580, U0126 and 
LY364947. In parallel, immunofluorescence experiments conducted by Dr
Helen Jones (Sonnylal et al., 2013), also showed that CTGF-mediated α-
SMA expression in the same T2 cell line was attenuated by LY364947, as
well as by using the TGF-β neutralising antibody 1D11.  
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Figure 4.12 CTGF induces expression of p
but not p-Akt in T2 cells
Confluent T2 cells were treated with CTGF (200 ng/ml) in 0.5% BSA in
DMEM for 15 – 30 min. Expression of phosphoproteins were assessed
Western blot (A) and quantified by densitometry. Columns show mean
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and ERK1/2
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4.3 Discussion
This chapter has explored the development of EMT-like changes in T2 cells
through various in vitro analyses. A series of experiments examining the
impact of exogenous TGF-β and CTGF on production of epithelial and 
mesenchymal cell type markers has highlighted the plasticity of T2 cells.
TGF-β is a key inducer of EMT, during embryonic development, 
carcinogenesis and fibrosis (Lee et al., 2013a), while the role of CTGF in
EMT on the other hand, is less well defined. It was of interest to find out
whether CTGF alone could also induce changes similar to that of TGF-β as 
some previous reports have suggested CTGF is limited to acting as a
downstream mediator rather than a substitute for TGF-β function in mink lung 
epithelial cells (Grotendorst, 1997; Kothapalli et al., 1997).
In order to establish whether the T2 cell line could be used as an in vitro
model of EMT with quantifiable end-points, T2 cells were initially treated with
TGF-β.  Using the experimental techniques developed from this preliminary 
work on TGF-β treatment, the effect of recombinant CTGF on T2 cell 
phenotype was investigated.  In culture, T2 cells treated with either TGF-β or 
CTGF appeared to be more proliferative, which is interesting as T2 cells in
the lung do not normally divide except in response to environmental stimuli.
Phase contrast microscopy of the T2 cells in culture demonstrated that
treatment with TGF-β and CTGF induced a change in cell morphology, from 
a cuboidal structure laid out in a tightly-packed cobblestone arrangement to
adopt a more elongated, spindle shape that would usually be associated with
a mesenchymal cell type. These changes observed in the cell morphology
may be a reflection of the underlying changes to the genetic programme
inside the cells and to investigate this further, western blot,
immunofluorescence, qPCR and ELISA analysis were carried out, which
identified altered mRNA and protein expression in T2 cells after treatment
with TGF-β.  These changes were mirrored by CTGF treatment of these cells.  
The expression of a panel of EMT markers were analysed as typically
performed in studies of EMT, where experimental EMT may present a
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number of but not all the features of EMT, depending on variables such as
type of epithelial cell and cell cycle state (Lee et al., 2013a). Interestingly,
while T2 cells maintained E-cadherin expression, increased abundance of
RNA and proteins associated with mesenchymal cell types were identified by
qPCR and Western blotting, such as α-SMA, vimentin and collagen type I.  
Immunofluorescence staining of E-cadherin revealed that although E-
cadherin was still present in the T2 cells, there seemed to be a loss of
expression at the cell surface and redistribution within the cell. This is
reminiscent of the loss of cell-cell junctions and apical polarity in epithelial
cells during EMT (Lamouille et al., 2014).
Despite E-cadherin downregulation being a characteristic feature of classic
EMT in multiple cell types (Willis and Borok, 2007), this study has been
unable to show a significant decrease of E-cadherin protein in T2 cells by
Western blotting, indicating a lack of transcriptional downregulation of E-
cadherin.  In the human lung epithelial cell line A549, TGF-β treatment for 24 
to 72 hours has been shown to induce suppression of E-cadherin (Kasai et
al., 2005) as well as expression of a transcriptional repressor of E-cadherin,
Snai1, which can be reversed by inhibition of CTGF expression using siRNA
(Sonnylal et al., 2013). In a study of primary cultures of epithelial cells,
complete transition from an epithelial to mesenchymal phenotype was longer
than in cell lines and not observed until after 2 weeks of TGF-β treatment, 
although co-expression of epithelial and mesenchymal markers was seen 4
days post-TGF-β stimulation (Willis et al., 2006). Furthermore, it has been
suggested that morphological changes during EMT precede the cadherin
switch (Maeda et al., 2005). In an earlier study of EMT in A549 cells,
induction of the mesenchymal marker fibronectin was also suggested to
precede reduction of E-cadherin expression (Kasai et al., 2005). A possible
explanation then for the lack of suppression in levels of E-cadherin protein in
the cell lysates may be that E-cadherin becomes internalised but the cleaved
C-terminal E-cadherin accumulates in the T2 cells, as the protein has a
relatively long half-life in cells (2 to 3 days) (Willis et al., 2006). A
redistribution of E-cadherin in the cell may be sufficient to drive T2 cells to
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acquire an EMT-like phenotype as the polarity of epithelial cells, and cell
adherens junctions become disrupted, favouring a proliferative and pro-
migratory phenotype (Lamouille et al., 2014). A partial EMT has been
described previously in CTGF treated-renal tubular epithelial cells in a
mechanism dependent on miR-192/215 (Wang et al., 2010b).
Although E-cadherin expression did not appear to decrease, distribution of E-
cadherin expression was modified by TGF-β and CTGF treatment from a 
membrane-associated form typical of epithelial cells to a dispersed
expression within the cells, as described by previous studies in renal tubular
epithelial cells (Peinado et al., 2003; Wang et al., 2010b). Indeed, the
internalisation and translocation of E-cadherin to the nucleus concomitant
with β-catenin is typically observed during EMT as well as in metastatic cells 
(Kage and Borok, 2012). E-cadherin is the principal cell adhesion molecule
in the epithelium maintaining epithelial cell integrity. Loss of membranous E-
cadherin may disrupt cell-cell contact, and may facilitate cells to become
more migratory (Lamouille et al., 2014). Cleavage of E-cadherin allows the
C-terminal cytoplasmic domain to dissociate from the N-terminal portion of E-
cadherin and the plasma membrane. It was possible to detect a decrease in
membranous E-cadherin by immunostaining, as the antibody used
recognised the C-terminal domain, which is internalised. Moreover, CTGF
treatment of NMuMG mammary epithelial cells - a prototypical cell type
described to undergo EMT, did induce a significant suppression of E-
cadherin in this chapter. This suggests that in vitro, CTGF does have the
ability to induce a change mimicking a loss of epithelial cell phenotype, at
least in NMuMG cells.
This induction of EMT markers in T2 cells by TGF-β is consistent with effects 
of TGF-β induced EMT in A549 lung epithelial cells in vitro which have been
reported previously (Kasai et al., 2005; Shi-Wen et al., 2008), including
elevated production of CTGF in treated epithelial cells compared to controls.
The TGF-β-induced increase in CTGF expression in T2 cells suggests a role 
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for CTGF in mediating the EMT-like phenotype. Indeed, when the T2 cells
were exposed to CTGF they also expressed some proteins that belong to the
expression profile of mesenchymal cells in addition to epithelial markers.
Consistent with studies of EMT in A549 cells, vimentin and fibronectin
expression was also enhanced in the T2 cells treated with TGF-β or CTGF 
for 24 to 72 hours (Kasai et al., 2005), as was α-SMA expression (Sonnylal et
al., 2013). Surprisingly, despite maintenance of E-cadherin expression,
induction of α-SMA in T2 cells was already detected at 24 hours after TGF-β 
or CTGF treatment, which is usually thought of as an extreme of the
spectrum of EMT markers, as one of the last features to be acquired by
epithelial cells which have undergone a programme of EMT-like changes.
Not only was the level of α-SMA elevated, immunostaining also identified the 
expression of the α-SMA as stress fibres.  However, it is not uncommon for 
different epithelial cell types to express a different panel of mesenchymal cell
markers in response to EMT inducers such as TGF-β, and perhaps the α-
SMA expression is a reflection of the plasticity of the T2 cell line. One of the
challenges of investigating experimental EMT and comparing between
different cell types or even cell lines is that effects of each cytokine of interest
can be variable and context-dependent (Willis and Borok, 2007).
CTGF as a downstream mediator of TGF-β action has been well documented 
in the context of fibroblast cells (Grotendorst, 1997) but the relationship in T2
cells is less well defined. The T2 cells appeared to be a difficult to transfect
cell line in the siRNA studies and although only a modest decrease in CTGF
expression was achieved using CTGF-specific siRNA, it was sufficient to
demonstrate a significant reduction in TGF-β induced α-SMA.    This finding 
provides evidence to support the role of CTGF in mediating in vitro some of
the EMT-like downstream effects of TGF-β signalling.  This is contrary to 
some published studies which have suggested that CTGF does not act on
epithelial cells, based on observations that CTGF exposure did not inhibit
growth in the same way as TGF-β does (Frazier et al., 1996) and
neutralisation of CTGF action using an anti-CTGF antibody was unable to
attenuate TGF-β-induced growth inhibition (Kothapalli et al., 1997). However,
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it is important to bear in mind that these studies were conducted on mink lung
epithelial cells rather than type II epithelial cells and more importantly,
focused on the growth inhibition function of TGF-β rather than the EMT-
promoting property of the cytokine. The results of this chapter is however,
largely consistent with observations in A549 alveolar cells treated with TGF-β 
(Kasai et al., 2005) and also where blocking of CTGF expression using
siRNA reduced a panel of TGF-β-induced EMT markers including α-SMA 
(Sonnylal et al., 2013). As well as dependence on cell type, the effect of
CTGF on EMT may also vary depending on the tissue or organ. For example,
studies in our lab have been unable to demonstrate the occurrence of EMT in
SSc skin despite of the presence of an activated epidermis, perhaps a
reflection of the absence of increased cases of skin cancers in SSc patients
(Nikitorowicz-Buniak et al., 2010). In contrast, recent systematic reviews
and meta-analyses have highlighted an association between SSc and
phenotypic changes in lung epithelial cells that drive tumour formation
(Bonifazi et al., 2013; Onishi et al., 2013).
SOX9 belongs to the HMG box super-family of transcription factors with a
key role in gene regulation during chondrogenesis. As well as chondrocytes,
SOX9 appears to also play a role in epithelial cells; in the skin of Col1a2-
CTGF transgenic mice, SOX9 was present in basal epithelial cells in contrast
to its absence in WT animals (Sonnylal et al., 2013). Furthermore, in the
A549 human epithelial cell line, TGF-β induced SOX9 expression, which was 
subsequently reduced by blocking CTGF expression (Sonnylal et al., 2013).
Based on these observations, we were interested to find out whether SOX9
expression was also altered by TGF-β or CTGF treatment in T2 cells. 
However, no significant change in SOX9 expression was detected in this
study. An explanation for the discrepancy may be due to inherent differences
in the properties of each cell line. Like E-cadherin, it is also possible that
while the overall protein expression of SOX9 may be maintained, the cellular
location may be altered so the relative amounts of SOX9 present in the
nucleus and cytoplasm may be different between treated and control T2 cells.
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However, studying the activation status of SOX9, which is marked by nuclear
translocation, was beyond the scope of this project.
In addition to the canonical SMAD-dependent signalling pathway for TGF-β, 
non-SMAD pathways are also play a role in driving fibrosis, including
members of the mitogen-activated protein kinase (MAPK) family. Analysis of
phosphoprotein expression in T2 cells treated with CTGF indicated that
CTGF was able to activate the canonical TGF-β pathway as well as p38 and 
ERK1/2 signalling. Phosphorylation of p38 and ERK1/2 were also detected
by immunohistochemistry in the epidermis of the Col1a2-CTGF transgenic
mice overexpressing CTGF in mesenchymal cells (Sonnylal et al., 2013) and
were suggested to be associated with an increase in expression of the
transmembrane glycoprotein integrin β6 in the skin. The role of integrin β6 
may also be relevant in the activation of the p38 and ERK1/2 pathways in the
T2 cells as upregulation of integrin β6 occurs in the lung in response to injury 
(Hogmalm et al., 2010).  Integrin β6 is a receptor for extracellular matrix 
proteins including fibronectin (Hogmalm et al., 2010), which is also increased
after CTGF treatment.  ERK enhances TGF-β-induced SMAD signalling and 
collagen synthesis by phosphorylating serine residues in the linker regions of
Smad1–3 and ERK inhibition (Hayashida et al., 2003). Similarly, p38 MAPK
has been shown to be central to TGF-β mediated-collagen, α-SMA and 
fibronectin expression in SSc fibroblasts (Ihn et al., 2005; Meyer-ter-Vehn et
al., 2006).  In this study, it has been demonstrated that in addition to TGF-β, 
these signalling pathways may be activated by CTGF. It is possible that
CTGF may work in concert with TGF-β to modulate the TGF-β/Smad 
signalling response in alveolar epithelial cells. In lens epithelial cells, EMT
has also been shown to be dependent on SMAD3 signalling following injury
(Saika et al., 2004).  Furthermore, inhibition of p38, ERK1/2 and TGFβRI 
signalling resulted in suppression of CTGF-induced α-SMA expression, as 
shown by Western blotting. These findings, although preliminary, suggest
that p38, ERK and SMAD signalling is likely to mediate the induction of α-
SMA stimulated by CTGF in T2 cells. This also accords with our earlier
observations by immunofluorescence showing that both a TGF-β neutralising 
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antibody and a TGFβRI inhibitor was able to attenuate the expression of α-
SMA as longitudinal fibres in T2 cells in vitro. Together, these findings
provide evidence to suggest that the EMT-like modifications induced by
CTGF in vitro may be mediated by enhanced TGF-β signalling in a positive 
feedback loop. Indeed, the alveolar epithelium acts as a key source of
cytokines such as TGF-β during lung fibrosis (Xu et al., 2003). It is possible
that these observations are also applicable in the context of NMuMG
mammary epithelial cells which undergoes TGF-β-induced EMT mediated by 
TGFβRI (Miettinen et al., 1994).
Like fibroblasts, the importance of type II alveolar epithelial cells has been
implicated in both regeneration and tissue repair, as well as in the process of
fibrosis. A recent review highlighted the marked contribution of alveolar
epithelial cells to the fibroblast population during pulmonary fibrosis (Mouratis
and Aidinis, 2011). Previously, in vivo studies using fate mapping
experiments in bleomycin-induced pulmonary fibrosis identified that one-third
of fibroblast-specific protein (S100A4)-positive cells are derived from alveolar
epithelial cells compared to one-fifth being derived from bone marrow
(Tanjore et al., 2009). EMT-like responses were also detected in alveolar
epithelial cells in endoplasmic reticulum stress-induced lung fibrosis (Tanjore
et al., 2011). In lung fibrosis, increased CTGF production has been identified
not only in myofibroblasts, but interestingly, also in alveolar epithelial cells
(Konigshoff et al., 2009). However, the action of CTGF has primarily focused
on fibroblasts while the effects on other cell types remain largely unknown,
including the molecular mechanism which mediates effects of CTGF in
alveolar epithelial cells.
In summary, the observations from this chapter suggest that CTGF plays a
role in promoting alveolar epithelial cells to undergo changes that are
reminiscent of some of the characteristics of EMT, at least in vitro. We
speculate that in the T2 cells, p38, pSMAD and pERK signalling may mediate
the CTGF-induced EMT-like phenotype. The presence of EMT in lung
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fibrosis has been demonstrated in the Col1a2-CTGF model and in T2 cells,
consistent with observations of EMT in idiopathic pulmonary fibrosis
(Chapman, 2011) and in animal models of TGF-β- and bleomycin-induced 
pulmonary fibrosis (Kim et al., 2006; Kim et al., 2009; Tanjore et al., 2009).
The current chapter focused on CTGF-mediated EMT in the T2 cell line in
vitro. Further research should be done to investigate whether the same
EMT-like responses might occur in primary type II alveolar cells exposed to
CTGF, and also the overall contribution of type II alveolar cells in vivo,
perhaps using fate mapping or cell tracking methods in the Col1a2-CTGF
mice. Further work is also required to elucidate the potential role of CTGF-
mediated EMT in fibrosis associated with SSc, at least in the lung. Targeting
CTGF may help to attenuate accumulation of profibrotic cells, including
epithelial cells in the lung which have the potential to acquire mesenchymal
features.
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Chapter 5. The role of CTGF in human SSc
lung
5.1 Introduction
Pulmonary fibrosis affects over 70% of SSc patients; a higher prevalence of
lung involvement than in any other connective tissue disease (Tan et al.,
2011). Lung fibrosis involves tissue injury characterised by the activation of
fibroblasts and production of profibrotic factors, resulting in enhanced
extracellular matrix (ECM) deposition (Bouros et al., 2002; Steen and
Medsger, 2000). These pathological changes lead to disrupted lung
architecture and consequently impaired organ function. In many cases of
SSc lung fibrosis, increased burden on the heart also leads to pulmonary
hypertension (PH). Pulmonary complications, which involve interstitial lung
disease (ILD) and PH form the leading cause of death in SSc patients (Steen
and Medsger, 2007). Increased frequency and severity of lung disease is
often associated with subsets of patients showing diffuse skin fibrosis
(Cottrell T.R. et al., 2013; Steen, 2003). However, the mechanisms
orchestrating pulmonary fibrosis in SSc remain largely unknown (du Bois,
2007). For this reason, increased understanding of the underlying processes
are required for establishing future therapies for this condition, which to date,
are rather limited (Tan et al., 2011).
Although most studies in SSc have been conducted on skin biopsies and
dermal fibroblasts (Gardner et al., 2006; Sargent and Whitfield, 2011; Shi-
Wen et al., 2000), a growing number of experimental studies have explored
the role of potential profibrotic mediators in the context of lung fibrosis
(Hoyles, 2008; Ponticos et al., 2009; Renzoni et al., 2004; Shi-Wen et al.,
1997). The recent microarray studies comparing the gene expression
profiles of SSc lung tissue to that of healthy controls (Hsu et al., 2011;
Lindahl G.E. et al., 2013) suggest that pulmonary fibrosis in SSc is an area
which deserves further investigation. Connective tissue growth factor (CTGF)
is one of the profibrotic factors which have repeatedly appeared in the results
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of differentially expressed genes in these microarray investigations. In
addition to dermal fibroblasts (Shi-Wen et al., 2000), constitutive expression
of CTGF has also been identified in lung fibroblasts of SSc patients (Lindahl
G.E. et al., 2013; Renzoni et al., 2004).
The aim of this chapter is to investigate the role of CTGF in the SSc lung
disease through a series of experiments using lung tissue and lung
fibroblasts. Further to the results of the previous chapters, the possibility of
cell types other than resident fibroblasts giving rise to myofibroblasts in the
SSc lung will also be explored. The role played by CTGF in SSc lung
fibroblasts will be investigated by determing the effects of exposure to or
removal of CTGF on fibroblast gene expression and function.
5.2 Specific methods
Samples were taken from healthy volunteers and scleroderma patients
satisfying the American College of Rheumatology (ACR) preliminary criteria
for disease (Leroy et al., 1988). Informed consent and ethical approval was
obtained in all cases. For human lung samples, specimens were obtained
from open lung biopsies. All patients were undergoing treatment at the Royal
Free Hospital. For histological analysis, lung samples were obtained from: a
female patient, age 66, diagnosed with diffuse SSc (dcSSc), SCL70 positivity
and lung fibrosis; a 76-year old male with dcSSc, lung fibrosis, previous renal
crisis, and positive for anti- RNA polymerase antibodies. Healthy control (HC)
lungs were obtained from normal areas of lung resections for suspected
malignancy (female to male ratio 2:1, age 62-68 years).
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5.3 Results
5.3.1 Lung fibrosis characterised by collagen deposition and disrupted
lung architecture in SSc
Lung sections were stained with haematoxylin and eosin (H&E) which
revealed a marked difference in tissue morphology between the lung
parenchyma of healthy controls (HC, Fig. 5.1 A) and SSc patients (Fig. 5.1B).
Compared to the HC lung, decreased alveolar spaces and thickened alveolar
walls were detected in SSc lung. As shown by PicroSirius Red staining (Fig.
5.1C and D), the markedly thickened alveolar walls observed in SSc lung
compared to the HC lung can be attributed to the deposition of collagen,
which is likely to reduce gas exchange. Fibrosis and collagen deposition
were also detected around blood vessels in SSc lung. These histological
findings provide support for increased collagen expression in fibrotic SSc
lung.
5.3.2 Elevated CTGF expression in SSc lung tissue
Alongside these gross changes in lung architecture, immunostaining of HC
(Fig. 5.2A) and SSc lung (Fig. 5.2B) using an anti-CTGF antibody identified
increased CTGF expression in the SSc lung. This finding is consistent with
previous work using immunohistochemistry which elevated levels of CTGF in
SSc skin tissue (Igarashi et al., 1995), which is likely a result of increased
CTGF mRNA leading to increased protein expression (Shi-Wen et al., 2000).
Based on the morphology and location of the cellular structures, it was
observed that in HC lung, endothelial cells in the inner lining of blood vessels;
blood vessel and airway smooth muscle cells; and luminal macrophages,
stained positive for CTGF; identity of positively-stained cells were verified by
an independent pathologist (Histopathology, Royal Free London NHS
Foundation Trust and University College London Medical School). In SSc
lung, CTGF expression was also detected in pneumocytes, endothelial cells,
smooth muscle cells around vessels, and fibrotic foci. Although no staining
Figure 5.1 Altered tissue morphology and increased collagen
deposition in human lung tissue from SSc patient with pulmonary
fibrosis
Representative bright
PicroSirius red (bottom panel) staining of lung tissue from healthy control (A
& C, n = 3) and SSc patient (C & D, n = 3). (A a
purple and cytoplasm are stained pink. (C and D) Collagen is stained red on
a pale yellow background. Nuclei are stained grey or brown. Lung tissue from
SSc patient with pulmonary fibrosis showed thickening of alveolar walls and
reduced alveolar spaces. Bv, blood vessels. Magnification 100X, inset in D
shows an area of the SSc section at a magnification 200X.
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Figure 5.2 Differential CTGF expression in human SSc lung tissue
Representative images of lung sections from healthy controls (A, n=2) and
SSc patients (B, n = 3) were stained with CTGF antibody. (C) shows a
human lung section stained with an isotype
non-specific staining. Antibody binding was
DAB subtrate kit. Magnification 200X.
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was detected in luminal macrophages, alveolar macrophages were positive
for CTGF in SSc lungs. Overall, comparison of HC and SSc lung sections
suggested that CTGF-positive cells are more abundant in SSc lung. Double
immunofluorescence staining would be useful to verify specific cell types
expressing CTGF in the lung.
5.3.3 Elevated CTGF expression in lung fibroblast cells
Fibroblasts are considered the main effector cell type in pulmonary fibrosis
(Tomasek et al., 2002). In order to determine whether fibroblasts in lung
express CTGF, primary fibroblasts were isolated from the lungs of three HC
and three SSc patients. Fibroblast cultures were used between passages 2
– 6 for experiments. Confluent monolayers were quiesced in 0.5% BSA–
supplemented DMEM for 24 hours before determining expression of CTGF in
the whole cell lysates by Western blotting (Fig. 5.3 A). CTGF protein in SSc
lung fibroblasts was significantly increased compared to cells from HC lungs
(p = 0.0009; Fig. 5.3 B). These findings parallel the upregulation of CTGF
observed in cultured fibroblasts derived from skin explants of SSc patients
(Shi-Wen et al., 2000) and are also consistent with the identification of CTGF
as one of the dysregulated genes in gene expression profile studies of SSc
lung fibroblasts compared to control fibroblasts (Hsu et al., 2011; Lindahl
G.E. et al., 2013; Renzoni et al., 2004). These data provide further support
for an association between CTGF expression and lung fibrosis in SSc.
5.3.4 CTGF gene knockdown attenuates the fibrotic phenotype of SSc
lung fibroblasts in vitro
As CTGF expression was significantly upregulated in SSc lung fibroblasts
(Fig.5.3), we wanted to directly assess whether CTGF is involved in
mediating the fibrotic phenotype displayed by SSc lung fibroblasts. To
investigate whether blocking CTGF expression can attenuate the fibrotic
Figure 5.3 CTGF expression is el
Primary fibroblast cultures were established from lung
controls (HC) and SSc patients (SSc). (A) Cells were cultured for 24 hours,
and quiesced in 0.5% BSA
analysis by Western blotting. Expression of the 36 kDa and 38 kDa forms of
CTGF (without and wit
doublets. (B) Bars show mean ± SEM expression of CTGF normalised to
expression of the loading control
independent experiments). Lung fibroblasts showed significantly higher
expression of CTGF compared to healthy control cells (unpaired t
denotes p <0.001).
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tissue of healthy
–supplemented DMEM for 24 hours before
h glycosylation, respectively) can be observed as
β-tubulin (n = 3 samples per group in 2
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phenotype, experiments designed to block CTGF expression using RNA
interference (RNAi) tools in vitro were performed. The expression levels of
proteins reported to be up-regulated in SSc fibroblasts, including fibronectin,
collagen type I, tissue inhibitor of metalloproteinases-1 (TIMP-1) α-smooth 
muscle actin (α-SMA), and interleukin-6 (IL-6) (Abraham et al., 2007; Khan et
al., 2012; Sgonc and Wick, 2008; Varga and Abraham, 2007), were assessed
to investigate whether reducing CTGF expression influences expression of
profibrotic proteins by lung fibroblasts.  In SSc and TGF-β-treated lung 
fibroblasts, CTGF knockdown reduced expression of the profibrotic markers
(Fig. 5.4).
Two approaches were initially tested, including knockdown with small hairpin
(sh) RNA (Fig. 5.4) and with small interfering (si) RNA (Fig. 5.5), as the
efficiency of each method in primary adult lung fibroblasts were unknown.
Both methods yielded successful knockdown. In the shRNA approach, SSc
lung fibroblasts were cultured to 50 – 60% confluence (recommended by
manufacturers for optimum transduction) before the addition of shRNA
against CTGF delivered by lentiviral particles. The desired end-points of the
experiments were to determine the protein expression after shRNA
treatment, so the cells were treated for at least 72-96 hours, as
recommended by the manufacturer. In initial optimisation experiments (data
not shown), shRNA treatment for 96 hours appeared to result in a greater
reduction in CTGF expression compared to 72 hours. Also, the lipid-based
transduction reagent polybrene was required for successful uptake of the
shRNA/lentiviral particles and subsequent knockdown in gene expression in
the primary lung fibroblasts (data not shown). Cells were quiesced in serum-
free media for 24 hours prior to shRNA treatment. All cells used in the
optimisation were HC lung fibroblasts treated with TGF-β to induce CTGF
production. Two different shRNA sequences were tested (designated
shCTGF-01 and shCTGF-02; see Appendix for shCTGF sequences) for their
efficiency at CTGF gene knockdown. The two different sequences were
tested independently and in combination, as it was not known whether a
combination of the shCTGF molecules targeting different portions of the
Figure 5.4 Downregulation of CTGF expression in human lung
fibroblasts using lentiviral shRNA knockdown
Lung fibroblasts were isolated from control individuals and SSc patient lungs
and treated with non
targeting CTGF (shCTGF), and TGF
SEM of CTGF expression normalised to expression of the loading control
tubulin (n = 3 biological replicates per group from a single experiment,
unpaired t-test, * p <
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-β (T, 4 ng/ml). Bar chart shows mean ±
0.05, ** p < 0.01.
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Figure 5.5 Downregulation of CTGF expression in human lung
fibroblasts treated with CTGF siRNA
Lung fibroblasts were isolated from healthy control and SSc patient lungs and
treated with non-target control siRNA (siNTC) or siRNA specifically targeting
CTGF (siCTGF), and TGF
densitometry (B) analyses showed siCTGF treatment significantly reduced
cellular levels of CTGF in the lung fibroblasts. Bar chart shows mean ± SEM
of CTGF expression normalised to expression of the loading contro
(n = 3 biological replicates per group from a single experiment, unpaired t
test, * p < 0.05, ***
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CTGF mRNA sequence would have an agonistic or antagonistic effect.
Assessment of CTGF expression by Western blotting (Fig. 5.4) revealed that
compared to SSc lung fibroblasts treated with control non-target shRNA
lentiviral particles (shNTC), those treated with shCTGF displayed significantly
reduced CTGF expression; a decrease of 77.8% using shCTGF-01 (-0.702 ±
0.081, p = 0.0130) and 80.0% using shCTGF-02 (-0.722 ± 0.071, p = 0.0095).
In the same experiment, the effect on knockdown by combining shCTGF-01
and shCTGF-02 treatment was also tested. Although only an n-of-1 was
conducted for the combined treatment, the results suggested using both
sequences together does not reduce CTGF expression more than using
either construct individually.
For knockdown of CTGF in lung fibroblasts using siRNA, cells were cultured
to 80-90% confluence in the absence of any antibiotics in the cell culture
medium (due to inhibition of siRNA transfection by antibiotics). Cells were
incubated for 96 hours in the presence of non-target control siRNA (siNTC)
or a pool of various siRNA sequences targeting different regions of the CTGF
mRNA. Western blotting analysis of whole cell lysates (Fig. 5.5A and B)
showed that compared to transfection with siNTC, treatment with siCTGF
significantly decreased expression of TGF-β-induced CTGF expression by 
73.1% in control lung fibroblasts (-1.383 ± 0.4297, p = 0.0323), and in SSc
lung fibroblasts, attenuated both constitutively-expressed (-0.9030 ± 0.3130,
p = 0.0448) and TGF-β-induced CTGF (-2.420 ± 0.2171, p = 0.0004) by 
58.4% and 78.8% respectively. The main concern with the use of siRNA
was the low transfection efficiency sometimes observed in primary cells but
in these fibroblasts knockdown efficiency seemed to be comparable using
either lentiviral shRNA or siRNA. Although the shRNA approach has the
advantage of sustained gene knockdown as lentiviral particles containing
shRNA can be replicated in recipient cells and propagated to daughter cells,
the siRNA method was pursued because for this investigation, where the
cells were harvested after 96 hours of treatment, prolonged knockdown
beyond this time-point was not required.
Figure 5.6 CTGF siRNA knockdown attenuates expression of fibrotic
protein markers in SSc lung fibroblasts
Lung fibroblasts were isolated from healthy control and SSc patient lungs and
treated with non-target control siRNA (siNTC) or siRNA specifically targeting
CTGF (siCTGF), and TGF
densitometric (B) analyses showed CTGF knockdown resulted in reduced
expression of fibronectin, collagen type I, TIMP
fibroblasts compared to those treated with siNTC. . Bars show mean ± SEM
protein expression normalised to expression of loading control
expression (3 biological replicates per group in a single experiment, unpaired
t-test, * p < 0.05, **
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As shown in Fig. 5.6, expression of fibronectin, an extracellular matrix
glycoprotein and cofactor for TGF-β-induced myofibroblast 
transdifferentiation in SSc (Jelaska et al., 1996; Rajkumar et al., 2005), was
elevated in SSc lung fibroblasts compared to control lung fibroblasts (17.27 ±
2.579, p = 0.0026). SiRNA knockdown of CTGF significantly reduced
expression of fibronectin in SSc lung fibroblasts by 80.3% (-18.87 ± 3.001, p
= 0.0033) and also decreased TGF-β-induced fibronectin expression by 
69.0% (-28.61 ± 5.392, p = 0.0061), compared to cells treated with the
control siRNA. Consistent with previous reports of increased collagen type I
expression (Fig. 5.6) observed both in skin and lung fibroblasts isolated from
SSc patients compared to those from healthy controls (Leroy, 1974; Shi-Wen
et al., 1997), SSc lung fibroblasts showed significantly elevated expression of
collagen type I compared to control cells (25.85 ± 4.952, p = 0.0064). Here,
we show that collagen type I expression in SSc fibroblasts may be reduced
by 65% using siCTGF (-19.60 ± 4.636, p = 0.0134). Treatment with siCTGF
also lowered TGF-β-induced collagen type I expression by 47.8% (-24.67 ± 
8.151 p = 0.0389).
Expression of the contractile form of actin, α-SMA, was elevated (Fig. 5.6) in 
fibroblasts derived from SSc lungs compared to those from HC lungs (2.308
± 0.3733, p = 0.0035). With siCTGF treatment, a 33.1% (-0.9268 ± 0.3020, p
= 0.0374) reduction in α-SMA expression was observed in SSc lung 
fibroblasts and a 61.6% (-2.828 ± 0.1938, p = 0.0001) decrease was
detected in cells treated with TGF-β compared to the corresponding control 
groups treated with siNTC. As a repressor of matrix degradation,
dysregulated TIMP1 expression (Fig. 5.6) was detected in the SSc lung
fibroblasts compared to controls (0.8880 ± 0.2043, p = 0.0122). This
expression was attenuated by siCTGF, with levels reduced by 71.1% (-
0.7728 ± 0.2521, p = 0.0374) compared to that observed in cells treated with
siNTC.   Compared to TGF-β-treated lung fibroblasts without CTGF 
knockdown, siCTGF treated cells expressed 84.0% less TIMP1 (-1.658 ±
0.5241, p = 0.0341).
Figure 5.7 CTGF knockdown attenuates TGF
in the conditioned medium of human lung fibroblasts
ELISA analysis. Lung fibroblasts were isolated from healthy controls and
treated with non-target control siRNA (siNTC) or siRNA specifically targeting
CTGF (siCTGF).
concentration in cell layer as determined by BCA assay.
treatment significantly increased IL
(A vs C). CTGF siRNA reduced TGF
expression remained higher
mean ± SEM (3 biological replicates per group in a single experiment).
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than basal levels (A vs D). Histograms show
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ELISA analysis of the conditioned media (Fig. 5.7) revealed that in control
lung fibroblasts, treatment with TGF-β induced expression of IL-6 (p = 
0.0068).  Knockdown of CTGF expression resulted in attenuated TGF-β-
induced IL-6 in fibroblasts (p = 0.0022), but levels were still significantly
higher (p = 0.0275) than in control cells without TGF-β treatment.   
5.3.5 CTGF enhances fibroblast contractility and migratory properties
Myofibroblast migration is an important function in fibrosis as it is essential for
fibroblast accumulation at the fibrotic foci (Hinz et al., 2012). The scratch
wound assay is an in vitro method imitating cell migration into wound areas
(Liang et al., 2007). Lung fibroblasts derived from HC individuals were
cultured to confluence before a linear scratch was made across each
monolayer using a p-200 pipette tip. The cells were then cultured in 0.5%
BSA/DMEM with mitomycin C to inhibit cell proliferation, so that closure of
the wound can be attributed to cells migrating into the wound rather than due
to an increase in the number of cells. At 15 hours after the scratch was
made (Fig. 5.8), the concentration of secreted CTGF was observed to be 3.4-
fold higher in the conditioned media from scratch-wounded cells compared to
the conditioned media of uninjured monolayers (p = 0.0405).
The effect of recombinant CTGF (200 ng/ml) on lung fibroblast cell migration
was also investigated (Fig. 5.9). As a positive control, a group of scratched
monolayers were treated with 10% FBS. By 72 hours, FBS-treated lung
fibroblasts had completely closed the gap made by the scratch, and hence
this time was selected to be the end-point for analysis of the scratch assay in
the different experimental conditions. Closure of the gap formed by the
scratch was quantified by measuring the area of the gap using ImageJ
software. Although no significant difference was detected in the migration
assay between HC and SSc lung fibroblasts, exposure of HC and SSc lung
fibroblasts to CTGF did promote closure of the wound. At 72 hours after a
scratch was made, the gap area in CTGF-treated SSc fibroblast monolayers
Figure 5.8 In vitro
human lung fibroblasts
(A) Phase contrast microscopy of control (HC) lung fibroblasts at 0 and 15
hours (h) after a scratch was made in the cell monolayer using a p
pipette tip and cultured in 0.5% BSA/DMEM with mitomycin C to inhibit cell
proliferation. Magnification 400X. (B) The c
CTGF present in the conditioned medium of the lung fibroblasts at 15 h was
determined by ELISA. Bar gra
in the conditioned medium of HC lung fibrob
and those which were scratched
group in 2 independent experiments, unpaired t
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wound scratching induces CTGF expression in
oncentration (ng/ml) of secreted
ph represents the CTGF concentration at 15h
lasts which were not scratched
(mean ± SEM, n = 3 biological replicates per
-test, * p < 0.0
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Figure 5.9 Scratch wound assay
(A) Phase contrast microscopy (magnification 400X) of healthy control (HC)
and SSc lung fibroblasts at 0
monolayer using a
BSA/DMEM/mitomycin C with or without CTGF (200 ng/ml) or 10% FBS. (B)
Quantitative analysis of scratch area by Image J software. Bars represent
mean percentage ± SEM of scratch area at each time point of three biolo
replicates per group in 2 independent experiments (unpaired t
**p < 0.01).
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– 72 h after a scratch (green) was made in the
p-200 pipette tip and cultured in 0.5%
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was still significantly different to the gap area of cells treated with FBS (p =
0.0069), CTGF treatment did not completely close the gap at 72 hours.
However, a significant difference in percentage gap area was detected
between HC lung fibroblasts without and with CTGF treatment (p = 0.0032).
A significant decrease in gap area at 72 hours after scratching was also
observed between SSc fibroblasts without and with CTGF treatment (p =
0.0391). This data suggests a pro-migratory role for CTGF on lung
fibroblasts.
Stiffness of the ECM is another important regulator of fibrosis and
myofibroblasts play a pivotal role in detecting and modulating ECM
(Desmouliere et al., 2005; Hinz et al., 2012; Klingberg et al., 2013). In order
to investigate the effect of CTGF on lung fibroblast contractility, a floating gel
collagen contraction assay was performed (Fig. 5.10 A). Collagen lattices
containing lung fibroblasts from HC and SSc patients were cultured for 24
hours in the presence of 10% FBS, TGF-β (4 ng/ml) or CTGF (200 ng/ml).  
Previous studies quantified gel contraction by either gel diameter or gel
weight based on the phenomenon that contraction of fibroblasts induce a
denser arrangement of collagen fibrils, expelling water and therefore a loss of
weight (Bell et al., 1979). In this study, the area enclosed by the edge of the
gel as viewed from above (Fig. 5.10B) and gel weight (Fig. 5.10C) were
therefore measured. The SSc fibroblast-seeded gels were significantly
smaller than the HC gels in terms of gel area (p = 0.0259) and gel mass (p =
0.0239).  FBS, TGF-β, and CTGF induced HC fibroblasts to contract the 
collagen gel, marked by significant decrease in gel area and gel weight,
compared to the control group without treatment (Fig. 5.10 B and C). In SSc
cells, FBS and TGF-β also reduced gel weight and area significantly while
CTGF induced a significant reduction in gel area and a trend towards a
decrease in gel weight; a possible explanation for the modest decrease in gel
weight induced by CTGF may be that the basal weight of the SSc fibroblast-
seeded collagen gel is already lower compared to the HC counterpart.
Together, these results suggest CTGF induces contraction of fibroblast-
seeded collagen lattices.
Figure 5.10 SSc lung fibroblasts show enhanced
floating collagen gel matrices
Human lung fibroblasts from healthy control and SSc patients were placed in
collagen lattices.
treatment for 24 hours induced collagen gel matrix contraction
enhanced in matrices containing
was monitored by measuring gel area (B) and mass (C). Bars show mean ±
SEM of three samples per group from 2 independent experiments (n=3; *
denotes p<0.05).
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ability to contract
compared to those from healthy
10% FBS, TGF-β (4 ng/ml) and CTGF (200 ng/ml)
SSc lung fibroblasts (p<0.05).
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5.3.6 TTF-1- and CD31-positive cells also express α-SMA in SSc lung 
tissue
To investigate whether epithelial cells or endothelial cells might give rise to
the fibroblast cells during lung fibrosis in SSc, immunostaining with
antibodies against α-SMA as well as with antibodies against TTF-1 and 
platelet endothelial cell adhesion molecule (PECAM-1, CD31), a marker of
endothelial cells, was performed on serial sections of tissue from HC and
SSc lungs.
TTF-1 expression was examined to identify type II alveolar cells in the lung
(Fig. 5.11, left panel). Mostly nuclear expression of TTF-1 was detected in
HC lung tissue, which is the typical cellular localisation of this transcription
factor (Fig. 5.11 A, left panel) (Ikeda et al., 1995). In SSc lung, TTF-1
staining was also detectable, however, the staining appeared to be more
dispersed and less concentrated in the nucleus (Fig. 5.11 B, left panel).
In comparison to HC lung (Fig. 5.11 A, right panel), SSc lung (Fig. 5.11 B,
right panel) showed increased abundance of α-SMA-expressing cells, 
indicative of an activated profibrotic phenotype characterised by the presence
of myofibroblasts in the lung parenchyma. Absent from the HC lung tissue
(Fig. 5.11 A), some of the cells expressing α-SMA in the SSc lung 
parenchyma also showed positive staining for TTF-1, suggestive of an
intermediate cell phenotype sharing both mesenchymal and epithelial cell
markers (Fig. 5.11 B); TTF-1 is normally expressed in thyroid epithelial cells,
as well as Clara cells and type II pneumocytes in the lung (Comperat et al.,
2005).
In both groups, vascular endothelial cells in the intima of blood vessels
exhibited positive staining for CD31 (Fig. 5.12).  In HCs, α-SMA expression 
was mainly confined to the smooth muscle cells of the tunica media and
interstitial cells in the adventitia of blood vessels, and in airway structures
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(Fig. 5.12). In SSc lung, some of the endothelial cells, identified by staining
with anti-CD31, antibody also expressed of α-SMA (Fig. 5.12).  These data 
suggest that at least some of the α-SMA expressing cells may have been 
derived from an endothelial cell lineage. TTF-1-expressing type II alveolar
epithelial cells and CD31-positive endothelial cells present in the SSc lung
may potentially provide alternative sources of fibroblast-like cells during
fibrosis.
Figure 5.11 Co-expression of TTF
Serial formalin-ﬁxed pa
for α-SMA and TTF
expressing α-SMA and TTF
(magnification 5X). Antibody binding was visualised using a p
subtrate kit. Representative images of 2 samples per group are shown.
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Figure 5.12 Co-expression of CD31 and α
Serial sections of human lung from healthy control (top panel) and
(bottom panel) were immunostained for the endothelial cell surface marker
CD31 (left panel), and
binding was visualised using a peroxidase DAB subtrate kit. Red arrows
indicate cells co-expressi
nuclear (blue) staining indicate the presence of monocytic cells in the lumen
of the blood vessel, amongst red blood cells and platelets. Representative
images of 2 samples per group are shown.
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α-SMA (right panel; magnification 200X). Antibody
ng CD31 and α-SMA. CD31-positive cells with
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5.4 Discussion
This experiments described in this chapter explored some of the potential
roles of CTGF in SSc fibrotic lung using ex vivo and in vitro methods. The
phenotype of SSc lung was examined in relation to healthy control tissue
using routine histological staining and PicroSirius red staining of collagen.
The expression of CTGF in lung tissue was investigated by immunostaining,
and as the key effector cell in fibrosis, fibroblasts derived from lung tissue
were also examined for CTGF expression by Western blotting. To
investigate the significance of CTGF expression in SSc lung, experiments
involving the knockdown of CTGF expression were performed on lung
fibroblasts to determine whether this would attenuate the expression of
profibrotic proteins. As well as detecting changes in protein expression,
functional assays were also performed to assess the effects of CTGF on
fibroblast contraction and migration; these functional read-outs were selected
as fibrosis is characterised by ECM contraction and fibroblast accumulation.
To identify cell types other than resident fibroblasts which might contribute to
the fibroblasts that accumulate in fibrotic lesions (Ludwicka-Bradley et al.,
2004), human lung tissue were immunostained for protein markers of
myofibroblasts, type II epithelial cells or pneumocytes, and endothelial cells.
In this chapter, single IHC stains for each marker were performed on serial
sections with the view to optimise primary antibody staining for use in multi-
colour immunofluorescence staining to study co-expression of the cell type
markers in future work, which was beyond the scope of this project.
H&E staining revealed features indicative of a fibrotic lung in SSc patient
samples selected. Differences between the SSc lung parenchyma and that
of HC lung included decreased alveolar spaces, as a result of thickened
alveolar walls in SSc lung, which is likely to impair gas exchange in the lungs.
Normally, the alveolar septa dividing adjacent alveoli are composed of
basement membranes of alveolar-lining epithelium (mostly type I
pneumocytes) and capillary endothelium. Thickened alveolar septa may be
attributed to the presence of elastic fibres, collagen, interstitial cells, smooth
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muscle cells, mast cells, and infiltrating mononuclear cells (Solomon J.J. et
al., 2013). To assess the abundance of collagen in SSc lungs, PicroSirius
Red staining was performed which revealed increased deposition of collagen.
Fibrosis and increased collagen expression was also detected around blood
vessels in SSc lung. These histological findings provide support that
increased collagen expression and fibrosis are not only an important
characteristic of SSc skin (Dziadzio et al., 2004) but also in SSc lung.
In association with the altered lung architecture observed in SSc lungs,
immunostaining demonstrated differential CTGF expression pattern in the
lung parenchyma of SSc and control lungs. In addition to fibroblasts,
endothelial cells, pneumocytes, smooth muscle cells and macrophages
stained positive for CTGF. Prominent CTGF staining was detected in
alveolar macrophages, endothelial cells and smooth muscle cells around the
rim of blood vessels in SSc lung. These results are consistent with the
observation of increased levels of CTGF in bronchoalveolar lavage (BAL)
fluid of SSc patients with active pulmonary fibrosis compared to those without
lung involvement (Sato et al., 2000). The CTGF staining results are
reminiscent of CTGF expression in lung epithelial cells in patients with
advanced pulmonary fibrosis, which is in contrast to TGF-β expression by 
alveolar macrophages in the inflammatory phase of idiopathic pulmonary
fibrosis (Khalil et al., 1996).
As fibroblasts are considered the principal source of collagen in fibrotic
tissues, responsible for tissue remodelling, and the contractile characteristics
of the fibrotic lung parenchyma (Tomasek et al., 2002), the association of
CTGF with the activated fibroblast phenotype was investigated. Western
blotting analysis confirmed elevated expression of CTGF in SSc lung
fibroblasts. This is consistent with the upregulated CTGF expression
observed in SSc dermal fibroblasts as well as in sera of SSc patients (Leask
et al., 2001; Sato et al., 2000). These results also corroborate recent findings
which demonstrated augmented CTGF gene expression using microarray
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analyses of SSc lung fibroblasts (Lindahl G.E. et al., 2013; Renzoni et al.,
2004; Shi-Wen et al., 2000).
SSc lung fibroblasts also constitutively produced excessive collagen type I,
as well as fibronectin, TIMP1 and α-SMA, which is consistent with the 
association of CTGF expression with the diffuse subset of scleroderma
patients and correlation of CTGF with extensiveness of skin involvement and
severity of fibrosis (Sato et al., 2000). The elevated collagen expression
detected here is in accord with observations in bleomycin-induced mouse
models of lung fibrosis, where myofibroblasts prove to be the principal source
of collagen (Zhang H.Y. et al., 1996). CTGF knockdown reduced levels of
constitutively-expressed ECM components in SSc lung fibroblasts and
attenuated TGF-β-induced ECM proteins, providing further support that 
CTGF mediates some of the profibrotic actions of TGF-β.  In SSc skin 
fibroblasts, knockdown of CTGF using siRNA was previously shown to
significantly reduce expression of collagen (Xiao et al., 2006), but the effect
on lung fibroblasts was unknown. Here we were able to replicate the
attenuation of collagen type I expression in SSc cells subjected to siRNA
knockdown of CTGF in lung fibroblasts. A recent study on normal human
lung fibroblasts suggested that CTGF induces expression of collagen type I
via Rac1 activation of the mixed-lineage kinase 3 (MLK3)/ c-Jun N-terminal
kinase (JNK) signalling pathway, which subsequently activates the
transcription of activator protein-1 (AP-1) and the recruitment of AP-1-related
proteins, c-Jun and c-Fos (Lin et al., 2013). This may explain the attenuation
of collagen type I levels observed when CTGF expression was inhibited in
SSc lung fibroblasts.
Association between fibrosis and α-SMA expressing myofibroblasts has been
well documented in a number of fibrotic tissues (Tomasek et al., 2002). This
study showed that SSc lung fibroblasts produce an abundance of α-SMA, 
reminiscent of the phenotype of smooth muscle cells, and providing support
to the idea that fibroblasts in SSc lung are activated and responsible for ECM
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production and enhanced contraction of the lung parenchyma. Exposure to
CTGF was capable of differentiating normal lung fibroblasts to a
myofibroblast phenotype, although the mechanism of this differentiation
remains to be elucidated.  The attenuation in α-SMA expression after 
administration of CTGF siRNA suggests that targeting CTGF expression may
help to inhibit myofibroblast differentiation in pathogenic lung fibroblasts.
In addition to suppressing the increase in matrix protein expression, CTGF
gene knockdown also attenuated expression of IL-6, which may be relevant
in limiting the fibrotic phenotype since IL-6 overexpression has been detected
in SSc dermal fibroblasts, endothelium and inflammatory infiltrates (Khan et
al., 2012). Previous studies have demonstrated that, along with its receptor,
IL-6 is capable of inducing synthesis of ECM proteins such as collagen,
CTGF and -SMA in dermal fibroblasts (Gallucci et al., 2006; Khan et al.,
2012). CTGF knockdown-mediated reduction in IL-6 expression may help to
alleviate the fibrotic phenotype, as shown in a small-scale study
demonstrating that inhibition of IL-6 resulted in reduced skin hardening in
SSc patients (Feghali C.A. et al., 1992). The current data demonstrate that
knockdown of CTGF expression in vitro is able to attenuate expression of
profibrotic proteins by lung fibroblasts. This finding provides support that
CTGF is one of the mediators of lung fibrosis, and implicates blocking CTGF
as a potential therapy for relieving the fibrotic phenotype in SSc lung
fibroblasts.
Having observed changes in expression of a number of profibrotic proteins
altered by the down-regulation of CTGF, we were interested to investigate
whether CTGF also influences lung fibroblast function such as cell migration
and contractility. Previous studies have shown that fibroblasts from fibrotic
lung are generally more proliferative, migratory, resistant to apoptosis, and
produce more ECM than control lung fibroblasts (Hinz et al., 2012). In
addition, BAL-derived fibroblasts, showed enhanced proliferation upon
treatment with TGF-β and PDGF (Ludwicka et al., 1995).   
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An in vitro scratch injury increased CTGF expression in normal lung
fibroblasts, which is consistent with the idea of CTGF release during wound
healing (Alfaro et al., 2013).  Here we showed that TGF-β and FBS also 
promoted lung fibroblast migration as treated cells demonstrated more rapid
resolution of the scratch in the monolayer. As expected, FBS treatment
resulted in the greatest decrease in the wound area 72 hours after the
scratch was made, as FBS contains a mixture of pro-migratory growth factors
such as PDGF and FGF. Addition of exogenous CTGF alone also enhanced
fibroblast migration compared to control cells during resolution of the in vitro
scratch injury. A previous study also concluded that recombinant CTGF
induced migration in normal and SSc lung fibroblasts (Bogatkevich et al.,
2008) via the C-terminal domain of CTGF and signalling involving ERK
pathway (Bogatkevich G.S. et al., 2000). However, in the study by
Bogatkevich et al., experimental conditions did not include use of any cell
proliferation inhibitors so their results may reflect a combination of
proliferation and migration of cells into the scratch wound area.
Contraction of collagen lattices containing lung fibroblasts from HC
individuals and SSc patients were compared following treatment with FBS,
TGF-β or CTGF.  Increased contractility was observed in collagen gels 
containing SSc lung fibroblasts compared to those containing control cells.
Enhanced contraction of collagen gels were also observed in the samples
treated with FBS and TGF-β as well as CTGF.  These results support the 
findings of a previous study which showed enhanced contraction of control
lung fibroblasts by CTGF, particularly via the VWC domain (Bogatkevich G.S.
et al., 2000). In this chapter, we demonstrated that the greatest contraction
occurred in response to FBS treatment, and that SSc cells appeared to show
enhanced responsiveness to treatments with FBS, TGF-β and CTGF, 
compared to control cells. These results also correlate well with the Western
blotting results which revealed higher levels of the pro-contractile cytoskeletal
protein, α-SMA in SSc compared to control cells, and also in TGF-β- and 
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CTGF-treated cells compared to untreated. The SSC cells, although more
contractile that HC cells, still have the capacity to respond to stimuli.
Comparing SSc and HC fibroblasts, both TGF-β and CTGF enhanced HC
fibroblast contraction so that they resembled untreated SSc fibroblasts.
To explore the potential precursors to these pro-contractile, pro-migratory
and ECM-producing SSc fibroblasts, immunohistological staining was
performed on serial sections to identify cells which co-express the
mesenchymal cell marker α-SMA and markers of other cell types.  As 
endothelial cells and pneumocytes (or type II alveolar epithelial cells) were
found to express CTGF, we investigated whether α-SMA positive cells could 
be derived from these cell types by assessing expression of α-SMA, TTF-1 
and CD31. Although the relative contribution of alternative cell types such as
circulation-derived mesenchymal stem cells, endoMT and EMT to the
fibroblast population has been identified in other organs and pathologies
(Piera-Velazquez and Jimenez, 2012; Quaggin and Kapus, 2011), their
contribution in the SSc lung has not been reported. Consistent with the
elevated α-SMA levels in SSc fibroblasts detected by Western blotting, 
immunostaining confirmed increased abundance of α-SMA-expressing cells 
in SSc lung compared to control tissue, indicative of an activated profibrotic
phenotype characterised by the presence of myofibroblasts in the lung
parenchyma.
Serial sections of SSc lung revealed the presence of cells co-expressing α-
SMA and TTF-1 in the lung parenchyma, suggestive of an intermediate cell
phenotype and potential derivation of a mesenchymal cell type from an
epithelial cell type.  Cells co-expressing α-SMA and CD31 were also present 
in the endothelial lining of blood vessels in SSc lung, suggesting that at least
some of the α-SMA- expressing cells may have been derived from an 
endothelial cell lineage. TTF-1-expressing type II alveolar epithelial cells and
CD31-positive endothelial cells present in SSc lung may potentially provide
alternative sources of fibroblast-like cells during fibrosis. Endothelial cells
The role of CTGF in human SSc lung | 200
and type II alveolar epithelial cells may undergo transition in response to
injury during SSc pulmonary fibrosis (Harrison et al., 1991). The ability of
alveolar epithelial cells to synthesize and respond to TGF-β may help to 
promote EMT in these cells (Willis et al., 2005).
One of the challenges of this study has been obtaining healthy control lung
tissue due to the lack of open-lung surgery now being performed. As an
accepted source of control tissue in studies of interstitial lung disease,
samples were obtained from cancer resected specimens, rather than from
healthy subjects. While areas of lung with normal histological appearance
were used, there may be underlying differences in gene expression between
this tissue and completely normal tissue. However, a previous study
identifying differential gene expression between fibroblasts derived from
areas with lung cancer and areas of normal lung from the same patient,
provides encouraging evidence that the cancer-associated fibroblast
phenotype is restricted to the cancer stroma (Navab et al., 2011). In the
present study, SSc patients with fibrotic lungs were selected as we wanted to
investigate the role of CTGF in fibrotic lungs. However, the findings from
these experiments may not apply to other subsets of SSc patients. Further,
caution should be applied in the interpretation of the histological analyses as
only 2 or 3 samples were examined in each group and data from preliminary
findings need to be confirmed in a greater number of control and SSc
samples per group.
In summary, the data presented in this chapter has shown an elevated
expression of CTGF in SSc lung which present a fibrotic phenotype, marked
by increased collagen deposition and destruction of normal lung architecture.
Previous reports on SSc showed that in vitro suppression of CTGF
expression alleviated fibroblast expression of proteins associated with
fibrosis (Abraham and Distler, 2007; Khan et al., 2012; Sgonc and Wick,
2008; Varga and Abraham, 2007) while culturing HC and SSc lung fibroblasts
with recombinant CTGF enhanced the contractile and migratory functions of
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the fibroblasts. Complementary to the wealth of studies on SSc skin fibrosis
(Gardner et al., 2006; Sargent and Whitfield, 2011; Shi-Wen et al., 2000),
these findings suggest that CTGF also plays a pivotal role in modulating
deposition of ECM components and propagating the profibrotic fibroblast
phenotype in the SSc lung.
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Chapter 6. Overall conclusions and
discussion
Elevated expression of CTGF is a recurring theme in fibrotic diseases such
as SSc - at least in the fibrotic stages (Dendooven et al., 2011a), as well as
in animal models of fibrosis (Derrett-Smith et al., 2010; Liu et al., 2011).
However, the exact mechanism of CTGF action in the context of fibrosis
remains to be elucidated. The current absence of an established cure for
SSc has provided a drive to develop novel treatments targeting organs and
the molecular mechanisms underlying fibrotic pathogenesis (Asano, 2010).
In particular, interstitial lung disease and pulmonary hypertension together is
currently the major cause of death in SSc (Solomon J.J. et al., 2013).
Greater understanding of CTGF involvement in initiating and driving fibrosis
will likely aid the development of effective anti-fibrotic therapies to treat SSc.
In this thesis I have considered the influence of CTGF on the profibrotic
phenotype, particularly in lung tissue and cells. Furthermore, the putative
role of CTGF in mediating transition of epithelial cells is proposed.
6.1 Constitutive overexpression of CTGF in mice induces tissue
fibrosis and abnormalities in the alveolar epithelium
When compared to WT mice, Col1a2-CTGF mice develop tissue fibrosis as
well as changes to the alveolar epithelial lining. In chapter 3, the role of
CTGF in fibrosis was directly assessed by studying the phenotype of a
transgenic mouse (Col1a2-CTGF) that constitutively expresses CTGF in
fibroblasts using histological techniques and cell culture of isolated fibroblasts.
This fibroblast-specific expression of CTGF induced tissue fibrosis
prominently in the skin and lung. These results corroborate the findings of
previous work on this mouse model (Sonnylal et al., 2010), which is able to
replicate some of the fibrotic changes observed in the skin of SSc patients
such as skin hardening associated with excess matrix deposition.
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Western blotting of mouse embryonic fibroblasts (MEFs) cell lysates and
conditioned medium confirmed overexpression of CTGF protein in the
fibroblasts of Col1a1-CTGF-transgenic mice. Additionally, the fibrotic marker
collagen type I was also upregulated in the Col1a2-CTGF fibroblasts
compared to WT. This suggests that CTGF is able to act in an autocrine
fashion since the CTGF produced by the fibroblasts appeared to cause
profibrotic changes in the fibroblasts such as collagen upregulation. These
observations are consistent with the histological evidence of tissue fibrosis in
the Col1a2-CTGF mice and also with previous associations of CTGF within
fibrotic disease settings (Dendooven et al., 2011). Stimulation of fibroblasts
with TGF-β in vitro enhanced CTGF expression, which confirms previous
findings that TGF-β acts as an inducer of CTGF expression (Leask and 
Abraham, 2006). Taken together, these results support the theory that CTGF
alone, independent of TGF-β induction, is able to drive fibrosis. 
An interesting observation that was absent in the WT mice was the presence
of histological changes to the lung epithelia of Col1a2-CTGF mice. This
suggested that the fibroblast-derived CTGF not only acted on the fibroblasts
themselves, but also signalled in a paracrine manner on neighbouring
epithelial cells leading to the observed epithelial abnormalities. Alveolar and
bronchial epithelial cells express profibrotic cytokines/chemokines such as
TGF-β, PDGF, TNF-α as well as antifibrogenic chemokines, and chemokine 
receptors (Khalil et al., 1991). In addition to infiltrating inflammatory cells,
alveolar epithelium also serves as a major source of profibrotic factors such
as TGF-β during lung injury and fibrosis (Xu et al., 2003), and is able to
regulate its TGF-β responsiveness by differential expression of TGF-β 
receptors (Khalil et al., 2002). The ability of epithelial cells to produce and
respond to TGF-β, regulate fibroblast function and differentiation, and 
undergo changes in cell morphology and gene expression after injury are all
highly suggestive of a direct contribution to the activation of mesenchymal
cells (Agostini and Gurrieri, 2006) and a central role in pathogenesis (Willis et
al., 2005).  As shown in chapter 3, α-SMA was expressed on the alveolar 
epithelial lining of Col1a2-CTGF mice. This result may have important
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implications in lung fibrosis, and highlighted the possibility that CTGF may
mediate epithelial-to-mesenchymal (EMT) in the fibrotic lung, which was
further investigated in chapter 4.
6.2 CTGF-mediated EMT in vitro
Type II alveolar epithelial (T2) cells may serve as an important source of
fibroblasts and myofibroblasts through EMT (Willis and Borok, 2007).
Chapter 4 shows CTGF induced EMT-like changes in alveolar epithelial cells
in vitro, via p38, pSMAD and pERK pathways. In order to explore the
possible role of CTGF in EMT in lung fibrosis, a rat alveolar epithelial cell line
was treated with CTGF. Addition of CTGF altered the expression of a panel
of EMT marker genes similar to that observed when the same cells were
treated with TGF-β, which is a classical inducer of EMT as shown in other 
epithelial cell lines including the human alveolar cell line A549 (Kasai et al.,
2005), RLE-6TN type II alveolar epithelial cells (Willis et al., 2005) and
primary rat type II alveolar cells (Yao et al., 2004). This finding is consistent
with the multipotent nature and plasticity of T2 cells (Crapo et al., 1982). As
well as playing a major role in embryonic development, EMT has also been
implicated in fibrosis and in cancer tumour invasion; described by Kalluri et al.
as type one, type two and type three EMT, respectively. EMT provides an
alternative fate for T2 cells to escape apoptosis (Mason and Williams, 1977).
The significance of epithelial cells as potential sources of myofibroblasts via
EMT at the fibrotic foci is likely to be tissue dependent, since reports of EMT
have been associated with interstitial pulmonary fibrosis, renal fibrosis and
hepatic fibrosis but there is a lack of evidence for EMT in the skin of SSc
patients (Nikitorowicz-Buniak et al., 2010; Yamada et al., 2013). In a study
by Burns et al., CTGF was able to mediate EMT-like changes in cultured
renal tubular cells (NRK-52E), and interestingly, while transfection with anti-
CTGF siRNA attenuated TGF-β-induced EMT, neutralising TGF-β antibodies 
did not suppress CTGF-induced EMT changes, indicative of TGF-β-
independent CTGF action (Burns et al., 2006).
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The relative contribution of epithelial-derived cells – in comparison to other
cell types such as resident fibroblasts, pericytes and bone marrow-derived
cells (Binai et al., 2012; Hinz et al., 2012) – to the pool of profibrotic
fibroblasts during SSc fibrosis development in vivo remains to be determined.
Similar to the debate surrounding whether EMT occurs as part of the
development of kidney fibrosis, there is also evidence for and against EMT
as a contributor to myofibroblast accumulation during lung fibrosis. A recent
study using mouse genetic tools to track the fates of lung epithelial cells
suggested that both alveolar type II cells and Scgb1a1-positive lung cells
undergoing EMT are not a major source of myofibroblasts (Rock et al., 2011).
Conversely, another study suggested that epithelial-to-mesenchymal
transition appears to be a major contributor to the lung fibroblast population
(Mouratis and Aidinis, 2011). Furthermore, a study using cell fate reporter
mice found that lung epithelial cells contributed to one-third of S100A4-
positive fibroblasts present after bleomycin administration, compared to those
derived from bone marrow which accounted for one-fifth of the fibroblast
population (Tanjore et al., 2009).
One of the arguments against the notion of EMT in fibrosis is the query over
how epithelial cells “escape” through the basement membrane and enter the
interstitium. One of the most compelling pieces of evidence for EMT
contributing to the fibroblastic pool in vivo is from a study showing that 36%
of interstitial fibroblasts derived from genetically-tagged proximal tubular
epithelial cells following acute injury, which the authors attributed to EMT
(Iwano et al., 2002). Recent data demonstrated that conditional
overexpression of CTGF either in the lung epithelium from postnatal days 1–
14 disrupted alveolarisation and vascular development leading to vascular
remodelling and hypertension (Chen et al., 2011; Wu et al., 2010).
Overexpression of CTGF led to thickened alveolar septa and increased
myofibroblast differentiation via activation of the integrin-linked kinase/ AKT
signalling pathway. A recent study showed that a humanised single-chain
variable fragment antibody against CTGF attenuated collagen deposition and
decreased severity of alveolitis and pulmonary fibrosis induced by bleomycin
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(Wang et al., 2011). This provides support for the concept that blocking
CTGF action may provide an effective means of treating fibrotic disorders,
including those involving the lung. Furthermore, it has been demonstrated
that TGF-β signalling through TGF-β receptor II (TβRII) plays an important 
role in regulating the lung epithelium during pulmonary fibrosis (Degryse et
al., 2011; Li et al., 2011).  Deletion of TβRII specifically in the lung epithelium 
of transgenic mice resulted in decreased lung fibrosis, which was attributed
to a reduction in the numbers of fibroblasts, including those derived through
EMT (Degryse et al., 2011; Li et al., 2011).
EMT is a dynamic process and the markers detectable in cells undergoing
EMT may vary depending on the stage of EMT or between different cell lines
(Kalluri, 2009), hence a panel of markers were used to study the T2 cell line
in this thesis. E-cadherin, an epithelial cell marker, is usually downregulated
during EMT concomitantly with the upregulation of mesenchymal cell
markers (Willis and Borok, 2007). Surprisingly, in this study, the total protein
levels of E-cadherin were not significantly decreased by exposure of the cells
to TGF-β or CTGF.  This suggested either that EMT was absent in these 
alveolar epithelial cells, or the cells may be in an intermediate transitional
stage between two extremes of epithelial and mesenchymal cell types.
Evidence for the latter explanation is three-fold. Firstly, E-cadherin
expression appeared to be redistributed, as immunostaining showed that
while E-cadherin was present intracellularly, E-cadherin was lost from the
plasma membrane. This suggests the E-cadherin present may be
dysfunctional as an adhesion molecule, leading to disruption of cell-cell
contact and apical polarity, supportive of a pro-migratory profile for epithelial
cells undergoing EMT.   This is consistent with a previous study of TGF-β-
induced EMT in a rat kidney epithelial cell line (NRK-52E), which
demonstrated a relatively modest fold-change in E-cadherin protein
expression on a Western blot, despite of a clear disappearance of E-cadherin
from the cell surface shown by immunofluorescence staining, and
pronounced down-regulation in mRNA expression of E-cadherin (Burns et al.,
2006). A relatively modest reduction in E-cadherin protein compared to
Overall conclusions and discussion | 207
mRNA expression has also been shown in other TGF-β-induced cell systems 
modelling EMT, including Madin Darby canine kidney (MDCK) cells (Peinado
et al., 2003) and a kidney epithelial cell line (NP-1) (Strutz et al., 2002). A
possible explanation of E-cadherin still being present in the T2 cells is the
long half-life of E-cadherin in cells, which has been shown to be 2 to 3 days
in MDCK cells (Peinado et al., 2003). In rats with renal tubulointerstitial
fibrosis induced by unilateral ureteric obstruction, and in porcine kidney
epithelial cells (LLCPK-1) treated with TGF-β, no significant decreases in E-
cadherin levels were detected by q-PCR or Western blotting (Docherty et al.,
2009) but authors speculated that the E-cadherin present became
dysfunctional and/or fragmented. Various fragments of E-cadherin such as a
30 kDa C-terminal fragment found in MDCK cells, have been reported in
renal tubular cells and prostate and mammary epithelial cell lines (Keller and
Nigam, 2003). As highlighted in a review by Kalluri and Weinberg,
internalisation of full length or the C-terminal, β-catenin-binding portion of E-
cadherin and subsequent nuclear localisation of β-catenin is associated with 
induction of EMT (Kalluri, 2009).
Secondly, TGF-β- and CTGF-treated cells developed a spindle like shape in 
contrast to the untreated cells displaying the prototypical cobblestone
morphology (Mason, 2006) indicative of EMT-associated morphological
changes. As Maeda et al. suggested, it is possible that morphological
changes to epithelial cells may precede the switch of E-cadherin to N-
cadherin expression during EMT (Maeda et al., 2005).  Thirdly, TGF-β- and 
CTGF-treated cells expressed α-SMA, vimentin and collagen type I, which 
were either absent or at lower levels in the untreated cells. This finding is
consistent with the panel of markers expressed in previous reports of in vitro
EMT (Willis et al., 2005).  I also found TGF-β induced CTGF expression in 
the T2 cells, consistent with Kasai et al.’s report of TGF-β-induced EMT in 
A549 cells which included increased levels of CTGF (Kasai et al., 2005).
Changes in α-SMA and vimentin expression may contribute to the 
cytoskeletal rearrangement leading to the morphological changes in the
treated T2 cells, supporting the observations described by Yao et al in
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primary type II alveolar epithelial cells (Yao et al., 2004). In this study cells
were treated up to 72 hours, and co-expression of epithelial and
mesenchymal markers have been reported 96 hours post-TGF-β stimulation 
in epithelial cells (Willis et al., 2006). A previous study showed primary
human tubular epithelial cells grown on plastic to co-express mesenchymal
markers vimentin and α-SMA as well as the epithelial markers E-cadherin 
and cytokeratin. The cells were described as being in a transitional
phenotype (Forino et al., 2006). Together these results indicate CTGF plays
an important role in mediating EMT in lung epithelial cells.
Historically, it has been extremely difficult to obtain functional recombinant
forms of CTGF. This may be a reflection of the cysteine-rich nature of CTGF,
which makes folding of the protein outside its physiological environment a
challenging task. As described in Chapter 1, the protein is susceptible to
cleavage by proteases such as chymotrypsin and plasmin (Bork, 1993),
which also makes obtaining full-length protein difficult. As a marked and
consistent increase in α-SMA was observed in the experiments with TGF-β-
induced T2 cells, expression of α-SMA protein was used to investigate 
whether CTGF may induce similar EMT-like changes as TGF-β in these cells.  
It may be argued that the fold-change observed is relatively small considering
the high concentrations of CTGF used, which were above physiological
levels of CTGF (plasma concentrations of CTGF have been reported as 23
ng/ml, 33 ng/ml and 50 ng/ml in normal adults, and limited and diffuse forms
of systemic sclerosis, respectively) (Dziadzio et al., 2005b), suggesting the
low potency of this product. It is also a stark contrast to the potency of
recombinant TGF-β, which is usually used at concentrations typically 
between 2 – 10 ng/ml in cell culture. However, recombinant forms of CTGF
have been typically used in in vitro experiments at concentrations above
circulatory levels (50 ng/ml or above). It is also likely that the local
concentration of CTGF in situ in tissues and at the sites of injury may be
elevated above what is considered the physiological levels detected in the
circulation.
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Both canonical and non-canonical TGF-β signalling pathways play a role in 
fibrosis (Leask and Abraham, 2004). In chapter 4, CTGF is shown to activate
the SMAD pathway, as well as p38 and ERK1/2 signalling in T2 cells. The
observation of SMAD activation is supported by results of a previous study
on lens epithelial cells, which demonstrated that SMAD3 signalling-mediated
EMT in response to injury (Saika et al., 2004). The findings are also
consistent with the detection of phophorylated p38 and ERK1/2 in the
epidermal keratinocyte cells of the Col1a2-CTGF transgenic mice by Dr
Shonali Sonnylal (Sonnylal et al., 2013). In the skin, the transmembrane
glycoprotein integrin β6 is speculated to participate in activation of p38 and 
ERK1/2 signalling (Sonnylal et al., 2013).  The upregulation of integrin β6 in 
the lung in response to injury (Hogmalm et al., 2010) and its function as a
receptor for extracellular matrix proteins such as fibronectin (which was
induced by CTGF in T2 cells) suggest that integrin β6-mediated p38 and 
ERK1/2 signalling may also be relevant in T2 cells.  ERK enhances TGF-β-
induced SMAD signalling and collagen synthesis by phosphorylating serine
residues in the linker regions of SMAD3 (Hayashida et al., 2003). Similarly,
p38 MAPK has been shown to be central to TGF-β-mediated collagen, α-
SMA, and fibronectin expression in SSc fibroblasts (Ihn et al., 2005; Meyer-
ter-Vehn et al., 2006).
Although experiments require repetition to confirm reproducibility, preliminary
results in Chapter 4 showed that inhibition of p38, ERK1/2 and TGFβRI 
signalling attenuated CTGF-induced α-SMA expression, suggesting that 
signalling through these pathways is likely to mediate the induction of α-SMA 
stimulated by CTGF in T2 cells. The results are supported by observations
made by Dr Helen Jones where blocking TGF-β signalling by inhibition of
TGFβRI or by using a TGF-β neutralising antibody, both lowered the levels of
α-SMA longitudinal stress fibres in T2 cells in vitro (Sonnylal et al., 2013). It
is possible that CTGF may work in concert with TGF-β to modulate the TGF-
β/SMAD signalling response in T2 cells as the alveolar epithelium acts as a 
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key source of cytokines such as TGF-β during lung fibrosis (Xu et al., 2003).
The EMT-like modifications induced by CTGF in vitro may be mediated by
enhanced TGF-β signalling in a positive feedback loop.  
6.3 Conditional CTGF expression may provide a more accurate
model of CTGF upregulation in SSc
One of the limitations of the Col1a2-CTGF mouse (chapter 3) is that these
mice overexpress CTGF from birth, which may not form the most accurate
representation of the CTGF expression pattern in SSc, which peaks at a
particular stage rather than continuously throughout the entire course of the
disease. In light of this, we set out to investigate the phenotype of an
inducible CTGF overexpression mouse for comparison with the Col1a2-
CTGF transgenic mouse. Conditions were being optimised for inducing
CTGF expression in vivo and preliminary histological analysis revealed that
the system resulted in elevated CTGF expression in the lung parenchyma of
the induced mice. The inducible model is likely to be an invaluable tool for
elucidating the in vivo role of CTGF and confirming the observations made
from the in vitro studies of fibroblasts and epithelial cells in this study.
6.4 Conditional CTGF gene knockout in vivo attenuated
bleomycin-induced fibrotic changes in the lung
Homozygous CTGF knockout mice are neonatal lethal due to impaired
chondrogenesis and ECM abnormalities (Ivkovic et al., 2003), and hence an
inducible CTGF knockout mouse may be useful for studying the effects of
CTGF gene knockout on bleomycin-induced pulmonary fibrosis. Inducible
deletion of CTGF in mice attenuated bleomycin-induced lung fibrosis. H&E
and PicroSirius red staining demonstrated that CTGF deletion abrogated
bleomycin-induced collagen expression and accumulation of fibrotic masses
in the lung parenchyma (chapter 5). A limitation of this study thus far is that
assessment of the fibrotic phenotype has been made by histology mainly.
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Although only some preliminary micro-CT analyses were performed,
additional sampling for micro-CT analyses is likely to strengthen the
histological results by providing a representation of the whole mouse lung in
three dimensions. However, due to some of the mice not surviving and due
to time constraints, a limited number of mouse lungs were obtained for
microCT analysis. Although the focus of this study was on the lungs, it would
be interesting to characterise the effects of CTGF knockout on other organs
and tissues in these mice, which may be relevant for SSc.
6.5 Sources of CTGF expression and putative origins of
fibroblasts in SSc lung
CTGF plays a key role in lung fibrosis. Expression of CTGF was more
widespread in lung tissue from SSc patients, and augmented in SSc lung
fibroblasts as well as pneumocytes, endothelial cells, smooth muscle cells
and macrophages (chapter 5), in line with results of recent DNA microarray
studies performed on lung fibroblasts (Lindahl G.E. et al., 2013; Renzoni et
al., 2004; Shi-Wen et al., 2000). These results are consistent with the
association of SSc pulmonary fibrosis with increased levels of CTGF present
in bronchoalveolar lavage (BAL) fluid (Sato et al., 2000). The findings also
correlate well with the association of CTGF expression with scleroderma
lesional skin (Igarashi et al., 1995) and in the circulation (Leask et al., 2001).
Additionally, increased collagen deposition and disrupted lung architecture
provided evidence of a fibrotic phenotype in the SSc lung tissue sampled.
As the principal effector cells in fibrosis (Tomasek et al., 2002), the origins of
myofibroblasts is of interest in fibrotic diseases. The relative contribution of
various putative precursors of myofibroblasts (Hinz et al., 2012) in the SSc
lung is unknown. TTF-1-expressing type II alveolar epithelial cells and
CD31-positive endothelial cells present in SSc lung may potentially provide
alternative sources of fibroblast-like cells during fibrosis. In chapter 5, cells in
the lung parenchyma co-expressed α-SMA and TTF-1, suggestive of an 
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intermediate cell phenotype and potential derivation of a mesenchymal cell
type from an epithelial cell type.  Cells co-expressing α-SMA and CD31 were 
also present in endothelial cells lining blood vessels in SSc lungs, suggesting
that at least some of the α-SMA- expressing cells may have been derived 
from an endothelial cell lineage. Endothelial cells and type II alveolar
epithelial cells may undergo transition in response to fibrotic injury in SSc
(Harrison et al., 1991). The ability of T2 cells to synthesize and respond to
TGF-β (Willis et al., 2005) and CTGF (chapter 4) may help to promote EMT
in these cells. In idiopathic pulmonary fibrosis, TGF-β expression in lung
epithelial cells is linked to advanced lung fibrosis (Khalil et al., 1996).
6.6 Blocking CTGF attenuates expression of fibrotic factors in
lung fibroblast cells
In addition to the involvement of CTGF as a profibrotic factor in skin, as
highlighted by earlier studies on SSc skin fibrosis (Dziadzio et al., 2004; Shi-
Wen et al., 2000), the results of chapter 5 also adds to the evidence of CTGF
as a key mediator of the profibrotic phenotype of SSc lung fibroblasts. CTGF
mediates the expression of fibrotic proteins in SSc lung fibroblasts, and also
in TGF-β-stimulated conditions in control and SSc lung fibroblasts, providing 
support for involvement of CTGF signalling in the TGF-β-mediated fibrotic
phenotype in lung fibroblasts. These findings together with correlations of
CTGF with tissue fibrosis in SSc (Lindahl G.E. et al., 2013), suggest that
intervening with CTGF signalling may help to attenuate the fibrotic effects
mediated by CTGF action. Silencing of CTGF resulted in significant
suppression of fibrotic proteins basally expressed in SSc fibroblasts, and in
TGF-β-treated fibroblasts, including collagen type I, fibronectin, α-SMA, 
TIMP1 and IL-6. Blocking CTGF is an attractive target for anti-fibrotic
therapy. Anti-CTGF antibodies currently under study to target pre-clinical
models of diabetic kidney disease (Adler et al., 2010), glaucoma (Wallace et
al., 2013) and acute lymphoblastic leukaemia (Lu et al., 2013) may be useful
in targeting lung fibrosis.
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Although animal and in vitro studies have revealed that the some of the roles
of TGF-β and CTGF are intertwined in fibrosis (Barrientos et al., 2008), the
exact mechanisms underlying the relationship between them remains to be
fully elucidated. TGF-β alone is unable to sustain a fibrotic response and is
likely require the cooperation of other mediators such as endothelin-1 and
CTGF (Leask, 2007).  TGF-β induces CTGF expression in fibroblasts 
(Igarashi et al., 1993) and CTGF may act as a downstream mediator of TGF-
β-induced processes such as cell proliferation, adhesion, collagen synthesis, 
and myofibroblast differentiation in the pathogenesis of fibrosis (Leask and
Abraham, 2006).  CTGF is essential for TGF-β to activate SMAD1-ERK1/2 
signalling but not for the SMAD3 signalling (Nakerakanti et al., 2011).
Another study supporting CTGF as a downstream mediator of TGF-β showed
that CTGF antisense oligonucleotide attenuated fibrosis in vivo while
maintaining levels of TGF-β (Okada et al., 2005). Other studies support the
alternative view that TGF-β and CTGF function synergistically to sustain 
fibrosis (Bonniaud et al., 2003; Mori et al., 1999). These studies
demonstrated a persistent fibrotic phenotype in mouse skin only upon
exposure to both TGF-β and CTGF.
Upregulation of TGF-β expression in skin begins in the inflammatory stages 
of SSc while CTGF overexpression is more prominent during the fibrotic
stage of disease (Igarashi et al., 1995b; Querfeld et al., 1999). In contrast to
the elevated levels of CTGF observed in SSc fibroblasts, there is no
difference in expression of either active or total TGF-β between normal and 
SSc fibroblasts (Holmes et al., 2003).  This suggests that TGF-β signalling 
alone may only provide a partial explanation for the development of tissue
fibrosis.  TGF-β and CTGF may act at different times or they have 
overlapping but differential roles, for example, CTGF may play a more central
role in sustaining fibrosis as opposed to initiating fibrosis, a process more
strongly influenced by TGF-β.  The above results suggest that while CTGF is 
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able to mediate some of the activities induced by TGF-β, CTGF may also
promote fibrosis independently of TGF-β.   
6.7 CTGF modulates fibroblast contraction and migration
CTGF treatment also altered key functions of fibroblasts. Fibroblast
migration is an important feature in the progression of tissue fibrosis
(Suganuma et al., 1995). The mechanism involved in fibroblast accumulation
in the lung interstitium during fibrosis has not been fully resolved, although
TGF-β, PDGF and FGF are known regulators of this process. In chapter 5,
upon subjection to an in vitro scratch injury induced CTGF expression in
normal lung fibroblasts, which is consistent with the idea of CTGF release
during wound healing (Alfaro et al., 2013). Although to a lesser extent than
FBS stimulation, addition of CTGF alone promoted fibroblast migration in
control and SSc lung fibroblasts. This is consistent with a previous study
demonstrating that CTGF, via its C-terminal domain, could induce ERK-
dependent migration of normal and SSc lung fibroblasts (Bogatkevich et al.,
2008). However, in the study by Bogatkevich et al., experimental conditions
did not include use of any cell proliferation inhibitors so their results may
reflect a combination of migration and proliferation of the cells. CTGF is
likely to have promoted proliferation as high levels of TGF-β and PDGF in 
SSc BAL fluid is associated with enhanced proliferation of SSc lung
fibroblasts (Ludwicka et al., 1995). The findings from the current study are
also consistent with a previous report highlighting enhanced proliferation,
migration and resistance to apoptosis in fibrotic lung fibroblasts (Hinz et al.,
2012). Similarly, the migration of metastatic melanoma cells in a scratch
assay was dependent on CTGF expression (Finger et al., 2013).
Myofibroblast contractile function was examined as extracellular matrix
remodelling and contraction is a principal feature of fibrosis which is
mediated by myofibroblasts (Hinz et al., 2012). Myofibroblast contraction,
involving the generation of α-SMA stress fibres and the fibronexus, a  
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transmembrane connection between extracellular fibronectin filaments and
intracellular actin microfilaments (Gabbiani, 2003), results in hardened tissue,
which in turn promotes myofibroblast differentiation (Hinz et al., 2012). In
vitro collagen matrices were used to investigate the influence of CTGF on
fibroblast matrix contraction since collagen forms the key component of the
ECM (Ngo et al., 2006). Compared to control cells, SSc lung fibroblasts
increased collagen gel contraction. Treatment of control cells with FBS,
TGF-β or CTGF showed enhanced collagen gel contraction comparable to 
that of SSc lung fibroblasts; the greatest effect on gel contraction was
observed with FBS. This is likely a reflection of serum being composed of a
mixture of cytokines and growth factors. Although SSc cells were more
contractile than control cells, they still had the capacity to respond to TGF-β
and CTGF stimulation. These results correlate well with the induction of the
pro-contractile cytoskeletal protein, α-SMA in SSc compared to control cells, 
and also in TGF-β- and CTGF-treated cells compared to untreated.  CTGF 
may mediate lung fibroblast contraction via its VWC domain (Bogatkevich
G.S. et al., 2000).
6.8 General Summary
The overall goal of this study was to elucidate the role of CTGF in the
pathogenesis of fibrosis in SSc. The aims of this project were to investigate:
1. whether CTGF can mediate fibrosis independently of TGF-β 
2. the cellular mechanisms underlying CTGF action
3. whether blocking CTGF action attenuates fibrosis
Results of this study suggest:
1. CTGF can induce a fibrotic phenotype independently of TGF-β.
Overexpression of CTGF in mice results in tissue fibrosis. Increased
CTGF expression in human lung fibroblasts promotes differentiation of
fibroblasts into α-SMA-positive myofibroblasts with enhanced 
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contractile and migratory functions. Conditional CTGF overexpression
mice also present with lung fibrosis and may provide a useful model
that more accurately portrays the upregulation of CTGF in SSc, but
requires further characterisation.
2. CTGF induces EMT-like changes in type II alveolar epithelial cells in
vitro.  Co-expression of E-cadherin and α-SMA in lung tissue of 
Col1a2-CTGF mice and also in parts of the SSc lungs suggest a role
for CTGF-mediated EMT in lung fibrosis.
3. Silencing CTGF expression suppresses expression of profibrotic
proteins in TGF-β-treated control fibroblasts, and SSc lung fibroblasts.  
Deletion of CTGF abrogates bleomycin-induced pulmonary fibrosis in
mice.
Taken together, the results of the current study demonstrate the pivotal role
of CTGF in fibrosis. CTGF mediates EMT-like changes in T2 cells in vitro,
and in vivo, and CTGF upregulation leads to development of tissue fibrosis
accompanied by EMT-like changes in the alveolar epithelia. Blockade of
CTGF using siRNA in SSc fibroblasts in vitro resulted in attenuation of
proteins upregulated during fibrosis while deletion of CTGF in vivo provided
some protection from bleomycin-induced lung fibrosis in mice. Ultimately,
blocking CTGF activity may be useful as a specific method of attenuating
tissue fibrosis in SSc without altering cellular events that are TGF-β-
dependent and CTGF-independent. CTGF may prove to be a more attractive
therapeutic target in treating fibrosis than TGF-β because of the inflammatory 
and immunosuppressive responses associated with TGF-β.   
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Chapter 7. Future work
The results from this thesis show that CTGF plays an important role in the
pathogenesis of fibrosis. However several areas were beyond the scope of
this thesis and further experimentation is required to elucidate the pathogenic
mechanisms underlying CTGF in the disease pathways.
7.1 Conditional CTGF overexpression mice
Future studies of the conditional CTGF overexpression mice should fully
elucidate which cell type(s) is the most important contributor to lung fibrosis
and PAH. This may be pursued by using alternative conditional mice to that
described here which uses the ROSA promoter construct to globally
expresse CTGF across multiple cell types. An attractive alternative is to
employ the collagen-Cre system to drive CTGF overexpression specifically in
fibroblasts or the V-cad promoter for endothelial cell-specific CTGF
expression, as CTGF was first isolated from endothelial cells.
Characterisation of the pulmonary physiology of the mice such as lung
function tests, measurement of pulmonary pressures, as well as examining
cardiac function using heart ECHO for example, to investigate any PAH-
related changes that may accompany lung fibrosis. Multiplex cytokine
profiling could be performed to identify serum and BAL-fluid levels of CTGF
and other biomarkers, and changes in these levels at various time-points and
in response to therapeutic interventions.
7.2 Fibroblast and myofibroblast progenitor populations
Several progenitor populations have been identified that may contribute to
the fibrotic process. Future studies could be envisaged whereby
immunofluorescent multiplex staining or the use of cell lineage mapping of
different progenitor cells could be used identify non-resident fibroblast cells
which may contribute to the activated fibroblast population during fibrosis.
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Staining of mesenchymal cell markers and markers of alternative cell types
such as those of epithelial, endothelial, bone marrow derived and pericyte
cells may be performed in order to assess the proportion of cells which may
have been derived from EMT, endo-MT, and circulating progenitors. Future
studies of the involvement of CTGF in promoting alternative cell types to
becoming fibroblast-like cells in vitro could focus on cell culture of various cell
types including fibrocytes and pericytes. The cells could be exposed to
recombinant CTGF and the effects of this treatment on the changes in
expression of cell surface markers and secretome profile could be assessed
using ELISA, Illumina arrays, or mass spectrometry. In order to fully define
the mechanisms of CTGF on the differentiation of cells to become fibroblast-
like, we could expand the study using blockade experiments with neutralising
antibodies and small molecule inhibitors to map out the signalling pathways
involved in more detail.
Extending the study on EMT, primary alveolar epithelial cells could be
obtained commercially or isolated from the transgenic mice to assess
whether CTGF induces the same EMT-like signature as observed in the T2
cell line. A new avenue of research may be pursued through cell fate
mapping analyses in vivo using conditional CTGF overexpression mice and
reporter genes to investigate whether CTGF upregulation induces T2 cells to
undergo EMT-like changes.
7.3 CTGF-dependent signal transduction pathways
In order to further elucidate CTGF-dependent signalling pathways,
experiments deleting or blocking CTGF expression could be pursued. More
in depth characterisation of bleomycin-treated CTGF KO mice may be
performed to assess the physiological changes. These could include
additional micro-CT scanning of lungs to assess whether lung volume is
increased as an indication of fibrosis, measuring pulmonary pressures and
cardiac function through heart ECHO. These could be followed up by
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histological analysis of the lungs ex vivo for signs of fibrosis such as
decreased alveolar spaces and increased ECM deposition. In vitro, various
cell types from WT and CTGF KO mice could be treated with recombinant
CTGF to investigate CTGF-induced signalling pathways. CTGF expression
could also be blocked in vitro using the established lentiviral shRNA
transduction system in the mouse cells to identify altered CTGF-dependent
signalling pathways. Experiments combining CTGF KO or shRNA
knockdown of CTGF with TGF-β treatment could be performed to identify 
CTGF-dependent pathways downstream of TGF-β.  Phosphoprotein 
signalling, genome-wide transcriptional profiles and the secretome of these
cells may be assessed further through phosphoprotein assays, proteomics,
ELISA, and ChIP assays.
7.4 CTGF and epigenetic changes
Epigenetic changes such as DNA methylation, histone acetylation and
miRNA expression downstream of CTGF action is a novel area to explore.
Epigenetic profiling could be performed on ECM and other related genes in
tissue fibrosis to identify epigenetic signatures of CTGF.
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Appendix
8.1 Primer sequences
Mouse primer sequences for genotyping
Target gene Primer sequence (5’ 3’)
Fabpi-200 Forward
Reverse
TGGACAGGACTGGACCTCTGCTTTCCTAGA
TAGAGCTTTGCCACATCACAGGTCATTCAG
Lac Z Forward
Reverse
GTTGCAGTGCACGGCAGATACACTTGCTGA
GCCACTGGTGTGGGCCATAATTCAATTCGC
Rat primer sequences for qPCR
Target gene Primer sequence (5’ 3’)
18S Forward
Reverse
TTGACGGAAGGGCACCACCAG
GCACCACCACCCACGGAATCG
B2M Forward
Reverse
GCTCGCTCGGTGACCGTGAT
TTCTCCGGTGGATGGCGAGAGT
CTGF Forward
Reverse
ACTGACGGGGAAGGGCTCTT
TCTTCCAGTCGGTAGGCAGCTAGG
E-cadherin Forward
Reverse
GATCCTGGCCCTCCTGAT
TCTTTGACCACCGTTCTCCT
RLP13A Forward
Reverse
GCCCTGGAACGCCTCAAGGT
TCCACCCGACCTCATGAGCCA
SDHA Forward
Reverse
CACCGAATAAGAGCAAAGAAC A
CCGAGTGACCATGGCTGT
α-SMA Forward
Reverse
TGCCATGTATGTGGCTATTCA
ACCAGTTGTACGTCCAGAAGC
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8.2 Western blot antibodies
Antibody target Host species Supplier Dilution in 5%
milk/0.1% tween/PBS
Collagen type I Mouse Millipore 1/1000
CTGF Goat Santa Cruz 1/1000
E-cadherin Mouse BD Biosciences 1/1000
GAPDH Mouse Abcam 1/5000
Vimentin Mouse Santa Cruz 1/1000
α-SMA Mouse Dako 1/1000 
β-tubulin Rabbit Abcam 1/1 000 
8.3 Immunohistochemistry antibodies
Antibody target Host species Supplier Dilution
CD31 Mouse Dako 1/100
CTGF Rabbit Abcam 1/200
E-cadherin Mouse BD Biosciences 1/200
TTF-1 Mouse Dako 1/100
Vimentin Mouse Cell Signalling 1/100
α-SMA Mouse Dako 1/100 
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8.4 Lentiviral-mediated small hairpin RNA gene knockdown
Sequences of shRNA against human CTGF
shRNA target Mature antisense sequence
shCTGF-01 ATGTCTTCATGCTGGTGCA
shCTGF-02 TCTTCTTCATGACCTCGCC
8.5 Small interfering RNA gene knockdown
Target sequences of the four siRNA constructs in the siRNA pool targeting
human CTGF
siRNA target Target sequence
CTGF-01 ACAAUGACAUCUUUGAAUC
CTGF-02 AGGAAGAUGUACGGAGACA
CTGF-03 CGAUUAGACUGGACAGCUU
CTGF-04 GAGAGACAUUAACUCAUUA
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